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ABSTRACT 
 
Melanoma is an aggressive disease with few effective treatment options. Non-
toxic, anti-tumor therapies and prophylactic approaches are currently being investigated 
to identify treatment options that will control and remove late-stage melanoma.  
The overall goal of this project was to establish an effective delivery method for a 
plasmid encoding human interleukin (phIL-15) into mouse melanoma cells (B16.F10) 
using the gene transfer technique electroporation (EP)
1
. The EP delivery phIL-15 was 
optimized using an in vitro 3D tumor model. The purpose was to translate these IL-15 
delivery conditions into an in vivo mouse melanoma model to study IL-15 signal 
transduction and stimulate immune cells to destroy tumor antigens as well as promote 
an anti-tumor immune memory response.  
The in vitro 3D tumor model and the mouse model demonstrated similar 
expression patterns when delivering phIL-15 with different EP conditions. Intra-tumoral 
delivery using 500V/cm 20ms enhanced gene delivery and increased IL-15 protein 
expression compared to 1300V/cm 100µs. There was also a visible increase in 
transfection efficacy between tumor cells compared to skin cells when delivering pmIL-
12 and phIL-15 plasmid constructs in vivo. The plasmid+EP groups 1300V/cm and 
500V/cm stimulated increased expression of cytokines IL-1β, IL-6, INFγ, MIP-1β and 
TNFα. These EP groups also promoted tumor regression by up-regulating CD8+ T cells 
and CD4+ T cells which targeted melanoma. Regression and survival studies 
demonstrated that 73.3% of mice cleared B16.F10 cells when treated with phIL-
xi 
 
15+1300V/cm and pVax+500V/cm. In addition, 53% of the mice responded to the phIL-
15+500V/cm treatment group. Furthermore, 75% of the mice from group phIL-
15+500V/cm survived secondary inoculation and tumor challenge. In conclusion, 
plasmid with encoding gene insert phIL-15 delivered by EP has the potential to act as an 
anti-tumor therapy because it promotes melanoma regression and enhances mouse 
survival through innate and adaptive cell-mediated immune responses. 
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INTRODUCTION 
 
Melanoma Disease Target  
Melanoma is a poorly immunogenic and aggressive cancer localized in the 
epidermis, it is very dangerous when left untreated, but the survival rate increases if 
detected early and removed completely
1
. Currently, melanoma’s 5 year survival rate is 
≤10% for stage IV metastatic cells that have spread to other organs, ≤30% for stage IIIC 
metastatic cells that have spread to nearby tissue and lymph nodes, ≤45% for stage IIC 
ulcerated tumors, at least 1mm thick and cells have not migrated to the lymph nodes and 
≤95% for stage IA tumors that are not ulcerated, nor undergoing mitosis and are less 
than or equal to 1mm thick
2-3
. Melanoma is sometimes difficult to identify and lesions are 
located in places that can easily be ignored. Melanoma cells are melanocytes that have 
undergone genetic mutations and exhibit enhanced oncogenic properties. Melanoma 
transformation can develop from UV irradiation activating p53 gene mutations causing 
melanocytes to lose their cell cycle control. Many pathways are affected by excessive 
UV exposure (Figure 1) such as continuous autocrine stimulation by growth factors 
4-5
 
which causes prolonged MEK/ERK activation resulting in cell proliferation and 
differentiation
6
 and constitutive oncogenic g-protein N-RAS activity
7
 that binds to 
receptor tyrosine kinase (RTK). Additional oncogenic mutations are found in kinase 
activating domain V599E of B-RAF
7-9
 which enhances DNA proliferation and cell 
survival. Mutations cause loss of receptor function and enhanced melanogenesis, for 
example mutations in melanincortin-1-receptor constitutively bind α-Melanocyte 
2 
 
Stimulating Hormone (αMSH) causing increase in tumor survival
4,10-14
. Additionally, 
melanoma mutations cause down regulation of tumor suppressor genes PTEN/AKT and 
inhibitory pathways P53/APAF-1 in non-metastatic melanoma
7
 which increases cell 
survival. Also, melanoma evades the immune response by using immune suppressor 
factors to decrease cytokine production stimulated by the JAK/STAT pathway
14
. 
 
 
 
Melanoma formation also occurs when there is a continuous stimulation by 
mitogenic growth factors promoting excessive melanocyte formation into a population of 
pigmented cells called nevi or moles
15-16
. Nevi formation is dependent on distinct growth 
factors like bFGF different from the growth factors stimulating other melanocytes found 
ubiquitously in the epidermis. When CDKN2A/P16
INK4
 cell cycle inhibitor is up-regulated 
Figure 1: Melanoma Development and Oncogenic Mutations 
 (Figure Referenced in Literature
4-18
). 
3 
 
it controls nevi proliferation
4,14-17
. Nevi that do not undergo senescence and replicate 
uncontrollably form many nevi or moles that may give rise to melanoma due to a defect 
in CDKN2A/P16
INK4
,
14,18 
(Figure 1). 
Melanocytes are highly migratory cells that move towards keratinocytes when the 
epidermis is exposed to UV radiation. The melanocytes function by transferring their 
melanin to keratinocytes to shield against UV exposure
19
. Melanocytes also elevate anti-
apoptotic properties like BCL-2 and αMSH which contribute to cell immortalization
10, 20
. 
These properties associated with up-regulating melanocyte protection from UV exposure 
are the same properties that protect melanoma cells from cell death and immune attack. 
Once melanoma invasively migrates to deeper layers of the skin and invades the blood 
stream it causes secondary disease and spreads to the liver, lung, and brain
2,14
. 
Treatment options for late stage melanoma are limited and the aggressive disease 
rapidly floods the body causing irreversible damage. The current treatment options are 
surgery, chemotherapy, cytotoxic drugs and radiotherapy
2,7
. Melanoma is highly 
resistant to chemotherapy and alkylating agents that cause cytotoxic DNA cross-linking. 
Melanoma is resistant because cells can undergo increased DNA repair and detoxify 
chemotherapeutic drugs by up-regulating alkyl transferases like glutathione S-
transferase to chemically reduce cytotoxic cross-linking
2
. Melanoma can also impair 
drug transport and drive out the chemical via P-glycoprotein efflux pumps. Melanoma is 
known to be resilient to cytotoxic drugs at doses which cause toxicity in patients. 
Scientists are investigating other alternative therapies to target melanoma such as 
cytokine immune therapy
2,7
.  
 
 
 
4 
 
Current Melanoma Gene Therapy  
Some of the cytokines that have been studied for their potential use in immune 
therapies are INFα, IFNγ, IL-2, IL4, IL6, IL-12, IL-18, IL-21, GMCSF, IL-12, and TNFα
2
.  
In 2007, a study using FDA approved high dose recombinant protein INFα and IL-2 was 
administered to patients with advanced stage melanoma (II, III and IV). The results 
showed limited tumor response 10-15% and resulted in high platelet toxicity
2,21
. 
Currently, investigators are developing adjuvant therapies that will promote anti-tumor 
efficacy dependent on the stage of tumor growth. One idea is to target early stage (I/II) 
melanoma in patients not at risk of relapse and increased survivability with resection, is 
to use low dose recombinant proteins to target early stage existing disease. The 
approach is to induce a protective immune response against new primary melanoma
22
. 
Another strategy is to mount a protective immune response against tumor cells by 
employing an adjuvant delivery system that will transfect genes encoding cytokines into 
specific cells and signal surrounding immune effector cells to enhance their own 
cytotoxic effect against intermediate and late stage melanoma
23
.  
 
Gene Delivery Techniques  
There are many gene delivery techniques that are used to promote the 
introduction of nuclei acid into cells, these include viral vectors, gene gun, charged 
polymers, liposomes, calcium phosphate precipitation, ultrasound, intracellular 
microinjections, pressure perfusion, and electroporation (EP)
23-25
. The purpose is to use 
a safe and minimally toxic system that can effectively target specific cells and deliver 
specific genes which would direct downstream events leading to an enhanced immune 
response
23-24
.The injection of naked DNA into tissues or cells is not an efficient  
5 
 
transfection approach. This efficiency can be significantly improved using physical 
approaches such as gene gun or EP. Both devices facilitate transport of DNA through 
the cell membrane and cytosol allowing them to reach the nucleus at high proficiency
23-
24
. The pressure perfusion method (hydrodynamic) forces large volumes of plasmid DNA  
into a vein. A typical target using this technique is the liver and the high injected volume 
inflates the organ and leads to efficient gene delivery and high expression. While 
successful, this approach is not easily translated to the clinic
23-25
. Although recombinant 
viral vectors can deliver DNA efficiently and achieve high levels of protein expression, 
they are accompanied by some safety concerns. These include immune response to the 
virus, possible insertional mutagenesis and over expression of a gene resulting in high 
toxicity
23-25
. An alternative is to use a non-viral vector that will deliver therapeutic genes 
into the cell’s nucleus without damage as well as limiting systemic toxicity. Delivery of 
plasmids using mechanical devices such as EP, is safe, promotes efficient, transient 
delivery and allows short-term gene production for downstream stimulus
24, 26-27
. The 
goal is to deliver a gene encoding a cytokine to stimulate pathways of the immune 
response and promote antigen recognition by effector cells that can up-regulate multiple 
arms of the immune response as well as a protective response by memory cells
28
. 
Many laboratories such as the Heller Lab utilize gene delivery systems to employ 
anti-tumor therapies into existing disease. Based on previous studies with interleukin 12 
(IL-12), intra-tumoral delivery of the gene using EP enhanced DNA delivery into mouse 
melanoma (B16.F10) improved protein production by tumor cells compared to injection 
of IL-12 plasmid only
28-30
. These studies showed that local delivery of the plasmid to the 
tumor reduced tumor burden, prevented tumor metastasis and increased mouse 
survival. The study also showed up-regulation of innate and adaptive immune  
6 
 
responders such as IFNγ by ELISA and CD8+/CD4+ T cells by immunohistochemistry. 
The delivery of IL-12 was able to reduce tumor size using EP intra-tumoral delivery and 
prevent melanoma lung colonization when delivering IL-12 into the gastrocnemius 
muscle. The mice responded well to treatment, had no deleterious side effects and did  
not succumb to melanoma metastasis
28-30
. The purpose of the subsequent study was to 
expand upon the knowledge gathered from the IL-12 studies and characterize EP 
delivery conditions for human interleukin-15 (IL-15). The goal was to test the delivery of 
IL-15 primarily in vitro and then translate the information in vivo. Activation of immune 
responses against B16.F10 antigens and evaluation of memory response could be 
studied following delivery of plasmid encoding IL-15 (pIL-15). Evaluation of those results 
would contribute to understanding what effector cells caused reduction in tumor burden 
and increased mouse survival
31
.  
 
Electroporation  
Electroporation is a technique that provides temporary permeabilization of cells 
allowing the entry of molecules and desired genes
32-36
. “Poration” occurs when electric 
fields are applied across charged electrode plates and creates potential energy at the 
poles to help feed molecules or DNA into cells
32,37
. It is suggested that DNA is 
introduced into the cells by different mechanisms, such as electrophoretic forces
26,32,35-
37
, endosomes envagination
38
, and binding of DNA to the membrane with lateral 
diffusion
34
. To promote DNA entry into the cells, it has been suggested that the electric 
fields cause deformation of the DNA to compensate for the bulky supercoiled size. The 
pulses orient the DNA parallel to the electric field and facilitate movement of the DNA 
into the cytosol within milliseconds
33
. The “pore” radius depends on the size of the DNA 
7 
 
providing passage of excess DNA found in the extracellular matrix
33-34
. The plasma 
membrane regulates resealing of the “pores” a few minutes after the pulses to reduce 
cellular damage by reverting to normal transmembrane potential
33
. Once inside the cell, 
it is suggested that the DNA uses the cells’ transcription and translation factors to 
produce protein
31,35,38
. The process of DNA introduction into the cell is still being 
investigated; studies are attempting to unravel the process of uptake and translocation of 
the DNA into the nucleus for protein expression
33,35-36
. 
Electroporation has been utilized to enhance DNA delivery of many types of 
genes into different cells and promote specific up-regulation of protein signaling
28,31,36,39
. 
This technique uses the protein stimuli in cells to up-regulate different down-stream 
pathways that are beneficial to target disease or restore signaling in cells
29
. To promote 
specific immune responses the delivery system must ensure efficient transfection of 
DNA into target cells. Delivery of the plasmid and resulting expression can be controlled 
by regulating EP parameters. EP is controlled by adjusting pulse parameters such as 
pulse duration, length and frequency as well as plasmid concentration
29,39
. The applied 
electric field must exceed a minimal threshold to destabilize the membrane and ensure 
DNA transfer
36,39-40
. 
The delivery of luciferase using low electric fields with long pulse durations 
(600V/cm 5ms 1Hz 8 pulses) demonstrated increased expression of luciferase 
compared to the combination of high electric fields with short pulse durations and very 
low electric field with longer pulse durations (1200V/cm 100µs 2Hz 1 pulse and 140V/cm 
50ms 2Hz 8 pulses, respectively)
30
. Researchers found that long, low voltage electric 
pulses enhance DNA movement into cells compared to combination pulses
30,36,41
. 
Additionally, the route of plasmid administration, orientation of the electric fields and 
8 
 
direction of pulses influence the magnitude of transfection when delivering to a particular 
tissue type. It has been suggested that delivery to the liver, spleen, and kidney show 
more luciferase and β galactosidase expression than muscle and skin
41
. While this one 
study demonstrated higher expression with the specific EP parameters tested in liver, 
spleen and kidney, it is quite possible that utilizing different pulse parameters could lead  
to higher levels in muscle and skin. Many factors influence EP delivery such as cell size, 
cellular characteristics, relative conductivity since EP is limited to the area the field is 
applied, the amount of plasmid available and direction of pulses applied. The application 
of electric fields in multiple directions enhances delivery of the gene to many cells at one 
time reducing cell damage
39,41-42
. The electrode applicators utilized to deliver pulses to 
the cells are also tissue specific. Penetrating needle electrodes are used for muscle and 
tumor, while multi-electrode arrays and plate electrodes are used for skin and muscle 
39
. 
It is important to determine EP parameters for specific cells and tissues to select 
appropriate delivery conditions that would result in the appropriate protein expression 
and down-stream signaling.  
 
3D Modeling and Tissue Engineering 
There is a concerted effort to develop an in vitro model that mimics cellular 
properties similar to cells in vivo. It is important to develop models that will help elucidate 
the cellular physiology, pathology, drug interactions, cellular behavior, and protein 
signaling
43
. Two dimensional (2D), monolayer cell cultures have provided extensive 
information on cellular behavior, cell signaling and function. However, cells seeded in a 
2D monolayer culture differ from cells cultured in vivo, because they are morphologically 
different than structures observed in vivo which may lead to physiological differences 
44-
45
.  
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It is suggested that cells cultured in a monolayer may differ from cells in vivo because  
of the way they are cultured, specifically altering cell interaction, communications, 
differentiation, growth, migratory properties, metabolism, adhesive properties, protein 
expression, protein secretion, cytoskeleton organization, intracellular and extracellular 
signaling characteristics, receptor stimuli, agonist and antagonistic properties
45-49
. It has 
been demonstrated that tumor cells grown in a 2D culture are less likely to be drug  
resistant than cells grown in a 3D model
45,50
. One method used to test the differences in 
cellular properties is to develop a 3D model sitting in a synthetic micro-environment that 
will allow cells to mimic their natural state
51
. Generation of a 3D tissue-like construct has 
become a useful tool in cell culture providing the ability to study cell-cell interactions from 
homogeneous or heterogenous cell populations. This model gives researchers the 
opportunity to study cellular functions independently from other factors found in vivo that 
enhance or inhibit cellular processes
43-44,52-53
. 
The key is to generate a 3D model that can sustain cells in suspension, provide 
passive diffusion of oxygen, nutrients and allows cells to behave similar to their cell cycle 
in vivo. A microgravity bioreactor was engineered to promote cellular aggregation in a 
free-floating synthetic environment constantly rotating at less than 1 gravitational force 
(1g)
51,52
. The bioreactor allows cells to be submerged in media and is equipped with a 
silicon membrane to ensure oxygen and carbon dioxide exchange for the cells. This 
device known as the high aspect ratio vessels (HARVs) was engineered by NASA 
in1986 and Synthecon in 1990, to promote 3D growth of cells in a microgravity 
environment. The cells residing in the vessel experience minimal interference and 
shearing, while growing in a state of free fall or solid body rotation
52,54-58
. The rotation of 
the vessels concentrate cells in one location allowing aggregation and cell-cell contact 
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amongst epithelial adherent cells
59
, immune cells, stem cells
54
, melanoma
59
, sertoli cells 
60
, and pancreatic islets
51,54
.  
Cells grown in suspension forming 3D cellular aggregates are a good model to 
study tumor development and cell interactions. Tumor cells residing in a 3D construct, 
mimic cells in vivo they can organize themselves, polarize and support tumor cell 
behavior
51
. Tumor cells can organize into small masses mimicking the properties of  
tumor lesions in nature, proliferating in an oxygenated or hypoxic environment containing 
viable cells residing on the surface while dying, necrotic cells reside in the center
51-52
. 
Tumor cells grown in a 3D model instead of in a 2D culture will provide advantages to 
understanding the pathology of tumors and answer questions about drug targeting, gene 
therapy, angiogenesis, migration, tumorigenesis, cells cycle pathways, evasion of 
apoptosis and invasive properties
51,56,61
. Although this is not a completely organized 
natural system it is a good template for understanding the biology of tumor cells growing 
in a synthetic 3D microenvironment that can be translated and further tested in vivo
51
. 
The construction of a 3D tumor model must contain cell types that will properly 
interact and appropriately signal. These signals include growth factors, protein 
regulators, and adherent proteins that enhance synthesis of extracelluar matrix and 
scaffolding. These proteins will also help promote growth, differentiation, and survival of 
cells involved in the 3D model
62-64
. For instance, melanoma is a common skin cancer 
that is studied in vivo to identify early and late stage treatment protocols. This is an 
interesting model to study because it is poorly immunogenic and resistant to 
chemotherapy
2
. The tumor cells cultured in the 3D model will possibly mimic cellular 
behavior and help isolate cellular mechanisms that attribute to the disease pathology. 
The information gathered from the model may reveal signaling pathways that can be  
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targeted using chemotherapeutics or optimize expression levels of genes using EP 
delivery methods to regulate down-stream signaling
45
. A good tumor model is one that 
contains complementing cells that normally interact such as keratinocytes from the 
epithelium with melanoma that reside in the skin. Melanoma are melanocytes that act to 
protect the skin, but that have undergone genetic alterations, mutations and up-
regulation of oncogenic properties
45,51
.  
In vivo, the basal layer is the germinal layer of the epidermis and contains 
proliferative, non keratinized keratinocytes that house melanocytes
14
. The keratinocytes 
communicate with melanocytes and melanoma through their dendrite-like processes. 
Keratinocytes provide survival signals to melanocytes in the epidermis and prevent 
apoptosis, promote melanocyte differentiation, and migration
14
. As mentioned 
previously, keratinocytes are constantly controlling and communicating with melanocytes 
as well as melanoma. Melanocytes need keratinocytes because if they migrate to the 
dermis they can undergo apoptosis in the absence of keratinocyte survival signals
14,65
. 
The interesting feature of melanoma is that they have the ability to escape keratinocyte 
control. The keratinocytes control melanoma by preventing escape from deregulation 
and invasion. At early stages, keratinocytes express adhesive proteins E-cadherin to 
limit melanoma migration
66
. One evasion tactic used by melanoma is the down-
regulation of E-cadherin and up-regulation of N-cadherin through PI3K pathway
67
 as well 
as reducing the integrins in keratinocyte for melanoma migration. E-cadherin is 
expressed by epidermal cells Langerhans, keratinocytes and melanocytes while N 
cadherin is expressed by vascular endothelial cells and fibroblasts
66,68
. Some studies 
show an up-regulation of N-cadherin by melanoma cells themselves to escape 
keratinocyte control
66
. Melanoma migrates into deeper layers of the epidermis reaching 
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the blood stream and metastasizing to distant sites from the primary tumor site
17,69
. Up-
regulation of integrins is a result of UV irradiation in order to promote migration of 
melanocytes to the area of UV exposure
70-72
. 
Investigators interested in 3D models want to analyze specific processes to 
clearly understand mechanisms such as receptor up-regulation, protein synthesis, 
protein phosphorylation, mutation of genes, uncontrolled cancer cell proliferation, and 
tumor evasion
56,61
. A 3D tumor model provides an alternative method for analyzing 
treatment regimens using gene delivery methods and will assist in unraveling additional 
therapeutic options for melanoma
45
. Evaluating the effectiveness of cytokine therapy  
against cancer cells in vivo could be first optimized for EP delivery conditions in vitro 
using a 3D model and then translated to in vivo testing thus, reducing the use of animals 
for EP optimization.  
 
Interleukin-15 
One of the cytokines that is being studied for delivery to tumors using EP is 
interleukin-15 (IL-15). IL-15 is a 14-15kDa pleiotropic cytokine
73-74
 that was discovered 
in 1994 by JD Burton and KH Grabstein. IL-15 protein forms a 4-α helix structure that 
specifically binds with high affinity to IL-15Rα, but can also bind to IL-2Rβ and IL-2Rγ
73-
77
. The IL-15 gene consists of 9 exons and 8 introns. When translated, the IL-15 protein 
is 114 amino acids (aa) long encoded from 4 exons and 3 introns containing structural 
similarities to IL-2
77
. IL-15 binds IL-15Rα with high affinity; the IL-15Rα contains a 
positively charged sushi domain that binds negatively charge IL-15
77-78
. Mouse IL-15 
shares 73% aa homology with human IL-15 and human IL-15Rα shares 54% aa 
sequence homology with mouse. While the human IL-15Rα sushi domain which actively 
13 
 
binds ligand IL-15 shares an 85% aa sequence homology with mouse IL-15 sushi 
domain
77,79-80
.  
IL-15 and IL-2 share many activities, but differ in functional properties of the 
immune system
74,76-77
. IL-2 is mainly a modulator of T cells
77,81
, while IL-15 protein is a 
potent producer of NK cells
77,82
, IFNγ, CTL effector cells and most importantly 
maintaining the survival of memory CD8+ T cells. IL-15 messenger RNA is expressed by 
dendritic cells (DC)
77,83
, monocytes
77,84
, macrophages
77,85
, fibroblasts
77,86
, epidermal 
skin cells, keratinocytes
77,87
 and epithelial cells such as lung, heart, kidney
77,88
, nerve 
cells
77,89
, skeletal muscle, and placenta
74,77
 IL-15 protein is expressed by epithelial cells 
77,87
, fibroblasts
77,86
, monocytes
84
, and DC
77,83
. Although, IL-15 is ubiquitously 
expressed it is difficult to detect because IL-15 is tightly regulated at the level of 
translocation, transcription, translation, protein expression, intracellular trafficking, and 
secretion from the golgi apparatus
77,90-97
. There are two alternatively spliced isoforms of 
human IL-15 expression that exist, there is long signal peptide (LSP) that measures 48-
aa and short signal peptide (SSP) measuring 21-aa
77,90,94,98-100
. Human IL-15 isoforms 
differ from mouse IL-15 isoform measuring 26-aa in length even though they share a 
73% aa sequence homology
77,79,98
. The IL-15 SSP is sequestered and stored 
intracelluarly in the cytoplasm while IL-15 LSP is found in the golgi, leading to secretion. 
The role of IL-15 SSP has been elucidated as a type of autocrine regulatory signal that 
binds to IL-15Rα in the nucleus and regulates IL-15 gene transcription. Messenger RNA 
for IL-15Rα is also expressed by many cell types including B cells, NK cells, T cells, 
macrophage, bone marrow and thymic cells, kidney, lung, heart, skeletal muscle, brain, 
intestine, and liver
77,79,101-105
. When IL-15 binds to IL-15Rα, cells show low levels of 
signal transduction by the receptor
77,106-108
, in turn when IL-15 binds to IL-2Rβγ there is 
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an increase in signaling transduction. IL-2Rβγ recruits JAK kinases and activates STAT 
transcription. The phosphorylated STAT proteins translocate to the nucleus and 
activates gene expression of inflammatory responses, which signals differentiation and 
expansion of T cells
77,109-111
 (Figure 2).  
IL-15Rα exists in two forms, membrane bound and soluble. The cleaved soluble 
form was detected in the mouse serum and cell supernatant from cultured human 
glioblastoma and mouse fibrosarcoma
77,80,112-113
. IL-15 has a short half life due to down-
regulation by monoctye or dendritic cell’s negative feedback inhibition pathway
77
. 
Soluble IL-15Rα acts as an agonistic binding IL-15 to prolong its half-life and regulates 
IL-15 concentration within a tissue over a period of time
77,114-115
. On the other hand, 
constitutively expressed membrane-bound IL-15Rα can act as an antagonist by binding 
soluble IL-15 through an autocrine pathway regulating excessive stimulation of IL-15 
signaling and limits activation
77,112-113,115
 (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: IL-15 Signaling and Stimulation of the Immune Response  
(Figure Referenced in Literature
74-86,109-131
). 
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IL-15 shares some of the same signaling pathways with melanoma, aiming to 
sustain tumor growth and reduce apoptosis. These pathways including Src family 
kinases PI3K and AKT, anti-apoptotic BCL-2, AP-1, and Ras/Raf/Mek/MAPK
106
. More 
importantly, IL-15 stimulates pro-inflammatory pathways NF-κB, to target tumor cells  
such as melanoma
77,106,110
. This information could help elucidate why IL-15 is so tightly 
regulated when stimulated by immune effector cells. Membrane associated IL-15/IL-
15Rα complex expressed on monocytes allows for trans endosomal recycling to 
enhance memory CD8+ T cell stimuli
77,116-117
 or trans-presentation of IL-15 to stimulate 
adjacent CD8+ T cells and NK cells
77,105,118-119
. It is suggested that this is the main 
signaling function of IL-15Rα during trans-presentation and up-regulation of the adaptive 
immune response and memory response
77,105,119
 (Figure 2). 
 
IL-15 Stimulates the Immune Response 
IL-15 induces a strong innate immune response recruiting DC, macrophage, NK 
cells, augments INFγ production, and in turn up-regulates the adaptive response by 
enhancing costimulatory molecules CD40, CD86, MHC class I, CD8 T cells CTL, MHC 
class II CD4+T cells, Th1 cytokines, and ultimately promoting the production of long 
lasting CD8+ T cell memory immune response against the antigens of interest
77,83,120-
122
. IL-15 expands, stimulates functional activities and maintains balance of NK and 
survival of memory CD8+ T cells
77,81-82,93,123-124
. IL-15 also regulates B-cell survival and 
proliferation. B cell follicular DCs produce IL-15 which promotes the production and 
secretion of IgA, IgG and IgM by CD40L activated B- cells
77,125-126
. IL-15 produced by 
monocytes up-regulate proinflammatory cytokines IL-6, IL-8, TNFα
77,112,127
 which 
increases phagocytosis, inhibit neutrophil and eosinophil apoptosis
77,128
. IL-15 also 
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enhances mast cell development and proliferation
77,129
 and up-regulates adjacent 
monocyte production of cytokines IL-12
77,130
, IL-8, and chemokines MCP-1
77,131
 to 
promote neutrophil phagocytosis of pathogen infection for the body’s protection
77,108 
(Figure 2).  
IL-15 is also expressed by non-immune cells like fibroblasts, epithelial, 
endothelial, muscle cells, adipocytes, osteoclasts, neuronal and glial cells
77
. IL-15 
functions to protect these cell types from apoptosis, stimulates proliferation pathways, 
supports microglial growth, T cell migration in endothelium, reduce proteolysis in skeletal 
muscle, weakens nitric oxide production from microglial cells, stimulate angiogenesis 
and inhibits lipid deposition
77,132-137
. 
IL-15 has many useful qualities for clinical therapies to promote or inhibit 
signaling in many diseases and disorders. It is important to regulate IL-15 expression 
because over production of IL-15 can lead to hypersensitivity, tissue damage and 
autoimmunity
77
. Currently, IL-15 is being used as a target to ameliorate difficulties 
patients face with rheumatoid arthritis, Lupus, inflammatory bowel disease, diabetes type 
1, hypertension, muscle degeneration, and B-cell lymphoma
77,135,138-145
. IL-15 protein is 
ubiquitously expressed and it can bind more than one receptor IL-15R and IL-2R. IL-15 
signaling can be presented in many forms such as a free soluble protein, soluble 
receptor bound, or membrane receptor bound. This suggests that regulatory 
mechanisms of IL-15 can serve as a good mediator to control therapeutic mechanisms 
against aggressive form of melanoma
77
.  
 
Significance 
Melanoma and other cancers have the ability to increase immunosuppressive 
genes expression, decrease their adhesive properties, lose MHC expression and lose 
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expression of T cell co-stimulatory molecules, enhance tumor progression, and build 
Tcell tolerance against an immune response that could up-regulate effector cells to 
target tumorogenic epitopes22. It is predicted that a gene therapy approach can promote 
sufficient levels of a particular cytokine from the transfected cells to stimulate and restore 
the body’s own natural defenses to destroy cancer cells. By controlling levels of the 
cytokine it is possible to induce an immune response that recognizes tumor burden, 
promotes apoptosis, CTL response, and memory response while reducing the potential 
toxicity often associated with cytokine therapies performed with recombinant protein. It 
has been previously demonstrated in both preclinical and clinical IL-12 studies that an 
effective cytokine therapy against melanoma could be established utilizing EP to induce 
an appropriate immune response with minimal toxicity
28,146,147
.  
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OBJECTIVES 
 
The long-term goal of this study is to establish an immunotherapy using a non-
viral gene delivery approach to specifically target advanced-stage cancer cells like 
melanoma
28
. Although gene therapy is a relatively young field, it is a promising system 
to treat existing disease
24-25
. The purpose of the project is to establish a gene therapy 
technique entailing the delivery of a gene encoding cytokine human IL-15 using EP into 
an established mouse melanoma B16.F10 tumors. It is anticipated that the delivery of 
pIL-15 will stimulate an innate and adaptive immune response removing existing disease 
and adapting a protective response against continuous tumor antigens
31
. The short-term 
goal is to characterize EP delivery methods using mouse melanoma B16.F10 and 
human keratinocytes HaCaT cells in vitro prior to translating the delivery parameters in 
vivo. Melanocytes, melanoma and keratinocytes contain functional properties shared by 
both human and mouse providing a useful alternative for testing delivery conditions in 
vivo. There are no known macroscopic free-floating tumor models that can adapt EP 
electrodes for delivery experiments
59
. The in vitro 3D model will be used to examine 
delivery conditions and compare results to an in vivo C57BL/6 mouse model for the 
delineation of further treatment options in vivo. The objective of using a mouse model is 
to determine the type of immune response attained during EP delivery of IL-15 directly 
into tumor cells.  
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Hypothesis  
The hypothesis of the following project is the 3D tumor model does mimic natural 
cellular properties that will provide a platform to establish EP delivery conditions in vitro 
and translate delivery conditions in vivo. Delivery of IL-15 by EP in vivo will recruit 
effector cells to the tumor site causing tumor regression and promote a long-term 
immune response during secondary tumor challenge.  
 
Specific Aims 
Specific Aim 1: 
To develop a three-dimensional tumor model that could be used to evaluate gene 
transfer procedures and to examine cell to cell interactions. 
 The work in Aim 1, included generating an in vitro 3D tumor model to study 
delivery of different genes using EP to identify the best transfection efficiencies attained 
when delivering into tumor cells and skin cells. The EP conditions were tested amongst 
different cell types HaCaT, B16.F10 and human melanoma SKMEL-5 to examine the 
differences in gene expression. To ensure positive delivery of genes into the cells of the 
in vitro 3D model and to measure transfection efficiency, green fluorescent protein (GFP) 
and IL-15 were separately delivered at different EP conditions by varying electric field 
(EF) strengths, pulse duration and pulse number. The highest protein production 
obtained in vitro was then compared to patterns of transfection efficiency and protein 
production in mouse subjects. The 3D tumor model is a useful template to identify 
practical EP conditions and applicators that provide optimal transfection efficiency of 
genes into different cell types residing in a synthetic microenvironment. The 3D model 
helps predict how cells behave when subjected to gene delivery techniques and 
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translates observations of delivery in vivo to target melanoma. The model was used to 
not only translate delivery parameters in vivo, but more importantly reduce the animal 
subjects for gene delivery trials. Essentially, the purpose of designing a delivery system 
is to develop an immune adjuvant system that stimulates inflammatory responses 
against disease targets and prime surveillance cells for continuous recognition of 
specific epitopes.  
 
Specific Aim 2: 
To evaluate the intra-tumor delivery phIL-15 and the resulting protein expression to 
determine if expression of IL-15 would promote tumor regression and enhance mouse 
survival in an aggressive mouse melanoma model. 
The work in Aim 2, used the information gathered from preclinical studies
28
 and 
the 3D tumor model to further test delivery conditions in vivo. The purpose was to deliver 
a plasmid encoding human IL-15 (phIL-15) using EP into established melanoma tumors 
and determine by ELISA, the expression levels obtained at different time points. Also, 
test differences in transfection efficacy between tumor cells and skin cells when 
delivering pmIL-12 and phIL-15 both in vivo. It is inferred that EP conditions producing 
the highest expression level would promote the strongest immune response that would 
cause tumor regression and increase mouse survival. Three different treatment (Tx) 
protocols (1Tx, 2Tx and 3Tx) were used to deliver  on different days to understand the 
type of expression levels produced from the tumor cells and implement the protocol that 
would potentially enhance effector activity that would lead to  tumor regression. 
Established tumors were treated with the 3Tx protocol and tumor volumes were 
monitored for 50 days. The surviving mice were challenged and monitored for an 
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additional 50 days to understand whether phIL-15+EP+ could potentially enhance a 
long-term memory response against secondary tumor inoculation. 
 
Specific Aim 3: 
To identify key immune effector cells and cytokines that were directly or indirectly 
stimulated following intra-tumoral delivery of pIL-15 using EP. 
The work in Aim 3, characterized the signals involved in up-regulating the innate 
and adaptive immune response against treated tumor cells. In this section, melanoma 
was established in mice and treated with either the empty backbone pVax or phIL-15 in 
the presence or absence of EP. The primary response to the treatment protocol was 
analyzed at different time points to discern the type of immune cells and cytokines 
present during stimulation. The following assays were performed ELISpot, 
immunohistochemistry (IHC) and Luminex bead array to determine the types of immune 
modulators present at the time of tumor regression and contribute to mouse survival. 
Late stage cancer therapies are scarce and new types of treatment regimens are 
needed to work quickly against aggressive cancers and prolong patient survival. EP 
delivery system is a promising technique to control immune response stimuli, mount 
one’s own immune response against existing disease and improve survival outcome of 
patients
26, 31
.  
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MATERIALS AND METHODS 
 
Cell Lines  
B16.F10 mouse melanoma cell line (ATCC, Manassas, VA) was used in the in 
vitro 3D tumor model and inoculated into the mouse model to form solid tumors in vivo. 
The human melanoma cell line SKMEL-5 (ATCC, Manassas, VA) was also used in the 
3D tumor model. Both cell lines were primarily grown in a T275 flask as a 2D monolayer 
of cells diluted 1:10, B16.F10 were supplemented with McCoy’s media and SKMEL were 
supplemented with DMEM containing 10% FBS (Atlanta Biologicals Lawrenceville, GA) 
and 0.2% Gentamycin (Mediatech, Cellgro, Manassas, VA, Mid Sci St. Louis, MO) 
HaCaT human keratinocytes used in the 3D model to form the scaffolding, were a 
generous gift from Dr. Mark Jaroszeski (University of South Florida, College of 
Engineering). The HaCaT cells were supplemented with DMEM media containing 10% 
FBS and 0.2% Gentamycin. HaCaT cells originated from an immortalized, transformed 
cell line that had the ability to adhere tightly to the flask and to grow without feeder cells 
148
. All cells were grown in an incubator at 37°C and 5% CO2 in humidified air. Cells were 
removed from flasks using trypsin 1x without EDTA (Atlanta Biologicals Lawrenceville, 
GA). Following removal from the flasks, trypsinized cells were neutralized with media, 
washed in DPBS (Mediatech, Cellgro, Manassas, VA) and kept on ice until utilized for 
the 3D model or inoculation in to the mouse model.  
 
 
23 
 
 
Plasmids  
The IL-15 plasmid,  a generous gift from Dr. David B. Weiner University of 
Pennsylvania College of Medicine, was cloned using human IL-15 construct (Sequence 
from Gene Bank, Accessory number NM00585) into pVAX1 cloning vector (Invitrogen, 
Carlsbad, CA) and was carried out by PCR amplification. The plasmid was engineered 
to enhance IL-15 protein expression
149
. The long signal peptide was replaced with an 
optimized leader sequence 18aa human IgE region to increase secretion levels of IL-15. 
IL-15 mRNA was also optimized by removing inhibitory up-stream AUGs start codons 
which normally contains 8-10 AUGs contributing to the tight translational regulation. 
Also, the replacement of a weak kozak sequence with a stronger kozak sequence 
designed to enhance protein IL-15 production was introduced into the plasmid
149-151
. 
The optimized human IgE IL-15 insert was ligated into a pVax plasmid containing 
kanamycin resistant gene, a constitutively active human CMV promoter, high copy 
number pUC Origin of replication and bovine growth hormone polyadenylation site to 
enhance bacterial growth
151
. IL-15 plasmid was used in the 3D model studies and in 
mouse studies. Green Fluorescent Protein pEGFP-N1 (GFP) was purchased from 
Clonetech (Palo Alto, CA) to study transfection efficiencies in the 3D model. The IL-15 
plasmid, the empty backbone p-Vax1 plasmids (control vector) and GFP were 
commercially prepared by Aldevron (Fargo, ND) to be endotoxin free. Commercially 
produced plasmids provide lot consistency between experiments. Prior to use, the 
plasmids were diluted to the appropriate concentration using sterile saline for each 
experiment.  
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3D Model System  
The High Aspect Ratio Vessels (HARVs) promote 3D cellular aggregation while 
suspended in a microgravity environment (Synthecon, Houston TX)
54-55
. These vessels 
rotate on their base at 1 gravitational force (1g) providing an optimal environment for 
cells to grow without restraint, experiencing minimal shear and interference by the vessel 
walls or disruption from the media. The bubble less system allows cellular expansion to 
occur in a state of free fall or solid body rotation while floating in media 
52,55-58
. The 
vessels are equipped with two luer locks ports and an easy access sampling port. The 
vessels contain a silicon membrane for passive diffusion of oxygen and carbon dioxide 
enhancing growth of cells
44, 57,153-154
.  
 
HARV Bioreactor Utilization  
For long-term use the bioreactor motor systems RCCS-1 or RCCS-4SCQ were 
disinfected with 70% ethanol and sporicide to prevent rust and contamination by 
microorganism into cultured cells. In the incubator, the vessels were fastened to the 
base and rotate in a clockwise motion. To promote aggregate formation, the HARV 
apparatus was set to 15-17 rotations per minutes (rpm) depending on the density of the 
cells placed into the HARV. The cells remained suspended in media during the rotation 
and experienced minimal interference. The pH and oxygen levels between the cells and 
media remained balanced because the silicon membrane allowed passive diffusion of 
oxygen and carbon dioxide. This even exchange of gases ensured viability of cells 
providing the necessary nutrients for cellular replication. 
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3D Tissue Culture  
3-5X106 cells of HaCaT were seeded into four T275 flasks (Falcon BD 
Biosciences Franklin Lakes NJ) grown in DMEM (MediaTech Manassas, VA) containing 
0.2% 50mg/ml Gentamycin (MidSci St. Louis, MO), and 10% Fetal Bovine Serum (FBS) 
(Atlanta Biologicals Lawrenceville, GA). After 2-3 days, confluent cells were Trypsinized 
1x with EDTA (Atlanta Biologicals Lawrenceville, GA), collected and viability was 
determined using trypan blue. On Day 0, 35-50X106 live cells were seeded into a HARV 
in a final volume, dependent on vessel of choice 10ml or 50ml. After 1-2 days HaCaT 
cells aggregated into a spheroid measuring approximately 1 cm diameter. The HARVs 
were initially set for 15 revolutions per minute (rpm) for 12h and then increased to 16.5-
18.0 rpm depending on size and shape of spheroid and stability of rotation. After 20-24h 
fresh media was replaced into the HARVs containing the aggregated cells. In parallel, 1-
2X106 B16.F10 or SKMEL-5 cells were seeded separately into two T275 flasks and 
harvested for injection on Day 2.  
 
Loading Cells into the HARV  
To load the cells into the HARV or to change media, both knobs of the luer locks 
were turned to the open position and a 14 gauge cannula was attached to a syringe 
containing HaCaT cells suspended in media. The syringe was fastened to one open port 
and then cells were slowly injected into the HARV. It was necessary to remove all 
bubbles from the vessel to prevent disruption to spheroid formation. This was achieved 
by injecting the media containing cells into one port of the HARV and then slowly tilting 
the vessel gently forcing the bubbles with a piston-like motion into an empty syringe 
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attached to the opposite port. An important factor when handling the vessels is to avoid 
increased pressure on the membrane
57
. 
 
Injection of B16.F10 into Spheroids  
A monolayer of B16.F10 or SKMEL cells were harvested from T275 flask, 
washed, counted using a hemocytometer and resuspended in a small volume to 
concentrate cells in about 2-10x106 B16.F10 cells per 25-50µl. A 28 gauge ½ inch 
needle was used to inject B16.F10 into HaCaT spheroids. Once HaCaT spheroid 
aggregates formed a 1cm diameter construct, the vessel was removed from the base 
and the spheroid was manipulated towards the sample port for injection of tumor cells. 
The adherent properties of the HaCaT cells allowed for the spheroid to accommodate 
the volume of the introduced melanoma cells. This displacement of volume was easily 
observed by a slight ballooning of the spheroid during the injection. The spheroid was 
durable enough to withstand one to three different injection sites, although one injection 
site was sufficient. The sample port was sealed again and additional media was added 
to the HARV removing excess bubbles. A mixture of two different media were used to 
promote the growth of melanoma and Keratinocytes, this included 70% McCoy’s and 
30% DMEM for B16.F10 or 70% MEM and 30% DMEM for SKMEL-5. 50% of the media 
was changed daily in the HARV. To avoid two media changes in one day the CO2 levels 
were decreased to 1.5-1.9%. The reusable HARVs were cleaned and sterilized after 
every use, per manufactures’ instructions (Synthecon, Houston TX). Briefly, the HARVs 
were soaked in autoclaved deionized water or nanopure water overnight, then the 
HARVs were soaked in 70% ethanol for 8-16 hours (hr), air dried, wrapped in foil and 
autoclaved at 105-110°C for 30 minutes (min). 
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Plasmid Delivery to 3D Spheroid  
As mentioned previously, the HaCaT scaffolding forms after two days, the stable 
spheroids were removed from the HARV and placed into a chamber slide (Fisher 
Pittsburg, PA). 500µl of fresh DMEM was used to coat the spheroid, concentrating the 
media around the delivery area. The EP electrodes were submerged in the media 
around the spheroid during delivery. A 25-gauge-5/8 inch needle 1ml-syringe (BD 
Biosciences Franklin Lakes, NJ) was used to inject spheroids with 50µl of a mixture 
containing 3-5X106 B16.F10 or SKMEL-5 and 1.0mg/ml of GFP or IL-15 plasmid. The 
EP electrodes were placed around the spheroid and pulsed at different EP parameters, 
6-plate electrode (6-PE) 1300V/cm 100µs 6 pulses (P), 500V/cm 20ms 6P, 4-needle 
100V/cm 20ms 12P, 4-plate electrode (4-PE) 100V/cm 150ms 8P or 200V/cm 20ms 8P. 
After EP, 1-2ml of media was added to the chamber slide, covered and placed into a 
1.5% CO2 37˚C humidified incubator. The spheroids were monitored and harvested 24h-
48h after transfection.  
 
Stability of 3D Model Construct  
HaCaT cells aggregate to form spheroids containing 50X106 cells forming about 1 
cm in diameter “tissue-like” construct after 24 hours (h). The peak stability for HaCaT 
spheroids occurs by 48h. The stability time points were determined by collecting 
observations for HaCaT spheroid formation up to 15 days (d).The peak stability for 
HaCaT spheroids injected with B16.F10 or SKMEL-5 cells was 4d after inoculation, 
totaling 6d for the heterogeneous spheroid. By Day 6, melanoma had grown within and 
amongst the HaCaT cells. Additionally, we observed that HaCaT spheroid aggregates 
residing alone in the HARV reached terminal differentiation after 5-7d; viability was 
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determined using trypan blue. HaCaT spheroids injected with melanoma remained 
stable in the HARV for up to15d. 
 
Double Staining Immunohistochemistry  
(IHC) Paraffin-embedded samples were stained to identify different cell types 
within the spheroid B16.F10, HaCaT and SKMEL-2. Spheroids containing proliferating 
B16.F10 or SKMEL-5 cells were fixed in 4% paraformaldehyde or 10% formalin (Fisher 
Pittsburg, PA) for at least 6-24h, processed and embedded in paraffin wax for 
preservation. Before staining, the samples were depariffinized using Xylene (Sigma-
Aldrich St. Louis, MO). The recipe for deparaffinization included dipping sections in 
coplin jars separately containing Xylene, 100%, 95%, and 80% ethanol washes then 
placed in a humidified chamber. The samples were enzymatically pre-treated for antigen 
retrieval using 0.4% Pepsin in 0.01M HCL (Sigma-Aldrich, St Louis, MO). After the 
incubation period, samples were rinsed with 1x phosphate buffered saline (PBS, Sigma 
St. Louis MO). It was necessary to include an endogenous peroxide quenching step 
containing 10% hydrogen peroxide in 30% methanol (Fisher, Pittsburg, PA) to avoid 
non-specific binding of secondary conjugated Strepavidin-HRP antibodies that react with 
diaminobenzidine (DAB). The sections were blocked with 2.5% normal goat serum 
diluted (Thermo Scientific, Waltham MA) in 1x tris buffered saline (TBS, Boston 
Bioproducts, Worcester MA) containing 0.1% BSA (Fisher Pittsburg, PA). For samples 
labeled with primary antibody of mouse anti-human AE1/AE3 (MAB3412 Milipore, 
Billerica MA) goat anti-mouse IgG bound to alkaline phosphatase AP (80200 QED 
Bioscience Inc. San Diego CA) was used as the secondary antibody. For rabbit anti-
mouse S100 (AB941 Millipore, Billerica MA) 2.5% bovine serum was used to block for 
the secondary antibody bovine anti-rabbit IgG HRP (sc-2370 Santa Cruz Biotech, Santa 
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Cruz CA). In this experiment, AE1/AE3 (1-10mg/ml) was diluted 1:100 in TBS + 
0.1%BSA and then the secondary antibody goat anti-mouse IgG AP was diluted 1:20 in 
TBS + 0.1%BSA. The samples were developed using Fast Red substrate chromogen 
developer solution, per manufacturer’s instructions (Thermo Scientific, Waltham MA). 
Briefly, 3ml of Napthol Phosphate Substrate was mixed with 1 drop 40ul of Liquid Fast 
Red Chromogen. All staining procedures were repeated incubating S100 (1:800) in 2.5% 
normal bovine serum. Then the samples were incubated with secondary antibody bovine 
anti-rabbit IgG HRP (1:20) in 2.5% normal bovine serum. A DAB substrate was used per 
manufacturer’s instructions one tablet 10mg was mixed in distilled water (Acros 
EASYtablets, Geel Belgium) to develop the stain. The sample slides were 
counterstained using Hemotoxylin (Sigma, St Louis MO), rinsed, mounted and slides 
were observed under a light microscope (Leica Wetzlar Germany). Negative controls 
were included to show specificity of the primary antibodies and the lack of nonspecific 
binding of the secondary antibodies. For example, the primary antibody was added to 
the slide but a secondary antibody that did not match was also added and showed no 
reactivity. 
 
TdT-FragEL DNA Fragmentation Detection and Immunohistochemistry (IHC) 
Assay  
The TdT-FragEL DNA Fragmentation Detection assay (Calbiochem San Diego, 
CA) was performed on paraffin embedded samples to identify cells undergoing cell 
death followed by a double IHC assay to specifically identify the cells that were 
undergoing apoptosis. The assay was performed per manufacturer’s instructions. Briefly, 
a positive and negative control was performed simultaneously with the assay. The 
positive control, DNAse I (Promega, Madison WI) intentionally nicked the DNA ends and 
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the negative control was absent of the TdT reaction mix. The samples on the slide were 
deparaffinized and rehydrated by immersing slides in Xylene and then in different 
concentrations of ethanol (Sigma-Aldrich St. Louis, MO). The sections were 
permeabilized using 2mg/ml of Proteinase K (Thermo Sci Waltham, MA) 1:100 in 10mM 
Tris pH 8, then blocked for endogenous peroxidases 30% hydrogen peroxide (Thermo 
Sci Waltham, MA ) in methanol (Sigma-Aldrich). The sections were equilibrated, labeled 
with TdT labeling reaction mix and conjugated with Strep-HRP and developed with DAB 
solution. Double IHC staining, the primary mouse anti-human AE1/AE3 antibody was 
diluted 1:200 in 2.5% normal goat serum (All chicken, goat and rabbit serum Molecular 
Probes, Carlsbad CA) and the secondary goat anti-mouse IgG AP was diluted 1:50 in 
2.5% goat serum. All slides were developed using Fast Red. Then, sections were 
incubated with primary antibody S100 goat anti-mouse (sc-7849 Santa Cruz Biotech, 
Santa Cruz CA) diluted 1:100 in rabbit serum. The sections were incubated with the 
secondary rabbit anti-goat IgG HRP (HAF017 R&D Systems, Minneapolis MN) diluted 
1:20 in rabbit serum and developed using DAB. Finally, the sections were 
counterstained with methyl green, mounted using permount (Fisher, Pittsburgh PA) and 
then observed under a light microscope. A methyl green counter-stain distinguished 
normal cells from apoptotic cells by producing a tan or blue-green stain for viable cells 
and a dark brown stain for dead cells. Viable cells were counted using an ocular lens 
micrometer at 200x Magnification (Mag). 
 
Double Immunofluorescence (IF) 
This assay was performed based on protocol described on the Cell Signal 
website (www.cellsignal.com/support/protocols/IF.html). Briefly, the sections were 
deparaffinized and rehydrated using xylene and ethanols. The antigen retrieval step 
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involved using 10mM of sodium citrate pH 6 in deionized water. The slides were placed 
in a coplin jar and heated in a water bath up to 87°C for 20min. The sections were 
blocked using cocktail blocking buffer mixed separately from different host serum. Total 
volume 25ml: mixed 2.5ml 10x PBS, 1.25ml normal chicken or rabbit serum, 21.25ml of 
deionized water were mixed, and 75μl of TritonX-100 (100%, Sigma St. Louis MO). A 
primary antibody cocktail was prepared separately and then combined on the slide; a 
10ml antibody dilution buffer was prepared using 400μl of 10x PBS, 3.6ml of deionized 
water mixed, 0.040g of Bovine Serum Albumin (BSA Fisher, Pittsburgh PA) and 12μl 
TritonX-100. Mouse anti-human AE1/AE3 was diluted 1:100 and goat anti-mouse S100 
(sc7849 Santa Cruz Biotech, Santa Cruz CA) was diluted 1:50 in dilution buffer. The 
cocktail of antibodies were incubated at 4°C overnight. The following day the slides were 
washed in 1x PBS, an additional wash was added 0.4M high salt 1x PBS solution to 
reduce background staining. The sections were blocked again to avoid non-specific 
binding by the secondary antibodies. The rabbit anti-goat IgG FITC was diluted 1:100 
and chicken anti-mouse IgG Rhodamine was diluted 1:100 (sc-2777 and sc-2861 Santa 
Cruz Biotech, Santa Cruz CA). The sections were washed with PBS and high salt PBS. 
The sections were also re-incubated with rabbit anti-goat IgG FITC diluted to 1:50 to 
ensure binding of this secondary antibody. The samples were mounted using 
vectashield medium (Vectashield, Burlingame CA) and excited at two different wave 
lengths Fluorescein Iso-thiocyanate 490/520nm and Tetramethyl Rhodamine 
Isothiocyanate 557/576nm for detection. A negative control was performed 
simultaneously with this assay. The primary antibodies were added but mis-matched 
secondary antibodies were used to check for cross reactivity. 
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Proliferation Assay and Extracellular Matrix Staining  
A double IHC was performed to stain for proliferating cells and cells synthesizing 
their own extracellular matrix. An Abcam (http://www.abcam.com) protocol was used to 
perform staining procedures. Briefly, slides were deparaffinized, rehydrated, antigens 
were unmasked using 20μg/ml of Proteinase K 30min 37°C and samples were blocked 
using straight goat serum plus 0.025% triton X. The slides were labeled with primary 
antibody Ki-67 1:200 (ab15580 Abcam Cambridge MA) or Fibronectin 1:200 (ab2413 
Abcam Cambridge MA) and then incubated with secondary antibody goat anti-rabbit 
IgG-HRP 1:20 (ab6721 Abcam Cambridge MA). The labeled samples were developed 
using DAB and then visualized under a light microscope. The slides were counterstained 
using AE1/AE3 1:200 and secondary antibody goat anti-mouse IgG AP 1:200 as 
mentioned above.  A negative control was tested along with the sample slides where the 
secondary antibody was tested for non-specific binding in the absence of the primary 
antibody. 
 
Odyssey Western Blots  
The western blot was performed using 4%-15% separating ready-gels and 
transfer blot apparatus (Biorad Hercules, CA) to detect the following protein markers E-
cad (MAB3199Z Chemicon Millipore Billerica, MA), Cyto-8 (sc-8020 Santa Cruz Biotech 
Inc Santa Cruz, CA) and Beta Actin (#4967 Cell Signaling Danvers, MA). Total protein 
concentrations was determined by BCA protein assay kit (Pierce, Rockford, IL).The 32µg 
of total protein was loaded into each well of the SDS gel and the odyssey’s  two color 
protein molecular weight marker ranging 10-250kDa. Proteins were separated using 
120V for 5mins then 110V for 55mins. The bands were transferred onto a Millipore 
33 
 
Immobilon PVDF Membrane (Licor Lincoln, NE) for 1hr at 110V. The membrane was 
blocked using Odysseys’ Blocking Buffer (Licor) for 1hr, and then incubated with primary 
antibody 1:2,000 E-cad or 1:500 Cyto-8 at room temperature (RT) on a shaker overnight. 
After 16-18h the membrane was incubated with 1:15,000 secondary antibody 0.5mg 
goat anti-mouse IRDye 800CW NHS Ester for 1hr (Licor). An Odyssey Infrared 
scanner/reader was used to detect fluorescently labeled bands. A New-Blot PVDF 
stripping reagent (All reagents and products purchased from Li-cor Biosci Lincoln, NE) 
was used to analyze the two different primary antibodies. Protein bands were normalized 
against 1:5,000 Beta Actin (Cell Signaling Danvers, MA).  
 
GFP Delivery  
To ensure delivery of GFP in the spheroid, spheroids were formed by day 2, 
injected with a mixture of (1.0mg/ml) GFP+ (2-3X106) B16.F10 and immediately 
electroporated. After 24h, spheroids were collected, snap frozen and sectioned. Sections 
were labeled with nuclear (1:1,000) DAPI to visualize all cells and then sections were 
analyzed for GFP expression using an Olympus microscope at 200x Mag. The images 
show that spheroids that received EP at 500V/cm and 1300V/cm.  
 
Immunofluorescence Frozen Sections  
Spheroids were collected at 24-48h, snap frozen and cryo-sectioned. Samples 
were labeled with 1:1,000 DAPI (Sigma-Aldrich St. Louis, MO) for 10mins, blocked with 
2.5% chicken serum (Thermo Sci Waltham, MA) for 1hr, incubated with primary antibody 
1:100 AE1/AE3 (MAB3412 Chemicon Millipore Billerica, MA) for 2hrs and then incubated 
with 1:100 secondary antibody chicken anti-mouse IgG Rhodamine (sc-2861 Santa Cruz 
Biotech. Inc. Santa Cruz, CA) for 1h on shaker at RT. An Olympus microscope with 
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camera was used to analyze GFP transfection. Leica Stereoscope with digital camera 
was used to analyze GFP transfected into spheroids macroscopically. 
 
Flow Cytometry Analysis of GFP  
Spheroid aggregates were pressed through a 40µm Nylon cell strainer (BD 
Biosciences Franklin Lakes, NJ) and viability was determined by trypan blue (Fisher Sci. 
Pittsburg, PA). For live/dead gating, 1-3X106 cells were incubated with 10µl of Propidium 
Iodide 250ug/ml (Immunochemistry Bloomington, MN) for 30mins and then sampled 
using the FACS Aria I to quantitate GFP expression between controls and transfected 
groups. 
 
Tumor Production  
Cultured B16.F10 cells were harvested, counted for >90% viability by trypan blue 
exclusion dye method and resuspended in sterile 1XDPBS and diluted to 20 X106 
cells/ml prior to mouse inoculation. Female 6-8week-old C57BL/6 mice from Jackson 
Laboratories (Bar Harbor, ME) were injected subcutaneously into the shaved left flank 
with 0.05 ml containing 1x106 murine melanoma B16.F10. Tumors cells were incubated 
in mouse for 6-10 days or until the tumor measured approximately 30-60mm3 in size. 
Mouse studies were performed to study IL-15 transfection efficiency, establishing 
plasmid concentrations, tumor treatment schedules, immune response stimulatory 
assays, regression studies and challenge studies. 
 
Tumor Treatment  
Mice were anesthetized during all treatments. Anesthesia was administered by 
placing animals into an induction chamber infused with a mixture of 3% isoflurane and 
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97% oxygen for several minutes. After animals were anesthetized, the mice were fitted 
with a standard rodent mask and continuously anesthetized with 2-3% isoflurane in 
oxygen. Each mouse was closely followed after EP treatment until fully recovered from 
anesthesia.  
Intra-tumoral treatments were performed as described; anesthetized mice were 
injected with 50µl of 1.0mg/ml-2.0mg/ml of phIL-15 or mouse pmIL-12 plasmid DNA in 
sterile saline. An applicator containing 6 penetrating electrodes was placed around the 
tumor slightly penetrating the skin for full contact. Tumor was immediately electroporated 
with the following conditions: 1300 V/cm of 100 µs 6 pulses (P) or 500V/cm 20ms 6P 
using a six needle array. The six needle array was selected based on previous studies 
demonstrating that this electrode design was able to pulse in six different directions 
encompassing the entire area of the tumor (39). 
C57BL/6 mice were intra-dermally injected with phIL-15 or pmIL-12 and 
immediately electroporated using a 4-PE with 100V/cm 150ms 8p and 200V/cm 20ms 
8P conditions. All samples were collected after 12h, 18h, 24h and 48h; snap frozen and 
stored at -80˚C until processed for ELISA analysis. The mouse IL-12 plasmid was used 
to confirm EP parameters and compare transfection efficiency and protein production 
levels between cytokine plasmids. Tumor and skin samples were tested, to understand 
cytokine delivery outcomes between different tissue types using multiple EP conditions. 
 
Tumor Measurements  
To determine initial tumor volume and monitor tumor regression, tumors were 
measured prior to treatments and at periodic intervals following treatment using a digital 
caliper. Volume was calculated using the following equation V=ab2 /6: where (a) is the 
longest diameter and (b) is the shortest diameter perpendicular to (a). The tumor volume 
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+/- standard deviation (S.D.) was calculated for each group at each selected time point. 
The mice were followed up to 50 days or until the tumor volume reached 1000 mm3.The 
mice were humanely euthanized with CO2 under vivarium staff supervision. 
 
ELISA  
Levels of IL-15 were obtained using a monoclonal human IL-15 Quantikine kit 
(D1500 R&D Systems Minneapolis, MN) and ELISA performed following the 
manufacturer’s instructions. Spheroids and media were collected from the 3D model and 
snap frozen. Retro-orbital bleeding was performed on mice under anesthesia for serum 
collection and the mice were humanely euthanized for the collection of tumor samples. 
Tumors were snap frozen and stored at -80˚C until analyzed. The sample were thawed 
on ice, weighed, diluted in 500µl-800µl of phosphate buffered saline (Omnipur 
EMD4Biosci Darmstadt, Germany) plus Protease Inhibitor Cocktail (Roche Brandford, 
CT) dependent on sample size and homogenized using a PowerGen 700 (Fisher 
Scientific Pittsburg, PA ). The homogenate was centrifuged at 1000rpm for 5 minutes at 
4˚C and the supernatant was assayed the same day by colorimetric analysis to measure 
differences in protein levels. Serum levels were calculated as pg of cytokine per ml of 
serum (Average pg/mL). Cytokine levels were calculated as pg of cytokine per weight of 
tumor (Average Total pg/0.1g). 
 
Western Blot  
Tumor and serum samples were collected to test production of human IL-15. 
Hong Yang M.D. performed western blot analysis for phIL-15 expression following intra- 
tumoral delivery using EP. BCA assay was used to test total protein levels of 
homogenized supernatant. To a 15% separating gel, 40µg of each sample was added to 
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the wells. The samples were initially separated at 80V for 30 mins then 160V until 
molecular weight marker separated on the gel. The gel was wet transferred to 
nitrocellulose membrane (Bio-rad) by electrophoresis at 130V for 1 h. The membrane 
was blocked for 1hr at RT shaking in 3%BSA then incubated 1:5,000 rabbit anti-human 
IL-15 polyclonal antibody (PA0672 Cell Sciences Canton, MA) overnight in 3% BSA. The 
following day the membrane was washed and incubated with 1:1,000 secondary bovine 
anti-rabbit IgG HRP (sc2370 Santa Cruz Biotech Santa Cruz, CA) in 5% milk for 1h. 
Protein levels were normalized against internal control rabbit anti mouse β-actin (4967 
Cell Signaling Canton, MA) 1:1,000 in 5% milk 1hr and 1:5000 goat anti-rabbit IgG HRP 
(ab6721-1 Abcam Cambridge, MA)for 1hr. Developed the membrane using Super Signal 
West Pico chemilluminescent substrate solution (Thermo Sci Pittsburg, PA) for 5 mins, 
blot then expose to film 30s-1min. 
 
Frozen Immunohistochemistry  
Tumor samples were collected from mice and fixed in zinc fixative (BD 
Pharmingen BD Biosci Franklin Lakes, NJ) at room temperature for 2hrs up to 24hrs. 
Then samples were embedded in OCT (Tissue Tek Dublin, OH), snap frozen on dry ice 
and stored at -80°C until cryo-sectioning. The blocks were kept at -16 to-23°C during 
sectioning, the blocks were sectioned 7-10µm, fixed in cold acetone, then stored at -
20°C until staining. The samples were removed from -20°C, air dried for15-30mins and 
then marked with a pap pen (Biogenex optiplus Hyderabad, India).Sections were rinsed 
fixed tissue with TBS 2x for 10 mins in humidity chamber with gentle agitation at room 
temperature on a shaker at 50 rpm. Sections were blocked with 5% normal rabbit 
serum/TBS for CD4/8+T cells, or goat serum/TBS for NK at  room temperature for 1hr. 
Samples were also blocked with Avidin/Biotin kit for 15mins each (SP 2001 Vector Labs 
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Burlingame, CA). Primary antibody was added 1:20 purified rat-anti-mouse CD8a 
IgG2aκ (550281 Clone 53-6.7 BD Pharmingen), 1:20 rat anti-mouse CD4 IgG2aκ 
(220280 Clone RM4-5 BD Pharmingen) or 1:10 anti-mouse CD49IgM κ pan-NK-ells 
NK1.1 (108902 Clone DX5 Biolegend San Diego, CA) for 1hr. Washed then incubated 
with 1:250 secondary antibody IgG rabbit biotinylated antibody (BA-4001 Vector Labs) 
for CD4+ and CD8+ or 1:1,000 mouse absorbed affinity purified secondary antibody 
biotinylated Goat Anti-rat IgG, IgM, IgA (612106130 Rockland Gilbertsville PA) for 1hr. 
Washed then incubated in enzyme 1:300 Alkaline phosphatase streptavadin (SA-5100 
Vector Labs) or 1:100 Enzyme Horseradish peroxidase streptavadin 1:100 for 15mins 
(SA-5004 Vector Labs). Washed and then incubated in Alkaline phosphatase substrate 
kit red or blue for 7-8mins (SK5100 or SK5300 Vector Lab Burlingame, CA) or DAB kit 
Easy Tablets. Rinsed with DiH2O and counterstained using methyl green for 1-2 mins 
(H-3402 Vector Labs). Washed with tap water and dehydrated with ethanols, dried and 
mounted using a permanent mounting media (H5000.Vector labs). 
 
Luminex Bead Assay  
Milliplex (Millipore #MPXMCYTO-70k Billerica, MA) bead assay was used to test 
multiple cytokine stimulation from tumor and serum samples. These beads were 
purchased as a 10-plex kitassay measuring expression levels of specific antibody beads 
including INF-, TNF-, GM-CSF, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-12, and MIP1β. The 
color coded polystyrene beads bind to an unknown amounts of cytokines and quantified 
by Luminex xMap software analysis. Briefly, as per manufacturer’s instructions, 96-well 
plate is prepared by pre-wetting the filter plate using 200μl with wash buffer then vacuum 
filtered. Normalized samples were diluted for the assay and kept on ice. 25μl of 
standards, controls were added to 25μl of assay buffer. Matrix buffer PBS+PI was added 
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to the sample wells, then 25μl of samples were added to the wells, and finally 25μl of 
premixed beads were added to all wells. The plate was incubated on a shaker at 500-
800 rpm overnight, The next day, plates were washed and vacuumed, 25μl of detection 
antibodies were prepared and added for 1hr with shaking and then 25μl Streptavidin-PE 
was added directly to detection antibody for 30mins with shaking. The plate was then 
vacuum filtered. The beads were resuspended in 150μl of sheath fluid and then the plate 
was read on the Luminex. 
 
ELISPOT Assays:  
Spleen and PBMCs were collected at different time points to determine specific 
anti-tumor responses following treatment with various protocols.  Response was based 
on IFNγ production ex vivo following stimulation with tumor antigens. ELISpot assay was 
performed as per manufacturer’s instructions (R&D Systems Minneapolis, MN). Briefly, 
the day after the last therapeutic injection of IL-15 plasmid, samples were collected, 
prepped for cell culture, red blood cells were lysed with ACK (Quality Biologicals 
Gaithersburg, MD) and washed. The cells were counted using typan blue, a total of 
2X106 PBMCs isolated from blood and 30X106 splenocytes isolated from spleens. The 
cells were placed in 24-well plates and incubated overnight to stabilize cells. The next 
day 300,000 PBMCs and splenocytes were transferred to 96-well V-bottom plates with 
media and stimulated with target 30,000 B16.F10 cells for 4-6 days. The 96-well plates 
were coated with antibody IFN-γ on day 3 or 5 (SEL485 R&D Systems) then blocked at 
RT for 2h. After appropriate incubation and washing, the effector and target cells were 
added to membrane plates containing IFNγ and incubated for overnight in the incubator 
at 37˚C 5% CO2. The plates were washed the following day and then incubated with 
appropriate detection antibody overnight at 4˚C. The plate was washed on the following 
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day and then developed using a strepavidin-alkaline phosphatase/substrate system 
(SEL002 R&D Systems). Positive control concanavalin A (Sigma Aldrich) and 
recombinant protein IFNγ (Peprotech Rockhill, NJ) were tested and media served as a 
negative control.  
 
Statistical Analysis  
The results were analyzed using SPSS (IBM Chicago, IL) software to examine 
significance between treatment groups and controls samples using a two different tests. 
In the in vitro 3D tumor model experiments a one-way ANOVA post-hoc LSD test was 
utilized for statistical analysis. In the in vivo mouse model measuring phIL-15 and mIL-12 
expression a two- tailed Student’s t-test was utilized for statistical analysis. The data was 
graphed based on the groups mean and standard deviation. 4-6 independent 
experiments were performed depending on the assay. Results were considered 
significance at p≤0.05. The experimental variation was analyzed using standard 
deviation and fold change was compared between the mean of each group tested. 
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RESULTS 
Specific Aim 1 
To develop a three-dimensional tumor model that could be used to evaluate gene 
transfer procedures and to examine cell to cell interactions. 
 
The purpose for developing and utilizing an in vitro 3D tumor model was to 
evaluate EP conditions that efficiently deliver plasmids into specific cell types and in turn, 
promote gene expression by the cells’ own transcription/translation factors. The work 
performed in Aim 1 was focused on creating the 3D tumor model, testing the model’s 
stability, cellular functionality and over all applicability. The goal was to use the 3D tumor 
model to develop gene delivery techniques in vitro and translate those methods in vivo 
to develop a treatment regimen that would induce an immune response against 
melanoma. The objective was to grow a large synthetic tumor model (spheroid) to test 
plasmid delivery in vitro and compare results to preliminary studies in vivo and evaluate 
transfection efficiency and efficacy of delivery parameters. The advantage is that this 
model would reduce the number of animal subjects otherwise needed to test several 
preliminary plasmid delivery conditions. 
Many different methods have been used to generate 3D tumor models in 
particular to study melanogenesis. Several different methods have been attempted to 
generate a large-scale 3D tumor model. A few techniques that were assessed include 
the liquid overlay method
155
, matrigel/algi matrix (Gibco), cytodex/plastic beads scaffold 
(Sigma/Solohill) and extracel sponges (Glycosan).  
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The liquid overlay method consists of an agar/collagen platform that surrounds 
cells to help stimulate 3D growth and enhance proliferation of cells in a non-adherent 
matrix (Figure 3). Solidified agar coats the bottom of a plate keeping adherent cells such 
as B16.F10 cells from attaching. The cells are then coated with a collagen matrix that  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Algi Matrix containing B16.F10 
sampled after 17days in culture. Size: 
375µm. 
Figure 3: Liquid Overlay Method 
containing B16.F10 sampled after 26 
days in culture. Size: 500µm. 
Figure 5: Cytodex Beads Scaffold 
B16.F10 sampled from HARV after 
adhering to beads and expanding for 10 
days. Size 619µm. 
Figure 6: Plastic Beads Scaffold 
B16.F10 sampled from HARV 
aggregating after 10 Days. Size 407µm. 
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polymerizes around the cells to act as an extracellular matrix that supports cellular 
aggregation and migration. The system promotes collective “tissue-like” growth of cells 
in an artificial environment without the need of biological stimulus. It was observed that 
B16.F10 cells tend to adhere to one another stimulating continuous proliferation and 
expansion until they form a melanoma mass. In nature, aggressive growth of melanoma 
needs the presence of a germinal layer for mass formation and cellular expansion. The 
liquid over lay method thus provides this matrix and substitutes as a scaffolding, 
extracellular matrix, or basement membrane to promote proliferation and differentiation. 
The matrix facilitates adherent cells communication for cellular development. In this 3D 
method, cells aggregate and form several small tumor mass populations on top of the 
agar, but were limited to µm in size even after a month in culture. The separate 
populations formed small mass about 250-500µm in diameter over a 3-4 week period. 
The cells behaved similar to melanoma in nature because the aggregated cells formed 
masses that contained viable cells towards the outside and necrotic cells towards the 
center. Although, the isolated populations did not aggregate towards each other to form 
one large mass, they formed several small populations. The cells did form a 3D tumor 
system similar to in vivo tumors, but expansion rates were slow. This approach was 
Figure 7: Sponge Matrix Scaffold B16.F10 sampled from the HARV aggregating 
after 49 days. Size 750µm. 
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deemed unsuitable as the goal was to generate a tumor system that was about 1 cm in 
diameter to enable testing of delivery conditions using electrode applicators containing a 
1 cm gap. The objective was to administer electric pulses to enhance delivery to target 
cells or tissue in a manner that would simulate the in vivo procedure.  
Other methods were used to help promote cellular expansion and large-scale 
tumor mass formation in vitro. To enhance mass formation more cells were required to 
be present in the same location. Two methods were tested: the agar/collagen matrix and 
algi matrix. In both synthetic materials, the cells were pierced into the matrix. This 
allowed for more cells to grow together and expand more quickly in size. The idea was 
to increase the number of B16.F10 cells in a location to allow cells the opportunity to 
communicate, adhere to one another and expand into a tumor mass at a faster rate 
(Figure 4). The cells did aggregate and formed a 3D tumor model as suggested prior 
studies
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, but the size of the model remained too small to accomplish the goal of this 
study and for macroscopic manipulation. A few more matrixes were used to help 
promote larger cellular expansion such as an extracel sponge made of a polymer 
material that ensures expansion of cells, but was limited to µm in size. Experiments 
using the matrices described above were successful in promoting cellular aggregation of 
melanoma to a size of 50μm to 500μm. The techniques supplied useful information of 
3D modeling on a microscale. The matrices provided structure and scaffolding for 
cellular accumulation, but the aggregates were not solid and did not maintain mass 
formation, they were easily disturbed when manipulated or transferred. The other 
limitation was that cells needed to be in the same location and constantly bathed in fresh 
nutrients. Additional experiments were conducted to attempt to obtain tumor sizes closer 
to 1cm in diameter.  
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The necessity to keep cells close to each other was an important feature for 
cellular expansion and mass formation. The factors that possibly limited cellular 
expansion using the matrices was reduction in nutrient/oxygen availability to cells and 
possibly the act of embedding the cells into the matrix limited expansion. The key 
concepts for mass formation included continuous oxygen exchange, surplus supply of 
nutrients and cellular contact. A group of NASA scientists developed a bioreactor system 
(high aspect ratio vessel, HARV) that promoted large-scale cellular aggregation bathing 
cells in a large volume of fresh nutrients, while growing suspended in an oxygen-rich 
synthetic environment
57
. The HARV’s horizontal rotation exerts forces onto these dense 
particles and drives cells towards co-localization
56-57
.These researchers tested many cell 
types and found that cells aggregated into 3D constructs using homogeneous or 
heterogeneous cells populations
51
. The bioreactor provides a microenvironment suitable 
for cellular growth and development to facilitate natural cellular behavior. The next 
experiments utilized the bioreactor system to seed B16.F10 cells alone and use their 
own adherent properties to bind each other and promote mass aggregation. The 
bioreactors were also seeded with B16.F10 injected into sponge matrix, or grown onto 
plastic beads or cytodex beads to serve as a scaffold for cellular proliferation and mass 
formation  
B16.F10 cells were harvested and seeded onto cytodex dextrose coated beads 
(Figure 5), plastic beads (Figure 6) or extracel sponge(Figure 7) over night for 
adherence and then injected into the HARV. The use of cytodex beads, plastic beads or 
extracell sponge was to stabilize melanoma spheroid development (Figure 5-7). The 
cells were monitored for 10 days and up to 49 days. The beads facilitated mass 
formation and slightly increased aggregate stability during handling. The cytodex beads 
strongly adhered cells to the dextrose coating, but limited expansion by concentrating 
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cells to the beads themselves. The plastic beads and sponge matrix allowed slightly 
more cells to adhere to one another concentrating them into dense cellular populations, 
but again limited expansion because the construct was weak and cells would slough off 
into small sheets. The cells behaved as suggested by NASA/Synthecon bioreactor 
researchers forming a mass ranging from 600-700µm, but the magnitude and stability of 
the construct remained unresolved.  
B16.F10 cells were injected into the HARV without a scaffold or matrix and 
instantly these cells aggregated forming a tissue-like construct (Figure 8). The drawback 
of this method was that the cells were weakly attached to one another and were easily 
disrupted by stopping the HARV’s rotation or while changing media, leading to 
detachment of large cellular sheets from the mass. These observations led to the idea  
that cells must need a scaffold that would keep the cells in a stable mass formation. 
Based on the mechanics instilled on cells by the HARV, description in the literature on  
 
 
 
 
 
 
 
 
 
 
 
Figure 8: B16.F10 Cells Placed into 
HARV with No Scaffold. Loose cells 
were observed after 24h. 
Figure 9: HaCaT Aggregate. 
HaCaT cells placed into HARV forms 
a spheroid after 24h. Size 1cm. 
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Figure 10: Injecting B16.F10 and 
HaCaT into the HARV Simultaneously, 
formed two separate cellular aggregates  
after Day 2. 
the effects of the HARV has on adherent cells
56-57
 and the observations suggested that 
a biological scaffold would possibly provide the structure needed to maintain a stable 
aggregates containing melanoma cells that would enhance cell interaction and 
communication.  
 
 
 
The concept that melanocytes grow in the epidermis and that they are stabilized 
by keratinocytes gave the idea that adherent keratinocytes would act as the necessary 
scaffolding needed to promote adherent growth of melanoma cells. The human 
keratinocytes (HaCaT) were seeded in the HARV at many different concentrations 30-
60X106 cells/10ml. The HaCaT immediately aggregated into small and large sacs of 
cells or spheroids after 24hours (h) (Figure 9). The sacs of aggregated cells were tightly 
adherent to one another and the construct consisted of a smooth external layer, while 
the cells in the center were mostly loose and dense. Observing the cells under the 
microscope, the outer cells were sheets of tightly adherent cells and the cells in the 
center were smaller aggregates of HaCaT populations. These spheroids were so stable 
after 48h to 72h that interrupting the HARV’s rotation, changing the media or handling 
did not cause the spheroid to fall apart. These stable aggregates contained adherent 
Figure 11: HaCaT Layering Effect. 
Injecting B16.F10 and HaCaT into the HARV 
simultaneously and adding additional HaCaT 
cells every day for 6 days. 
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properties that formed the 3D construct measuring about 1cm in diameter (Figure 9). 
The spheroid was easily handled and had the potential to be used for plasmid delivery 
experiments. The large constructs remained intact when transferred from the HARV to a 
petri dish.  
To introduce the B16.F10 cells into the system and promote tumor mass 
formation, the HaCaT and B16.F10 were seeded into the HARV simultaneously (Figure 
10). The B16.F10 cells formed loose secondary aggregates that were unincorporated 
into the spheroids and were slightly adherent to the outside of the spheroid. Another way 
to incorporate B16.F10 cells into the HaCaT was to layer the B16.F10 cells with HaCaT 
by initially seeding a small amount of HaCaT, allowing spheroid formation and then 
B16.F10 incorporation. This process was repeated after 24h and thereafter, every 48h-
72h for 6 days (Figure 11). Unfortunately, the layering-effect also did not incorporate 
B16.F10 as well as expected. Both attempts at tumor mass formation were unsuccessful 
because B16.F10 did not incorporate into the system and enhance stability of the 
construct. The HaCaT spheroid did not form properly when B16.F10 were introduced. It 
seemed that when two populations of cells with different densities attempted to 
aggregate in the same space spheroid formation was less likely to occur. 
 
 
 
 
 
 
 Figure 12: B16.F10 Injection into 
HaCaT. 3-5X10
6 
B16.F10 injected into 
HaCaT spheroid by Day 2. 
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Since HaCaT alone spheroids were so stable, the thought was that the HaCaT 
may be able to withstand an injection of B16.F10 cells into the center of the spheroid 
(Figure 12). A total of 3-5X106 B16.F10 cells were injected into the HaCaT spheroid 
construct without losing its shape’s integrity. The spheroid stability after 24-72h was 
impressive; the spheroid was malleable, accommodated volume displacement during 
injections and was resilient to multiple needle punctures. The spheroid provided the right 
conditions for B16.F10 cells to expand within the HaCaT spheroid after 5 to 7 days 
(Figure 13-14). The tan colored cells were the HaCaT and the dark brown pigmented 
cells were the B16.F10. Figure 13 shows tumor spheroid in suspension and Figure 14 
shows a stable tumor spheroid transferred to a petri dish measuring about 0.9 cm. The 
construction of a 3D tumor model containing a heterogeneous population of 
HaCaT+B16.F10 cells was successfully developed. This is the first report of a large, 
free-floating 3D tumor model measuring about 1cm in diameter. The utilization of 
bioreactors provided the necessary qualities to promote heterogeneous cellular 
integration. 
 
 
 
 
 
 
 
 
 
 
Figure 14: Stability of HaCaT and 
B16.F10 Spheroid Measuring 
About 1cm, remained stable during 
transfer after a total of 6 days in the 
HARV. Size 0.9cm. 
Figure 13: B16.F10 and HaCaT 
Spheroid Residing in HARV 
remained bouyant and stable after a 
total of 6 days. 
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With the construction of an appropriate 3D tumor model, it was critical to test the 
3D model’s cell viability, proliferative properties, differentiation state, stability,  
communication, cellular interactions, functionality, and applicability. Cells viability was 
confirmed by paraffin embedded IHC. In Figure 15, an immunohistochemisty (IHC) 
analysis was performed on multiple paraffin embedded spheroid HaCaT+B16.F10 
samples. It was confirmed through histological evaluation by Jane Messina M.D.(H. Lee 
Moffitt Cancer Center Tampa, FL) that 80% of B16.F10 stained brown and HaCaT 
stained red, cells remained viable in this construct. Samples were injected with B16.F10 
on Day 2 after the spheroid was formed and 4-6 days later the HaCaT+B16.F10 were 
collected for staining. Dr. Messina confirmed that the cells’ nuclei were intact, cytoplasm 
was free of granules and model contained a 3:1 ratio of HaCaT cells to B16.F10. This 
indicated that the amount of B16.F10 cells grew rapidly over time making up one third of 
the construct, even though, initially, the spheroid contained 10 times more HaCaT cells 
than B16.F10 cells (Figure 15). 
Figure 15: Immunohistochemistry Viability Assay B16.F10 and HaCaT 
paraffin embedded and sectioned for pathologist analysis. Morphology and 
cell viability were analyzed after 6 days. Bar=20µm. 100x Magnification. 
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To provide further evidence of the viability of cells residing in the construct, TdT-
FragEL DNA Fragmentation Detection assay (TdT) and double IHC assays were  
preformed. TdT assay was performed to identify live from dead cells and IHC was 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: TdT and IHC analysis. B16.F10 and HaCaT sectioned for viability assay and stained 
with double immunohistochemistry. a. positive control DNAseI B16.F10 stained brown, apoptotic 
nuclei stained dark brown b. B16.F10 brown, HaCaT red viable cells stained tan, or blue-green, 
samples were collected 4-5 days after B16.F10 inoculation. Bar=100µm Magnification 400x. 
Figure 17: Double Immunoflourescence Orientation. B16.F10 and HaCaT cells were labeled 
with specific fluorescently labeled fluorophores. a. B16.F10 stained green in FITC channel, b. 
HaCaT staining red in TRITC channel. c. Merged image of B16.F10 and HaCaT, with enlarged 
magnification of a population of cells. Bar=200µm. 200x + 16x Magnification. 
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performed to show the specific cell types present such as HaCaT and B16.F10 (Figure 
16). Cells that were reactive to the TdT assay had stained dark brown nuclei and those 
that were non-reactive had tan or blue-green stained nuclei. To confirm the staining  
protocol a positive control slide was subjected to DNAseI enzyme, which nicked the DNA 
and allowed TdT labeling to bind free 3’OH groups and produce a dark brown stain. The 
nuclei that stained dark brown indicated that these cells were dead undergoing a pseudo 
apoptotic process (Figure 16a). The negative control showed that the nuclei of cells did 
not stain. In Figure 16b, the viable cells were stained tan or blue, were counted at 100x 
magnification, from 10 different quadrants, a total of 3 times from 3-4 different samples. 
It was observed that 80-90% of the B16.F10 cells and HaCaT cells remained viable after 
residing within the spheroid for 6-7 days (Figure 16b). These stained sections 
demonstrated that B16.F10 cells were proliferating and grouping together amongst the 
HaCaT cells forming isolated aggregates as though these cells populations were 
grouping to form tumor masses. 
Observations of the spheroid suggested that cells were interacting and 
communicating with one another.  A double immunofluorescence (IF) assay was 
performed to evaluate the spatial orientation of HaCaT cells relative to B16.F10 
tumorgenic cells (Figure 17). This particular spheroid construct was harvested 5 days 
after B16.F10 inoculation. Figure 17a, shows the fluorescent excitation of B16.F10 cells 
attached to S100 and conjugated Fluorescein Iso-thiocyanate (FITC) antibody bound 
fluorophore and Figure 17b shows excitation of HaCaT cells AE1/AE3 and conjugated 
Tetramethyl Rhodamine Isothiocyanate (TRITC) antibody bound fluorophore, each cell 
type fluoresced independently of one another. The final panel in Figure 17c shows the 
two images merged to analyze the amount of overlap that occurred between the two cell 
types growing in the HARV. The green fluorescently labeled B16.F10 cells were 
53 
 
surrounded by HaCaT and also integrated with HaCaT cells stained in red (single 
arrows). The B16.F10 cells appeared as though they were grouped in isolated 
populations as well as growing on top of the HaCaT cells (single arrows). The HaCaT 
cells appeared as though they were organized; flattening and stacking making up the 
walls of the spheroid, while B16.F10 grew on top of the HaCaT (triple arrows). A growth 
pattern and cellular arrangement amongst these cells were clearly identified in the 
pictures. B16.F10 cells appeared as though they were growing processes and beginning 
to display elongated morphological changes (Figure 18a). The development of cellular 
processes was also observed in a monolayer of cultured cell which indicated cellular 
growth and differentiation into mature cells types. Figure 18b represents a negative 
control of FITC in the TRITC channel to show specific fluorescent staining B16.F10 and 
Figure 18c shows both images merged. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Immunofluorescence B16.F10 Morphology. B16.F10 and HaCaT sectioned for 
3D cellular morphology analysis using specific fluorescently labeled fluorophores. a B16.F10 
demonstrating development of cellular processes b. negative control for FITC staining. c. 
Merged image of B16.F10 in the FITC and TRITC channel Bar=200µm. Magnification 200x. 
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Figures 16-18, provides initial evidence of active cellular proliferation, grouping of 
B16.F10 cells and possible maturation. To further confirm this type of cellular behavior, 
an IHC assay was performed on spheroid samples 3 to7 days after B16.F10 inoculation. 
The cells were stained using Ki-67 to identify whether B16.F10 cells were undergoing 
proliferation and to determine if cells are progressing through different phases of the cell 
cycle (Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The cells were stained and then analyzed at 200x for differential nuclei staining.  
Analysis of nuclei staining demonstrated different shades of brown (Figure 19b), 
indicating that B16.F10 cells were present at different phases of the cell cycle. The 
difference in staining ranged from dark to lighter nuclear staining (Figure 19b magnified). 
Although, the presence of differential nuclear staining was noted, additional nuclear 
Figure 19: Proliferation Assay. B16.F10 and HaCaT sectioned to identify cell cycle 
proliferation. a. negative control staining Bar=50µm 100X. b. Ki-67 staining and magnified picture 
of stained nuclei. Bar=100µm 200x + 16x Magnification. 
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staining assays are necessary to identify the specific cell cycle stage, this analysis was 
not performed
157
. A negative control was included to show that non-specific binding of 
Ki-67 was not observed (Figure 19a).  
The spheroids were also stained to identify whether B16.F10 cells proliferating in 
the spheroids had the ability to produce their own extracellular matrix. Another set of 
sections were stained with fibronectin antibody, a component of the extracellular matrix. 
fibronectin stains at the surface of cells as depicted in Figure 20. The AE1/AE3 specific 
staining displayed identifiable round cellular shape of HaCaT and the fibronectin 
antibody bound to the B16.F10 and HaCaT surfaces displayed an uncharacteristically 
matrix-like, fibrous shape surrounding the cells. A negative control slide showed that 
fibronectin antibody was specific to cell surface antigens. 
The 3D spheroid was used to promote growth, differentiation, and 
communication, between B16.F10 and the HaCaT scaffold. The next set of experiments 
performed were used to determine the model’s stability, potential to stimulate 
proliferation of a different cell line such as human melanoma SKMEL-5, understand the 
functional properties between melanoma and the HaCaT scaffold and to determine 
overall applicability of the model. It has been established that HaCaT cells aggregate to 
form spheroids after 24h
59
. These aggregates contain 50X106 cells forming a 1cm in 
diameter “tissue-like” construct and observations suggest that peak stability for 
replicating HaCaT spheroids occurs by 48h. The stability time points were determined by 
observing HaCaT spheroid formation over 15 days (d).The peak stability for HaCaT 
spheroids injected with B16.F10 cells is 4d after inoculation, totaling 6d for the 
heterogeneous spheroid. By Day 6, melanoma had grown within and amongst the 
HaCaT (Figures 13-15, Figure 17). To identify the 3D model’s ability to promote 
proliferation and aggregation of different cell lines, a human melanoma cell line, SKMEL-
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5, was injected into the HaCaT scaffold and monitored for 4-6d. The HaCaT and 
SKMEL-5 demonstrated the same stability and aggregation patterns as HaCaT and 
B16.F10. The viability of SKMEL-5 injected into spheroids was determined using the 
TdT-FragEL DNA Fragmentation Detection assay on paraffin sections (Figure 21). The 
SKMEL-5 cells were stained brown with melanoma specific antibody S100 and HRP 
conjugated secondary antibody. The HaCaT cells were stained red with keratinocyte 
specific antibody AE1/AE3 and AP conjugated secondary antibody to identify between 
the cells types. Nuclei that stained tan signified that cells were viable and the nuclei that 
stained dark brown indicated that cells had undergone apoptosis (Figure 21). The level 
of viability for the SKMEL-5 was >80%, similar to the TdT assay performed on B16.F10 
(Figure16) proliferating in spheroids
59
. During stability experiments, it was observed that 
HaCaT spheroid aggregates residing alone in the HARV reached terminal differentiation 
after 5-7d, viability was determined using trypan blue. However, the HaCaT spheroids 
injected with melanoma extended HaCaT cell proliferation and stability up to15d in the 
HARV. These observations suggest that terminal differentiation was delayed due to 
melanoma injection, evidence of these observations is provided in Figure 22. 
 
 
 
 
 
Figure 21: Viability Assay. SKMEL-5 
and HaCaT sectioned to analyze viability 
of human melanoma collected on Day 6. 
Bar=100µm 400x Magnification. 
Figure 20: Extracellular Matrix Analysis. 
B16.F10 and HaCaT sectioned to identify 
extracellular matrix production. Bar=100µm 
200x Magnification. 
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The 3D model demonstrated that two heterogeneous populations of cells could 
co-exist and form a viable and stable tumor model, but the functional properties were 
unknown. These IF sections illustrated also demonstrated dendrite-like processes 
radiating from melanoma cells when interacting with keratinocytes in the 3D model. This 
suggests a type of communication occurring between B16.F10 and HaCaT. To test the 
functional communicative properties of the B16.F10 or SKMEL-5 separately injected into 
the HaCaT spheroid construct, a western blot analysis was performed to identify up-
regulation of adherent proteins E-Cadherin (E-cad) and differentiating protein 
Cytokeratin 8 (Cyto 8) (Figure 22). The adherent proteins E-cad are known to be up-
regulated when keratinocytes and melanocytes or melanoma cells interaction. 
Keratinocytes promote melanocyte survival and controls melanoma proliferation and 
Figure 22: 3D Model Functionality Test. Testing the communication between HaCaT and 
B16.F10 by the up-regulation of adherent protein E cadherin and differentiation marker 
Cytokeratin 8. Samples were collected on Day 2 and 4. HaCaT alone was compared to 
HaCaT+B16.F10 or HaCaT+SKMEL-5. 
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invasion
14, 66
. The B16.F10 or SKMEL-5 were separately injected into HaCaT and then 
monitored 2-4d after inoculation, totaling 4-6d. Samples were collected on day 2 or Day 
4 after injection into the spheroid, homogenized and the supernatant was tested by the 
western blot to identify the up-regulation of cyto-8 and E-cad (Figure 22). Positive control 
MCF-7 breast cancer cells and negative control B16.F10 cells were collected from a 
monolayer of cultured cells to test primary antibody specificity and to detect protein 
expression. Each band was normalized against beta actin and fold-change (fold) was 
determined by comparing each melanoma inoculated spheroid group to control group 
HaCaT at Day 2 or Day 4. Cyto-8 differentiation marker presents consistently low band 
densities, <1-fold in groups HaCaT+B16.F10 and HaCaT+SKMEL-5 compared to 
HaCaT alone on Day 2 and 4. As predicted, there was a 2.3-fold up-regulation of 
adhesive protein E-cad in HaCaT+B16.F10 group at Day 2 and 1.9-fold increase at Day 
4. However there was slightly lower levels of E-cad expression <1-fold in 
HaCaT+SKMEL-5 group, as suggested in the literature there is a notable reduction in E-
cad expression in this cell line
158
. SK-MEL-5 does not up-regulate expression of E-cad 
even in the presence of keratinocytes, it is not clear in the literature, if this is due to an 
inhibitory mechanism. It was observed that the spheroid stability was reinforced while in 
the presence of HaCaT+melanoma compared to HaCaT alone. These observations 
were linked to the increased expression of adherent protein E-cad in HaCaT+B16.F10 
detected at Day 2 and reduction by Day 4.  The increase in E-cad was also linked to the 
decrease in differentiation marker Cyto 8 at Day 2 and Day 4 in HaCaT+B16.F10. It 
appears that melanoma had slowed HaCaT terminal differentiation to keep HaCaT cells 
receptive to melanoma signaling proteins and promote melanoma proliferation
59, 159
. 
Overall, comparing Cyto-8 to E-Cad there was a decrease in differentiation, but an 
increase in adherent protein when injecting B16.F10 into HaCaT. There were brighter 
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bands of E-cad and Cyto 8 proteins on Day 2 compared to Day 4, suggesting that 
protein production was controlled by keratinocytes at early stages.  
To evaluate the usefulness of the in vitro 3D model the delivery of plasmid DNA 
with electroporation (EP) into HaCaT and B16.F10 cells was tested. The transfection 
efficiency of plasmids into the spheroids using different EP parameters was also tested. 
To determine if there was difference in delivery and protein expression between the cell 
types, plasmid encoding green fluorescent protein (GFP) was delivered using EP to the 
3D spheroid containing only HaCaT cells. GFP expression was analyzed at 24h using a 
fluorescent stereomicroscope. The results indicated low GFP transfection levels in the 
HaCaT spheroids when delivered with a 4-needle penetrating electrode (4N) (Figure 
23a,b) and with a non-invasive 4-plate electrode (4-PE) (Figure 23c). The EP electrodes 
and conditions established for the skin were utilized because the HaCaT mimics 
epidermal cells sitting on the basement membrane in vivo
160
. Testing the skin EP 
conditions 4N 100V/cm 150ms 12 pulses (P) or 4PE 200V/cm 20ms 8P, on the spheroid 
did not result in the distribution or intensity level of GFP expression that was predicted. 
The GFP expression was produced near the surface of the spheroid and specifically 
those cells in close contact with electrodes (Figure 23b,c).  
In the next set of experiments, a mixture of (1.0mg/ml) GFP and 3-5X106 
melanoma in a 50µl volume was injected into a HaCaT spheroid to monitor differences in 
transfection efficacy with different EP parameters. Here, GFP was delivered using a non-
invasive 6-PE with EP conditions established for tumor
28
. Increased levels of GFP 
expression by melanoma cells were observed (Figure 23d-g) compared to the HaCaT 
alone spheroid in Figure 23b and Figure 23c. A good representation of GFP distribution 
and transfection efficacy was observed between the HaCaT and B16.F10 cells in vitro. 
Additionally, there was a difference in transfection levels when delivering 
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GFP+melanoma into the spheroid using different electrode applicators and EP 
conditions. For Example, 6-PE EP conditions including field strength of 1300V/cm, pulse 
width of 100µs and 6P demonstrated lower transfection efficacy than 500V/cm, 20ms 
and 6P. 
 
 
 
 
 
 
 
 
 
 
 
 
 
At GFP+1300V/cm (Figure 23d), expression was concentrated in two small locations and 
at GFP+500V/cm many more cells were found to express GFP mainly near the point of 
injection and some cells opposite the site of injection/EP (Figure 23e-g). 
The stereoscopic pictures indicate a difference in delivery and expression 
between HaCaT and B16.F10. Delivery of GFP+melanoma was further analyzed for 
GFP expression and distribution by cryosectioning frozen spheroid samples and staining 
with DAPI (Figure 24). 
Figure 23: GFP Transfection into HaCaT and HaCaT plus B16.F10. a. HaCaT cells 
alone, injection of reporter gene GFP and EP with 4-needle electrode. b. HaCaT GFP 
expression at 4-needle electrode puncture EP 100V/cm 150ms 12P. c. HaCaT GFP 
expression using 4-PE 200V/cm 20ms 8P. d. GFP expression in B16.F10+HaCaT 6PE 
1300V/cm 100µs 6P. e-g. GFP expression HaCaT+B16.F10 500V/cm 20ms 6P.  
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Sections were analyzed with an inverted fluorescent microscope and the sections 
demonstrated that there was an increase in GFP expression. There was an increase in 
GFP expression near the surface and towards the center of the spheroid and an 
increase in GFP distribution with the GFP+500V/cm group (Figure 24 a,b,c) than with the 
GFP+1300V/cm group (Figure 24 d,e,f) 
 
 
 
 
 
 
 
 
 
 
 
. Although there was visual evidence that there was an increase of GFP expression and 
distribution in the highest expressing groups GFP+500V/cm, it was not clear which of the 
cell types HaCaT, B16.F10 or both were actually expressing GFP. To differentiate GFP 
expression between HaCaT and B16.F10, HaCaT+B16.F10 spheroids were 
electroporated at GFP+500V/cm and collected after 24h, snap-frozen and cryo-
sectioned for immunofluorescent staining (Figure 25a). Sections were labeled with DAPI 
for all nuclear staining and HaCaT were stained with AE1/AE3 and conjugated red 
fluorescent antibody TRITC for contrast. The negative slides showed no auto-
fluorescence of the cells in the FITC (Figure 25b) or TRITC (Figure 25c) channels. The 
Figure 24: GFP Distribution Analysis. HaCaT+B16.F10 sections analyzed 
for distribution: Injection of reporter gene GFP and EP a. Spheroid 500V/cm 
20ms b. Section 500V/cm 20ms 6P Bar=200µm c. Section 500V/cm 20ms 6P 
Bar=200µm d. Spheroid 1300V/cm 100us 6P e. Section 1300V/cm 100us 6P 
Bar=200µm f. Section 1300V/cm 100us 6P Bar=200µm 200x Magnification. 
 
62 
 
positive slides showed specific GFP expression in the FITC channel (Figure 25d) and 
HaCaT cells showed specific Rhodamine staining in the TRITC channel (Figure25e) The 
DAPI and FITC channels were merged to show location of GFP transfection amongst all 
cells (Figure 25f). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Specific GFP Expression by HaCaT and B16.F10. HaCaT+B16.F10 sections 
analyzed for cell type transfection: Injection of reporter gene GFP and EP with a-j 
500V/cm 20ms. b-c. negative FITC and TRITC controls Bar=200 µm and 100µm. d. 
positive FITC control Bar=100 µm. e. positive TRITC control Bar=100 µm. f. merging DAPI 
and FITC channels Bar=200 µm. g-h. merging FITC and TRITC channel Bar=100 µm. i-j. 
merging of DAPI, FITC, TRITC channels Bar=100 µm 200x Magnification. 
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Merging of FITC and TRITC channels showed the fluorescent labeled HaCaT 
specifically stained red colocalized with green fluorescent GFP producing an orange hue 
meaning that HaCaT were transfected. The cells expressing green GFP protein 
indicated that solely melanoma cells were transfected with GFP (Figure 25 g-h). Merging 
the FITC, TRITC and DAPI channels showed localization of all cells transfected with 
GFP (Figure 25 i-j). Based on these images we visually examined the relative ratios of 
cells expressing GFP. There were many more solid green melanoma cells that were 
transfected with GFP compared to combined orange HaCaT cells. 
Flow analysis was utilized to quantitate GFP expression levels amongst four 
groups HaCaT, B16.F10, GFP+1300V/cm and GFP+500V/cm. Spheroids were injected 
with the GFP+B16.F10 mixture, immediately electroporated, and after 24h, spheroids 
were collected and processed for same day analysis. The transfected cells were 
analyzed using FACS ARIA I; P1 gates drawn around the HaCaT+B16.F10 cells, the 
ARIA I measured 100,000 events (Figure 26a,c,e,g), an H-gate was drawn around live 
cells and from those live cells a quadratic-gate was used to delineate between GFP 
positive and negative populations (Figure26b,d,f,h). The total percentages of GFP 
detected from the total population were as follows; HaCaT 0.29%, B16.F10 0.063%, 
HaCaT+B16.F10 1300V/cm 0.32% and HaCaT+B16.F10 500V/cm 1.88%. Mean 
Fluorescent Intensities (MFI) was statistically analyzed using a histogram curve derived 
from FlowJo software. HaCaT+B16.F10 GFP MFI levels in GFP+1300V/cm and 
GFP+500V/cm were 4.2-fold and 6.8-fold higher than HaCaT, respectively (Figure 27a-
b). Figure 27c demonstrated GFP background levels in both no treatment HaCaT and 
B16.F10 groups. The GFP+500V/cm group provided 1.6-fold higher level of GFP 
expression than GFP+1300V/cm group (Figure 27d). The MFI data obtained from the 
four histograms were plotted onto a graph. 
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Figure 26: Flow Analysis of GFP Expression. HaCaT +B16.F10 Flow analysis to 
quantitate GFP expression percentage from total population of cells from FITC 
channels Area/Height. a-b. HaCaT cells only control GFP 0.29%. c-d. B16.F10 cells 
only control GFP 0.063%. e-f. HaCaT+B16.F10+GFP expression 1300V/cm 100µs 
GFP 0.32%. g-h. HaCaT+B16.F10+GFP expression 500V/cm 20ms GFP 1.88%. 
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The MFIs indicated that both EP conditions expressed higher levels of GFP production 
than MFI background levels from HaCaT and B16.F10 (Figure 27). HaCaT+B16.F10 
transfected with GFP+1300V/cm expressed 3.2-fold higher GFP than HaCaT. The 
highest expressing group was HaCaT+B16.F10 GFP+500V/cm expressed a significant 
7.3-fold more GFP than HaCaT (*p=0.001) (Figure 27). 
Figure 27a: Flow Analysis GFP Quantitation Histograms. HaCaT+B16.F10 Flow 
analysis used to quantitate GFP expression from 3D model. a-d histograms of MFI. a. Solid 
line unfilled curve HaCaT MFI 7,811, Filled Curve HaCaT+B16.F10 1300V/cm MFI 32,882. 
b. Solid line unfilled curve HaCaT MFI 7,811, Filled Curve HaCaT+B16.F10 500V/cm MFI 
52,963. c. Solid line unfilled curve B16.F10 MFI 3,311, Filled Curve HaCaT MFI 7,811. d. 
Solid line unfilled curve HaCaT only 1300V/cm MFI 32,882, Filled Curve HaCaT only 
500V/cm MFI 52,963. 
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The next set of experiments tested the transfection efficacy of plasmid encoding 
human interleukin IL-15 (phIL-15) delivered to the 3D tumor model. The purpose was to 
demonstrate that the 3D model could be used to predict IL-15 expression patterns 
compared to delivery results in vivo. The spheroids were injected with mixture of 
(1.0mg/ml) phIL-15 and 3-5X106 B16.F10, electroporated, and collected after 24-48h. 
Both the spheroid (Average Total pg) and the media (Average pg/ml) were tested for IL-
15 protein production using ELISA analysis. The expression of IL-15 was compared 
between HaCaT only spheroids and HaCaT+B16.F10 spheroids amongst the following 
groups: no treatment, injection alone, phIL-15+1300V/cm and phIL-15+500V/cm. Low 
levels of IL-15 expression were detected in HaCaT only spheroid lysate (Figure 28a 
Figure 27b: Flow Analysis MFI GFP Quantitation. MFI graphed n=4 (*p=<0.001) 
compared to no treatment HaCaT cells alone. Error bars were calculated as standard 
deviation. Statistical analysis was performed using One Way ANOVA LSD Test. 
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dotted line), from groups phIL-15 injection alone, phIL-15+1300V/cm and phIL-
15+500V/cm groups compared to the HaCaT+B16.F10 groups (solid line Figure 28a). In 
the spheroid lysated there was a <1.2-<2.2-fold increase for phIL-15 injection, 
phIL15+1300V/cm and phIL-15+500V/cm at 24h and 48h in HaCaT alone. Transfection 
of phIL-15 into HaCaT+B16.F10, spheroid lysate mixture showed significant 3.1-fold 24h 
and 2.6-fold 48h increase in expression with the phIL-15+500V/cm group. Fold-change 
was compared to the no treatment group HaCaT+B16.F10 (solid line Figure 28a). In the 
media, there was a <1.6 fold increase for phIL-15 injection, phIL15+1300V/cm and phIL-
15+500V/cm at 24h and 48h in HaCaT alone (Figure 28b dotted line). Delivery to 
HaCaT+B16.F10 showed increased levels of IL-15 production in the media at 3.1-fold 
and 2.3-fold in phIL-15+1300V/cm group and a significant 13.7-fold and 19.5-fold 
increase with phIL-15+500V/cm at 24h and 48h, respectively, compared to no treatment 
group HaCaT+B16.F10 (solid line Figure 28b). Slight decrease in expression levels after 
48h in both the HaCaT and HaCaT+B16.F10, was possibly due to decrease in live cells 
after EP, or that HaCaT reached terminal differentiation decreasing overall transfection 
efficiency (Figure 28b solid and dotted line). 
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Figure 28: Expression of phIL-15 in the 3D Model. HaCaT +B16.F10 Delivery of human 
plasmid IL15 to quantitate expression of IL15 protein from the 3D tumor model. a. 
spheroid lysate HaCaT alone dotted line and HaCaT+B16.F10 solid line n=4-10 
(*p=<0.001). b. media supernatant from HaCaT alone dotted line and HaCaT+B16.F10 
solid line n=4-6 (*p=<0.05) all groups compared to no treatment HaCaT or 
HaCaT+B16.F10. Error bars were calculated as standard deviation. Statistical analysis 
was performed using One Way ANOVA LSD Test. 
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In vitro delivery of plasmids to a monolayer of cells is not always representative 
of what happens in vivo. It is expected that the 3D model will serve as a good indicator 
of expression levels when delivering phIL-15 to skin and tumor by utilizing HaCaT alone 
or HaCaT+B16.F10. To test whether the IL-15 results from the 3D model were indicative 
of expression patterns in vivo, the EP delivery conditions were performed in a C57BL/6 
mouse model to compare transfection efficacies between HaCaT+B16.F10 in vitro to 
skin and tumor in vivo. Four mice per group were injected intra-dermally with phIL-15 
(dotted line Figure 29). At 12h the phIL-15+100V/cm group showed a 1.9-fold increase in 
IL-15 expression and the phIL-15+200V/cm group demonstrated a 2.6-fold increase in 
expression compared to phIL-15 injection alone. The skin showed a slight increase of IL-
15 expression in groups phIL-15+100V/cm and phIL-15+200V/cm electroporated with 
skin EP conditions, but were insignificant at 12h. Many individual skin samples in these 
groups at 12h resulted in zero expression levels compared to ELISA standards. The skin 
samples at the 18h time point, expressed significantly higher levels of IL-15 than 12h, 
demonstrating a 17.9-fold increase in phIL-15+100V/cm group and a 38.2-fold increase 
in phIL-15+200V/cm group of IL-15 expression compared to phIL-15 injection alone. The 
24h and 48h time points were much lower and many individual samples expressed zero 
level of IL-15 plasmid (dotted line Figure 29). Another set of experiments containing four 
mice per group were inoculated with B16.F10 cells subcutaneously and after 6-10 days, 
tumors formed. The tumors were injected with phIL-15 and then electroporated using 
penetrating 6-needle electrode (similar to 6-PE in vitro)
161
 with EP conditions phIL-
15+1300V/cm or phIL-15+500V/cm. In the tumor, the phIL-15+500V/cm group had 
significant 8.9-fold increase in IL-15 expression at 12h compared to injection of pIL-15. 
The 1300V/cm group was not significant, the highest expression occurred at 12h with 
4.7-fold increase compared to injection of phIL-15 (solid line Figure29).  
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There was a difference in transfection efficacy between skin and tumor mostly at 12h 
and a slight difference at 18h and 24h. Expression in both tumor and skin dropped at 
48h.  
As predicted by the 3D tumor model there was a significant difference in IL-15 
expression between the cells types HaCaT only, HaCaT+B16.F10, skin and tumor. 
There were also differences in expression levels of IL-15 between EP parameters at 
100V/cm, 200V/cm, 1300V/cm and 500V/cm as well as the time points tested 12h, 18h, 
24h, and 48h. Transfection of phIL-15+EP+ (100V/cm and 200V/cm) into HaCaT and in 
the skin, revealed that there were similar IL-15 expression patterns at 24h and 48h from 
the HaCaT only group in the supernatant and in the media in vitro compared to the skin 
Figure 29: Comparison of phIL-15 Expression to Skin and Tumor In Vivo. 
Comparing IL15 expression to in vivo skin dotted line n=12 100V/cm18h *p=<0.02, 
200V/cm 18h *p=<0.001, 24h, *p=<0.03, and 48h *p=<0.02 and tumor samples 
solid line n=4; 12h 500V/cm *p=<0.02, 18h *p=<0.01, 24h *p=<0.02 compared to 
injection phIL-15 alone. Error bars were calculated as standard deviation. Statistical 
analysis was performed using the Student’s t-test. 
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homogenate in vivo. The in vitro 3D model demonstrated higher levels of IL-15 
expression at 24h in the HaCaT+B16.F10 samples, using EP conditions phIL-
15+500V/cm, transfected into mostly B16.F10 cells. This was compared to the in vivo 
model, the IL-15 expression levels were detected primarily in the established melanoma 
cells at 12h using the EP condition phIL-15+500V/cm. Although, IL-15 expression levels 
were detected at different time points between the in vitro model and the in vivo model, 
the expression patterns were very similar between the cell types and EP conditions used 
to deliver phIL-15. The highest expression of IL-15 was detected in B16.F10 
electroprated at 500V/cm groups in vitro and in vivo. The results demonstrate that the 
3D tumor model serves as a tool to predict EP conditions and plasmid expression levels 
prior to moving delivery techniques in vivo.  
Many studies show that IL-15 protein is highly regulated in nature and not easily 
detected in vivo
162
. The results showed that the 3D tumor model produced higher levels 
of IL-15 expression from cells secreted into the supernatant at 24h compared to the IL-
15 production measured from the tumor lysate at 12h in vivo. Compared to Kutzler et. al, 
the optimized plasmid human IL-15 showed greater IL-15 expression from human 
rhabdomyosarcoma cells
149
, compared to mouse B16.F10 cells. This is indicative that 
IL-15 protein was highly regulated in vitro and in vivo possibly due to cellular and 
extracellular regulatory mechanisms. The in vitro studies also showed that the plasmid 
does have the ability to express the gene of interest, but some IL-15 protein remains 
sequestered in the cytoplasm of the B16.F10 cells. The mechanism behind plasmid 
delivery using EP and IL-15 regulation at the cellular level remains to be further analyzed 
in vivo. 
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Summary 
The HARV vessel was used to promote tumor formation of B16.F10 cells in a 
free-floating environment that did not require a matrix. The 3D tumor model was a stable 
and functional system that could be used to evaluate plasmid delivery utilizing EP and 
subsequent protein expression. The delivery of GFP and phIL-15 using EP into the 3D 
model provided useful information about cellular reaction to different electric fields, pulse 
lengths and pulse number. The 3D model was used to test plasmid delivery between 
different cell types and the expression levels attained at different time points. The same 
expression trend was observed when plasmids were delivered using the in vitro 3D 
model containing HaCaT+B16.F10 and tumors in vivo. Delivery of phIL-15 with 
1300V/cm EP conditions promoted less IL-15 production at 1.0mg/ml than phIL-
15+500V/cm at 12h in vivo tumor samples and in vitro HaCaT+B16.F10 at 24h. There 
were also differences in transfection patterns between skin and tumor in vivo that were 
also detected in the in vitro 3D tumor model. Transfection of phIL-15+EP+ into the skin 
showed less IL-15 expression levels compared to tumor in vivo, and the highest 
expression levels was observed using EP 200V/cm 20ms at 12-18h compared to EP 
condition 100V/cm. In the 3D tumor model the HaCaT only group showed low levels of 
expression compared to HaCaT+B16.F10, comparable to results in vivo. 
 
Specific Aim 2  
To evaluate the intra-tumor delivery of phIL-15 and the resulting protein expression to 
determine if expression of IL-15 would promote tumor regression and enhance mouse 
survival in an aggressive mouse melanoma model. 
The work in Aim 1 evaluated the delivery of phIL-15 using a few EP parameters 
in the in vitro 3D tumor model and determined whether those in vitro results correlated 
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with in vivo experiments. This gave us a better understanding of the delivery conditions 
needed to obtain appropriate protein expression of the plasmid. In Aim 2, the work was 
designed to further explore EP conditions used to deliver phIL-15 into tumor and skin, 
and based on protein expression levels of IL-15 select the best route of plasmid 
administration and EP parameters to help target established melanoma.  
Several EP conditions at different time points were tested.  The phIL-15 results 
were compared to delivery of plasmid encoding mouse IL-12 to show differences 
between transfection efficacy and expression levels using different plasmids delivered to 
the tumor. The goal was to evaluate the delivery of phIL-15 intra-tumoral to elicit 
expression of the protein, promote tumor regression and enhance mouse survival 
against the aggressively fast growing melanoma.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 30: Gel Electrophoresis 1% agarose gel testing plasmid aliquots for 
back bone with and without gene insert. 
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The first few experiments tested plasmid purification using gel electrophoresis 
and plasmid functionality using western blot analysis. The purpose was to identify that 
the plasmids used in all experiments were identical and did not have contaminants that 
would interfere with results. All plasmid cDNA tested in vitro and in vivo were primarily 
separated by size exclusion on an agarose gel to verify aliquot content containing empty 
backbone pVax or plasmid including the gene insert phIL-15. Figure 30 shows backbone 
pVax and IL-15 plasmid cDNA separated on a standard agarose gel after each plasmid 
was double digested. Three backbone plasmids and three plasmids with inserts were 
purified by aldevron between 2005 to 2009, each plasmid was double digested with 
ECOR1 and XHO1 enzymes. The 2005 plasmids were stock aliquots, the 2007 plasmids 
IL15 protein 24h 
 
Β-Actin 
IL15 protein 48h 
 
Β-Actin 
Figure 31: Testing Functionality of phIL-15 for IL-15 gene expression from 2007 at 24h and 
48h. Western Blot performed by Hong Yang M.D.University of South Florida, Tampa, FL. 
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were used in the majority of the experiments from Aim 1-3 and the 2009 plasmids were 
also used for experiments from Aim 3. Each plasmid was a product of the stock 2005 
plasmid purified by Aldevron and guaranteed endotoxin free. The first three bands on the 
gel are ladders lambda Hind III, 100 base pair (bp) and 400 bp. The next three bands 
are cut pVax plasmid ranging about 3kb in size and the last three bands are human IL-
15 plasmid cut and separated into backbone and gene insert. The top band is the 
backbone pVax ranged 2.6kb in size and the bottom band is IL-15 gene insert ranged 
around 400 bp. The information gathered from the gel indicates that the IL-15 plasmid 
utilized is the optimized plasmid containing IL-15 insert 396 bp. All plasmids used in 
experiments were of the correct size and free of contaminants, as guaranteed by 
Aldeveron. 
The functionality of the plasmid was tested by western blot analysis for 
expression of IL-15 delivered into tumor cells.  The plasmid that was constructed to 
express the IL-15 gene was delivered using EP into mouse melanoma and the presence 
of IL-15 expression from tumor cells was analyzed (Figure 31). B16.F10 cells were 
injected subcutaneously into the left flank of C57Bl/6 mice, 6-10 days post B16.F10 
inoculations, tumors were monitored and volumes were measured. Mice containing 
tumor volumes ranging in size from 30-60mm3 were separated into 4 groups including no 
treatment (Tx), pVax injection (inj) plus EP, phIL-15 inj only or phIL-15 inj plus EP.  Each 
group contained four mice. Tumor bearing mice were administered 1.0mg/ml of phIL-15 
or pVax plasmid and then immediately electroporated at 1300V/cm 100µs 6P for those 
mice in the EP groups. The tumors were collected at 24h and 48h after one treatment 
(1TX), and then the samples were prepped for western blot analysis. Total protein of 
each group was determined using the BCA assay and then 100µg of total protein was 
loaded into the polyacrylamide gel. IL-15 protein expression tested from the four groups 
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is shown in Figure 31. The total protein loaded into the wells was verified by internal 
control β-actin. The no treatment group, pVax+EP+ and phIL-15 injection groups showed 
low background levels of IL-15 production, while the phIL-15+EP+ group showed up-
regulation of plasmid IL-15 expression at 24h. At 48h the tumors were tested, the no 
treatment, pVax+EP+, and phIL-15 injection groups showed low background levels of IL-
15 expression and surprisingly the phIL-15+EP+ group also demonstrated low levels of 
IL-15 production as well. The time period between 24h to 48h demonstrated that IL-15 
expression levels were decreased in the tumors. The observations attained from the WB 
reaffirm the results obtained in Aim 1. Aim 1 tested the EP conditions in the 3D tumor 
model and in vivo at 12, 18, 24, and 48h, and the ELISA results demonstrated reduced 
IL-15 protein expression over time. The reduction of IL-15 in the tumor was indicative 
that IL-15 production is short lived.  
The next step was to test a delivery approach using different EP parameters in 
tissues such as the tumor and skin and at the different time points 12h, 18h, 24h, 48h to 
understand expression kinetics of phIL-15. The goal is to establish a potential treatment 
regimen against mouse melanoma (B16.F10), to determine the best route of 
administration and expression levels of IL-15 when delivered into tumor or skin. Figure 
32 demonstrates expression levels of phIL-15 at different time points following delivery 
into existing B16.F10 tumors using a 6-needle electrode with different EP conditions and 
different concentrations of the phIL-15. Figure 33 demonstrates the expression levels of 
IL-15 detected in the serum after EP delivery to the tumor. The EP conditions were 
chosen based on previous studies
28
 and the results from the 3D tumor model. A high 
electric field 1300V/cm with short pulses 100µs and two low electric fields 500V/cm and 
200V/cm with long pulses 20ms were utilized in mouse studies. The plasmid 
concentrations selected for the studies were 1.0mg/ml and increased to 2.0mg/ml based 
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on low protein concentration observed in the western blot. Previous studies 
demonstrated low expression levels and suggested that small detectable IL-15 
production occurs because it is known to be highly regulated and short lived (163). The 
groups tested in the mouse studies were phIL-15 injection only, phIL-
15+EP+1300V/cm,100µs, 6P,  phIL-15+ EP+ 500V/cm and phIL-15+EP+ 200V/cm 20ms 
6P at 12h, 18h, 24h and 48h n=8-17 for each group (Table 1). Expression levels of hIL-
15 were determined from tumor lysate using a sensitive hIL-15 ELISA assay. 
 
N 
Values 
Time 
IL-15 
Inj 
1.0mg/ 
ml 
 
IL-15 
Inj 
2.0mg/
ml 
+1300V/ 
cm 
1.0mg/ 
ml 
 
+1300V/ 
cm 
2.0mg/ 
ml 
+500V/ 
cm 
1.0mg/ 
ml 
 
+500V/ 
cm 
2.0mg/ 
ml 
+200V/ 
cm 
1.0mg/ 
ml 
 
+200V/ 
cm 
2.0mg/ 
ml 
12h 8 8 16 12 16 11 8 8 
18h 8 8 13 8 12 8 8 8 
24h 16 8 16 8 8 8 8 NA 
48h 16 8 17 8 8 8 8 NA 
 
Fold change (fold) of all expression levels were compared to IL-15 injection at 
either 1.0 mg/ml or 2.0mg/ml. In Figure 32, the highest expression of IL-15 obtained from 
tumor lysate was collected at 12h in the hIL-15+EP+ 500V/cm 2.0mg/ml group after 1Tx 
and was found to be 23.6-fold higher than hIL-15 injection at 2.0mg/ml, but was not 
significant. The phIL-15+EP+ 500V/cm group was not significant because there was one 
sample that had expression of 602pg compared to the average 92pg. It is not real clear 
whether this one outlier was increased due to the damaging effects of this specific EP 
condition or error in the ELISA assay. Although it remains unclear, there was only one 
mouse from an n of 11 that showed this result.  
Table 1: Number of Animals Used to Evaluate of IL-15 Protein Production.  
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The following groups were found to have the next highest IL-15 expression levels 
in tumor lysate, 1.0mg/ml phIL-15+EP+ 500V/cm producing significant 17.6–fold 
(p=0.001) increase at 12h, 11.1-fold (p=<0.001) increase at 18h 1.0mg/ml and a 
significant 27.9-fold (p=0.0001) at 18h 2.0mg/ml in IL-15 expression compared to phIL-
15 injection. With respect to protein levels for phIL-15+EP+1300V/cm there was a 
significant increase in expression from 12-24h, containing expression levels with a 10.9-
fold (p=<0.0001) at 1.0mg/ml and 19.9-fold (p=0.001) at 2.0mg/ml. 
Figure 32: IL-15 Expression in the Tumor In Vivo. Comparing IL-15 expressions 
from in vivo tumor lysate. Delivery of phIL-15 1300V/cm, 500V/cm and 200V/cm at 
1.0-2.0mg/ml compared to injection of phIL-15.*p=<0.04. Error bars were calculated 
as standard deviation. Statistical analysis was performed using the Student’s t-test. 
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The phIL-15+500V/cm significantly dropped by 24h, and EP conditions phIL-
15+500V/cm and phIL-15+1300V/cm significantly dropped further by 48h. These IL-15 
expression levels were similar to expression levels obtained in the WB analysis when 
delivered with 1300V/cm.  In the western blot, protein expression was visible at 24h and 
no longer detectable at 48h (Figure 31). Expression of IL-15 in the phIL-
15+EP+200V/cm group was very low and not significant. For this EP condition, the phIL-
15 1.0mg/ml injected and electroporated at 12h, 18h, 24h, and 48h produced very low 
levels of expression. There was a slight peak at 18h for the 2.0mg/ml 200V/cm group, 
Figure 33: IL-15 Expression in the Serum Post Tumor Treatment. 
Comparing IL-15 expression from in vivo mouse serum to injection alone 
group *p=0.03. Error bars were calculated as standard deviation. Statistical 
analysis was performed using the Student’s t-test. 
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since expression levels were so low, delivery of phIL-15 using these EP conditions were 
no longer tested at 24h or 48h. Figure 33, shows IL-15 expression levels in the serum, 
there was small difference in expression between the time points. There was a slight 
significant peak for the phIL-15+EP+500V/cm groups 1.0mg/ml and 2.0 mg/ml in the 
serum, but overall expression levels were as low as tumor lysate phIL-15+200V/cm 
group from Figure 33. 
In Aim 1, using the 3D model experiments demonstrated a difference in 
transfection efficacy between the HaCaT and B16.F10 as well as delivery between the 
skin and tumor (Figure 29). Work in Aim 2, demonstrated that by increasing plasmid 
concentration for phIL-15 there was an increase in protein expression levels when 
delivering to tumors in vivo (Figure 32).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: IL-15 Expression in the Skin In Vivo. Comparing IL-15 expression from in 
vivo mouse skin. Delivery of phIL-15 at 100V/cm and 200V/cm compared to injection of 
phIL-15 at 2.0mg/ml.*p=<0.01. Error bars were calculated as standard deviation. 
Statistical analysis was performed using the Student’s t-test. 
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The next experiments tested delivery of phIL-15 to the skin and then compared 
expression levels to the tumor with increased plasmid concentrations 2.0mg/ml, as 
suggested by the 3D model. Three mice per group were injected intra-dermal with 
2.0mg/ml phIL-15 at 4 points on their dorsal side, each site received 100µg of phIL-15 
for a total of n=12 per group for evaluating expression levels in skin. Delivery to the skin 
used a 4 PE applicator injecting phIL-15 with 2.0mg/ml and immediately electrporating, 
phIL-15+EP+200V/cm group showed a significant (p=<0.001) increase in expression at 
12h compared to 1.0mg/ml plasmid dosage (Figure 29), but expression quickly 
decreased over time (Figure 34). The phIL-15+EP+ 100V/cm maintained significant 
expression levels 12-24h and then significantly dropped at 48h. The expression levels in 
Figure 35: IL-15 Expression in the Serum Post Skin Treatment. Delivering phIL-
15 2.0mg/ml and comparing IL-15 expression from in vivo mouse skin serum to 
injection phIL-15 alone. Error bars were calculated as standard deviation. Statistical 
analysis was performed using the Student’s t-test. 
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the skin were lower than expression in tumor lysate at 12-48h. Serum levels also 
showed very low and insignificant expression levels with an n=3 (Figure 35). 
Surprisingly, many samples did not demonstrate higher IL-15 expression in the serum 
especially since the three mice per group received 4 doses of the plasmid injected intra-
dermal and electroporated. Based on these observations the skin delivery was no longer 
pursued as a treatment route for tumor regression studies. The IL-15 expression 
experiments showed that delivery of phIL-15 to the tumor with EP had a direct 
correlation of increased expression with a higher concentration of plasmid as observed 
in the 3D tumor model. Also, there was a difference in expression levels between skin 
and the tumor. The differences in expression of IL-15 seem to be dependent on plasmid 
dose, different EP conditions and the different EP electrode applicators used.  
Delivery of a plasmid encoding a different cytokine was able to demonstrate a 
difference in expression levels using varied EP conditions when delivered into tumor and 
skin. The use of a different cytokine that may not be as highly regulated as phIL-15, was 
used to demonstrate that the low expression may not have been due to the EP delivery 
parameters but the gene being delivered. There was a significant increase in expression 
when delivering mouse plasmid interleukin-12 (pmIL-12) into the tumor using a variety of 
EP parameters after 1Tx (Figure 36). The 1.0mg/ml of pmIL-12 delivery was able to 
promote increased IL-12 expression levels in the tumor lysate and serum. There was a 
significant increase in mIL-12 protein expression at 24h compared to mIL-12 injection 
(Figure 36) and to the hIL-15 expression levels at 24h (Figure 32). EP was able to 
ensure delivery of both plasmids and while hIL-15 expression decreased over time, all 
EP conditions that delivered pmIL-12 maintained expression levels 24h-96h. 
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The best EP conditions that demonstrated increased mIL-12 expression at 24h 
utilized a caliper electrode to deliver pmIL-12 with EP condition 667V/cm 100ms 1 pulse 
(24h p=0.001, 48h p=0.03, and 96h p=0.02) into the tumor, n=12. The level of 
expression was significantly higher amongst all EP conditions and expression levels did 
not diminish quickly between 24-96h. EP conditions 1300V/cm and 500V/cm using the 6-
needle electrode, showed significant expression of mIL-12 (p=<0.01, p=<0.04) over time 
compared to injection only. After 24h there was a significant decrease of expression in 
the 1300V/cm group (p=0.01 24h, p=<0.01 48h and p=0.01 96h), although 500V/cm 
maintained expression past 48h (p=0.01 24h, p=0.004 48h and p=0.04 96h). 
 
 
Figure 36: IL-12 Expression in the Tumor In Vivo. Delivery of pmIL-12 1300V/cm, 
500V/cm, 200V/cm, 804V/cm, 667V/cm compared to injection pmIL-12 1.0mg/ml. 
**p=<0.05. Error bars were calculated as standard deviation. Statistical analysis was 
performed using the Student’s t-test. 
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Overall, both groups delivering pmIL-12 with 1300V/cm and 500V/cm showed a 
dramatic increase of mIL-12 expression compared to hIL-15 expression using the same 
EP conditions. As demonstrated in the 3D tumor model with GFP and phIL-15 delivery, 
there were differences in expression between tumor and skin also observed with the 
delivery of pmIL-12.  
As described in Aim1, the lower electric field and longer pulses provided the best 
genetransfer and protein expression levels 500V/cm and 667V/cm, but caused the most 
damage. Comparing EP conditions, the least damaging EP parameters used higher 
electric fields and shorter pulses, 1300V/cm seem to produce high expression early at 
24h in tumor lysate and leveled out with the other EP groups at 48h. The 804V/cm 
conditions expressed slightly lower levels of mIL-12 at 24h n=8 than 1300V/cm n=12, 
Figure 37 IL-12 Expression in the Serum Post Tumor Treatment. Delivery of 
pmIL-12 1.0mg/ml and measuring IL-12 expression from in vivo mouse. Serum 
compared to pmIL-12 injection alone.*p=<0.03, **p=<0.02, ***0=<0.007. Error 
bars were calculated as standard deviation. Statistical analysis was performed 
using the Student’s t-test. 
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while 1300V/cm dropped in expression, 804V/cm maintained expression levels possibly 
because they have slightly longer pulses than 1300V/cm. In addition to evaluating 
expression in tumor lysate (Figure 36), serum from these mice was also evaluated for IL-
12 expression levels (Figure 37).  There was significant expression (p=<0.007 24h, 
p=<0.03 48h and p=<0.02 96h) of mIL-12 in the serum n=7-12. The serum levels were 
slightly lower than tumor lysate in mIL-12 experiments and decreased over time, but 
expression patterns correlated with mIL-12 tumor expression. Tumor and serum 
increased at 24h, and slowly decreased 48h-96h. The information gathered from mIL-12 
tumor delivery supports the observations from the in vitro 3D model and in vivo mouse 
models in Aim 1, suggesting that IL-15 must be highly regulated at the cellular level 
causing a decrease in expression. Also there was a correlation between lower 
transfection in the skin and higher transfection in the tumor compared to 3D tumor model 
cell types. The highest expression levels were observed in the tumor using EP 
conditions 500V/cm and 667V/cm, low electric field strengths with longer pulses.  EP 
conditions enhanced higher transfection and promoted more expression of mIL-12 in the 
tumor cells than hIL-15 delivery. Both phIL-15 and pmIL-12 peaked at early time points 
after 1Tx, slightly decreased and maintained expression levels 48h and 96h, 
respectively. 
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 Delivery of pmIL-12 into the skin resulted in at least 30x less IL-12 expression 
compared to tumor levels (Figure 38). The mice were injected at one site on the dorsal 
side with pmIL-12 1.0mg/ml in a 50µl bubble. The 4PE was used to EP the plasmid 
bubble injected intra-dermal and then the skin was marked with permanent marker to 
identify location during tissue collection after 24h-48h. There was a significant increase 
in expression using the 4PE to deliver pmIL-12+EP+ 200V/cm after 24h (p=<0.01),the 
skin samples maintained expression up to 48h (p=<0.005) n=8-16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pmIL-12+EP+ 100V/cm group showed significant expression of IL-12 after 48h 
(p=<0.05), maintaining the same expression for 2 days after 1TX. The levels of IL-12 in 
the serum at 24-48h following delivery of pIL-12 to the skin resulted in even less 
expression of IL-12 at 24h compared to serum levels following delivery to tumor (Figure 
39). mIL-12 increased at 24h pmIL-12+EP+200V/cm n=2-3 then dropped quickly by 48h. 
Figure 38: IL-12 Expression in the Skin In Vivo. Delivery of pmIL-12 at 100V/cm 
and 200V/cm compared to injection pmIL-12 1.0mg/ml and measureing IL-12 
expression from in vivo mouse skin compared to pmIL-12 injection alone *p=<0.05, 
**p=<0.01, ***p=0.005. Error bars were calculated as standard deviation. Statistical 
analysis was performed using the Student’s t-test. 
 
87 
 
The values were analyzed using the student t-test, but results did not present statistically 
significant expression levels in the skin serum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Overall, delivery to the skin resulted in much more defined mIL-12 expression 
than hIL-15 expression. The mIL-12 data is comparable to the levels of mIL-12 plasmid 
delivery in the Heller et al publications
160
. One observation that was noted in the in vitro 
3D tumor model, discussed in 3D model publications
42
, and also observed in vivo, was 
that loosely less adherent tumor cells were transfected more readily and expressed 
more protein compared to adherent, keratinized skin cells. Comparing mIL-12 to hIL-15 
protein production showed that high expression levels are lost over time after 1Tx and 
requires additional boosts to maintained expression. Short lived plasmid expression is 
beneficial because it reduces the chance of toxicity due to over expression of the 
protein. 
Figure 39: IL-12 Expression in the Serum Post Skin Treatment. Delivery of pmIL-
12 1.0mg/ml to skin and measureing expression of IL-12 measured in mouse serum 
compared to pmIL-12 injection alone. Error bars were calculated as standard 
deviation. Statistical analysis was performed using the Student’s t-test. 
. 
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The amount of protein expressed by the tumor cells following DNA delivery is 
dependent upon the plasmid vehicle, concentration of the plasmid, cells type, EP 
conditions, EP applicators and number of treatments. hIL-15 expressed lasted longer in 
the tumor than in the serum, to enhance protein expression and extend systemic 
stimulus, multiple treatment protocols of hIL-15 should be employed. Based on the 
expression levels and kinetics, the next sets of experiments were designed to evaluate 
expression levels of phIL-15 following multiple tumor treatments. Since hIL-15 
expression was short lived and peaked at 12h, the treatment protocols were performed 
on Day 0, 1, 2, and samples collected at 12h, 36h, or 60h to identify expression patterns 
Figure 40: One, Two, Three Treatment Protocol to the Tumor. Delivery of 
phIL-15 1.0mg/ml into tumor 2Tx and 3Tx on Days 0, 1 and 2and expression of 
IL15 measured in tumor compared to phIL-15 injection alone. Error bars were 
calculated as standard deviation. 
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with multiple treatment administration. Experiments were performed on 4 mice per group 
using a 1Tx protocol, a two-treatment (2Tx) protocol occurring on Day 0 and 1 and three 
treatment (3Tx) protocol on Day 0, 1, 2, delivering 1.0mg/ml phIL-15 with EP conditions 
1300V/cm or 500V/cm. The expression levels were similar to the levels of the one-
treatment (1Tx) protocol after 12h, 36, and 60h, but in the 2Tx protocol collected at 36, 
60h protein levels slightly increased, the phIL-15+EP+ 500V/cm did not increase beyond 
7.0 Total pg (Figure 40).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the 3Tx protocol, at Day 0, 1, 2, samples were collected at 60h and showed a 
slight increase, but IL-15 production did not increase beyond 7.7 Total pg. Multiple 
treatments did not increase serum levels of IL-15 (Figure 41), there was no additional 
Figure 41: One, Two, Three Treatment Protocol Tested in Serum. 
Delivery of phIL-15 1.0mg/ml into tumor and expression of IL15 measured in 
mouse serum from multiple treatment protocols on Days 0, 1 and 2. 
compared to phIL-15 injection alone. Error bars were calculated as standard 
deviation. 
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up-regulation of expression detected at these early time points 0, 1, 2 with multiple 
treatment administrations. In the next experiments the time was spaced further out 
between EP deliveries to test if expression levels were enhanced. 
The following 2Tx and 3Tx treatment regimens were similar to treatment 
protocols published in Lucas et al.,
28
. The 2.0mg/ml phIL-15 was delivered using EP on 
Days 0, and 3, for a 2Tx regimen and Days 0, 3, 6, for a 3Tx regimen with n=12 for each 
group. There was no real difference in expression in the tumor compared to Days 0, 1, 2 
treatments (Figure 42) and serum levels were very low (Figure 43). The 2Tx and 3Tx 
protocols at Day 0, 3, 6, demonstrated a significant increase of IL-15 expression in EP 
groups 1300V/cm with a 3.1-fold (p=0.02) and 500V/cm containing a 3.5-fold (p=0.001) 
increase of IL15 at Day 3, using the 2Tx protocol and significance increase in the 
500V/cm group containing a 5-fold (p= 0.04) increase of IL-15 at Day 6, with a 3Tx 
protocol compared to injection alone. Overall, the multiple treatment protocols did not 
show enhanced expression levels, but delivery methods were effective in maintaining 
protein levels in the tumor with each additional treatment. The initial experiments 
showed increase after 1Tx peaking at 12-24h and then decreased by 48h. It was 
decided that the 3Tx protocol with treatments at Day 0, 3, 6, would be the best protocol 
since significant increase in IL-15 expression was detected and based on the decreased 
tumor volume observations recorded during expression experiments. Some tumors were 
beginning to regress after 2Tx and 3Tx around Day 4 and Day 7. The injection of IL-15 
alone group continued to increase in tumor volume, while the mice treated with hIL-
15+EP+ began to decrease.  
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Figure 42: Two, Three Treatment Protocol Tested in the Tumor. Delivery of phIL15 2.0mg/ml 
into tumor and detecting expression of IL-15 after multiple treatment protocols on Days 0, 3 and 
6.1300V/cm Day 3 *p=<0.02, 500V/cm Day 3 *p=<0.001, 500V/cm Day 6 *p=<0.04 compared to 
phIL-15 injection alone. Error bars were calculated as standard deviation. Statistical analysis 
was performed using the Student’s t-test. 
 
Figure 43: Two, Three Treatment Protocol Tested in Serum. Delivery of phIL-15 
2.0mg/ml into tumor and detecting expression of IL15 in the serum after multiple treatment 
protocols on Days 0, 3 and 6. compared to phIL-15 injection alone. Error bars were 
calculated as standard deviation. Statistical analysis was performed using the Student’s t-
test. 
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Multiple and adjacent administrations of phIL-15 and EP delivery were necessary 
to control tumor growth. Previous studies by Heller and Lucas et al.,
28-29
 described that 
tumors did not regress after 1Tx and 47% of mice experienced tumor regression and 
mice survived after 2Tx. The best results were attained after administering 3Tx with 
mouse pIL-12 delivery using EP, there was 80% of mice that experienced tumor 
regression and survived. Based on these studies, it is important to maintain IL-15 
expression to promote continuous tumor regression by administering multiple treatments 
of phIL-15 and EP to the tumor and more importantly enhance mouse survival. As noted 
in the 2Tx and 3Tx protocols, the groups obtained multiple treatments with 2.0mg/ml 
maintained IL-15 expression showing initial signs of tumor volume reduction.  
 
 
Table 2, shows a set of 4 different regression studies that were performed to 
monitored tumor volumes over a period of days such as, Days 14, 30, 50 and 60. Mice 
3 Tx Regression 
Studies 
Day 0, 3, 6 
ST Exp 1 
 
Day 14 
n=4 
ST Exp 2 
 
Day 30 
n=4 
ST Exp 3 
 
Day 60 
n=4 
LT Exp 4 
 
Day 50 
n=15 
Primary 
Response 
Exp 3, 4 
Day 50-60 
No Treatment 25% - - - - 
pVax Injection 50% 0 0 0 - 
IL-15 Injection 75% 0 0 0 - 
pVax 1300 V/cm 100% 75% 75% 6/15 
40% 
9/19 
47% 
pVax 500V/cm 100% 75% 75% 11/15 
73% 
14/19 
74% 
pIL-15 1300 V/cm 100% 100% 100% 11/15 
73% 
15/19 
79% 
pIL-15 500V/cm 100% 75% 100% 8/15 
53%* 
12/19 
63% 
Table 2: Four Separate Regression Studies Measuring Tumor Volume. 
overtime 
Table 2: Regression Studies Short Term (ST) Experiments (Exp) and Long Term (LT) Experiments.   
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were inoculated with B16.F10, monitored for 6-10 days and tumors ranging 30-60mm3 
were treated with the 3Tx protocol on Days 0, 3, and 6. In the three separate short-term 
(ST) tumor regression experiments, mice tumors were monitored every 3 days to 
analyze tumor sizes and then tumors were collected for ELISpot and Luminex bead 
array analysis on Days 14, 30 and 60, as described in Aim 3. The following treatment 
groups were included in experiments: no treatment, pVax inj, IL-15 inj, pVax+1300V/cm, 
pVax+500V/cm, phIL-15+1300V/cm and phIL-15+500V/cm. Tumors were monitored in 
Experiment 1 Day 14, 8 days after the last treatment, in Experiment 2: Day 30, 24 days 
after and in Experiment 3: Day 60, 54 days after the last treatment. Observations were 
recorded for comparison regression studies (Table 2). In Experiment 4, a long term (LT) 
experiment was performed to observe tumor regression and mouse survival up to 50 
days. The surviving mice were challenged with injection of 5X105 B16.F10 cells 
subcutaneously on the opposite flank and monitored for an additional 50 Days. The 
purpose behind the challenge was to evaluate protection. It was predicted that mice 
would mount a primary immune response against tumor antigens and would build a 
stronger, faster secondary response against challenge against B16.F10 inoculation as 
well as prevent growth of tumors.  
In each separate experiment, tumor volume had decreased as early as day 4 and 
day 7 in pVax+EP+ and phIL-15+EP+ treatment groups, 1300V/cm and 500V/cm. The 
mice in the no treatment, pVax injection, and IL-15 injection groups had mice tumors that 
continuously expanded. Some mice became lethargic and grew weak by Day 14 in 
Experiment 1. In Experiment 2 by Day 21, the tumors had metastasized to the lymph 
nodes and/or spleen and the metastatic properties of B16.F10 caused labored breathing 
in the mice. The mice that had tumor volumes greater than 1000mm
3
 or grew sick 
because of metastasis were euthanized between Day 16-21 in Experiment 2 and in 
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Experiment 3. The mice treated with pVax+EP+ or phIL-15+EP+ 1300V/cm and 
500V/cm had tumors regress completely as early as Day 14-21, in Experiment 2 and 
Day 16-23 in Experiment 3. In Experiment 4, many tumors grew deep and some tumors 
were abnormally shaped due to initial tumor inoculation. In the IL-15+EP+500V/cm 
group, there were 5 mice that grew deep tumors and had succumb to metastasis, while 
2 mice were found dead because of EP condition 500V/cm powerful pulses. The needle 
placement around the site of injection was important in these EP groups since delivery of 
IL-15 was necessary to promote expression in enough cells to signal the innate and 
effector response against fast growing melanoma. Since IL-15 contains a short-half life it 
is important to deliver to as many cells as possible to overcome the down-regulation of 
IL-15 protein signaling, and promotes tumor regression in the non responding mice for 
increased survival. The mice in Experiment 3, Day 60 did not have abnormally shaped 
tumors or EP complications and all mice in phIL-15+EP 500V/cm survived out to 60 
days. Observations indicate that phIL-15 delivered using EP must encompass many 
tumor cells to properly administer phIL-15+EP+ treatments and avoid tumor escape 
using the short-lived IL-15 plasmid. The mice from Experiment 3, Day 60 and mice from 
Experiment 4 Day 50, were combined to determine the total amount of mice that had 
tumors regress and therefore enhanced mouse survival that were tumor-free (Table 2). 
Tumor regression was observed in the following groups: the pVax+EP+1300V/cm had 
9/19 (47%) of mice respond, pVax+EP+500V/cm had 14/19 (74%), phIL-
15+EP+1300V/cm had 15/19 (79%), and ph IL-15+EP+500V/cm had 12/19 (63%) mice 
that had regressed tumors remained alive (Table 2). The best primary response against 
tumors was obtained from mice in the phIL-15+EP1300V/cm and pVax+EP+500 V/cm 
groups.  
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The mice from Experiment 4 were monitored for 50 days after the 3Tx protocol 
on Day 0, 3, and 6. Tumor volumes were measured every 3-4 days. The volumes were 
plotted in Figure 42 a and b. The mice that reacted to treatments demonstrated 
decreased tumor volume, these mice were considered responders (Figure 44a). Mice 
that did not response to the treatments, known as non-responders contained large 
tumors that continued to grow until the tumor volumes reached 1000mm
3 
and then these 
mice were humanely euthanized. The mice that responded to the treatments and 
survived primary inoculation were plotted on a Kaplan-Meier survival curve (Figure 44c, 
Table 2). The phIL-15+1300V/cm and pVax+500V/cm showed that 73% of the mice 
remained alive, while phIL-15 500V/cm showed 53% and pVax+1300V/cm had 40% 
mouse survival. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. 
Figure 44a: Non Responders Tumor Volumes Monitored for primary response up to 50 
days after 3Tx on Days 0, 3, 6 a. Nonresponders, mice that have not responded to treatment 
conditions. n=15. The mice that did not survive were recorded as a percentage. 
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b. 
Figure 44b: Responders Tumor Volumes Monitored for primary response up to 50 days 
after 3Tx on Days 0, 3, 6. a. Responders, mice that have responded to treatment conditions. 
n=15. The mice that did survive were recorded as a percentage. 
 
 
c. 
Figure 44c Kaplan-Meier Survival Curve. Demonstrate survival data of mice 
receiving 3Txs on Days 0, 3, 6. n=15. 
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The surviving mice from Experiment 4 were challenged at Day 50 on the 
opposite flank with 5X10
5
 B16.F10 to determine the extent of secondary response 
against tumor cells (Table 3). The IL-15+EP+1300V/cm had 5/11 (45%) mice were 
resistant to the second injection of tumor cells compared to the pVax+EP+1300V/cm 
which had 3/6 (50%) mice that maintained tumor intolerance. The phIL-15+EP+500V/cm 
had 6/8 (75%) mice protected against secondary challenge compared to 
pVax+EP+500V/cm 4/11(36%). The best groups that promoted a secondary and long 
term immune response against melanoma were phIL-15+EP+ 500V/cm followed by pIL-
15+EP+1300V/cm.  
 
Challenge Exp 
3Tx Experiment 4 
Day 0, 3, 6 
Primary 
Inoculation 
 
Day 50 n=15 
Secondary 
Inoculation 
 
Exp 4Day 50 
IL-15 Injection 0 0 
pVax Injection 0 0 
pVax 1300 V/cm 6/15 
 
40% 
3/6 
 
50% 
pIL-15 1300 V/cm 11/15 
 
73% 
5/11 
 
45% 
pVax 500V/cm 11/15 
 
73% 
4/11 
 
36% 
pIL-15 500V/cm 8/15 
 
53%
+
 
6/8 
 
75% 
Table 3: Challenge Study Evaluating Tumor Relapse and Intolerance. 
Table 3:+ Mice in this group did not survive due to damaging EP conditions. 
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Summary 
The experiments in this section demonstrated that phIL-15 delivery using EP 
promotes more IL-15 expression at 2.0mg/ml electroporated at 500V/cm. The EP 
condition 500V/cm with long pulses delivered more energy to the cells compared to 
1300V/cm with short pulses. Both EP parameters maintained expression levels when 
delivering the plasmid with multiple treatments and spacing the treatments to promote 
cellular recuperation following each EP treatment. There were notable differences in 
human IL-15 compared to mouse IL-12 expression when delivery of plasmid using EP 
into different cell types, using different EP electrode applicators, and plasmid 
concentrations. It was observed that EP is an efficient way to introduce plasmids into 
cells. The next section explored the immunological effects obtained when using this 
delivery system to introduce phIL-15 plasmid into tumors.  
 
Specific Aim 3 
To identify key immune effector cells and cytokines that was directly or indirectly 
stimulated following intra-tumoral delivery of pIL-15 using EP 
The goal of Aim 3, was to characterize the immune response that was stimulated 
by phIL-15 and pVax delivered with EP. The purpose was to identify the key immune 
effector cells and cytokines that were directly or indirectly stimulated by IL-15 protein 
production introduced by intra-tumoral delivery of phIL-15 using EP.  
Immunohistochemistry assays were performed on zinc fixed and snap frozen 
tumor samples to identify the up-regulation of local CD8+ and CD4+ T cell responses to 
untreated tumors and compared to treated tumors. Tumors were harvested at 24h and 
48h and after 1 Tx, as well as Day 7 and Day 11 after 3 Tx. The tumor sample 
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containing periphery of skin tissue was stained for T cell markers CD8 and CD4 and NK 
cells. No NK cells were detected on Day 1, 2, 7, or 11.  
 
 
 
 
Tumor with skin samples were collected from the mouse, cryo-sectioned, fixed in 
acetone and then stored at -20C˚until analyzed. Sections were stained separately for 
CD8 or CD4 T cell markers and compared to negative controls. The negative controls 
consisted of the secondary antibody excluding the addition of specific primary antibody 
and unstained cells were counterstained with methyl green. 
Figure 45: IHC Sections CD4+ and CD8+ T cells Staining Day 1. 1Tx of mouse tumors 
collected after 24h and tested for specific CD4 and CD8 staining. 100x n=4 Bar= 50-200µm. 
Green staining is the methyl green counterstain, dark brown color is natural pigmentation of 
melanoma and the red staining is the specific antibody labeled CD4 or CD8 markers. 
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B16.F10 cells were naturally pigmented and were observed as a dark brown staining 
indicative of tumor location in the section. All pictures were taken with an Olympus 
microscope camera at 100x Magnification. Scale bars were added to indicate specific 
size of tissue in each picture.  
Figure 45, shows the up-regulation of T cells at 24h after one treatment, all 
groups showed the presence of CD4+ T cells (CD4) and select groups showed a small 
number of CD8+ T cells (CD8). Non-specific staining was not observed in negative 
controls exposed only to the secondary antibody. The T cells were observed mostly in 
the periphery of the tumor with only a few in the center of the tumor. The no treatment 
Figure 46: IHC Sections CD4+ and CD8+ T Cells Staining Day 2. 1Tx of mouse tumors 
collected after 48h and tested for specific CD4 and CD8 staining. 100x n=4 Bar= 50-200µm. 
Green staining is the methyl green counterstain, dark brown color is natural pigmentation of 
melanoma and the red staining is the specific antibody labeled CD4 or CD8 markers. 
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tumor samples demonstrated the presence of some CD4 in the center, but most were 
located in the periphery of the tumor and no CD8 cells were observed in the no 
treatment group at 24h. In the EP alone saline+1300V/cm and saline+ 500V/cm groups 
there was an increased of CD4 around the periphery and the center. The 
saline+EP+1300V/cm group showed some CD4 present in the periphery, but did not 
show presence of CD8, the same CD4 results were detected in the saline+EP+500V/cm 
group, but there were few CD8 cells in the periphery. The pVax injection group showed 
low presence of CD4 and no CD8. Also, at 24h, the injection of phIL-15 showed few CD4 
cells in the periphery similar to what was observed in the saline+EP+ groups. The phIL-
15 injection group did demonstrate a pronounced presence of CD8 throughout the tumor 
and around the periphery. The pVax+1300V/cm and pVax+500V/cm groups showed 
very low presence of CD4 and no CD8 at 24h. The phIL-15+EP+1300V/cm showed 
detected low staining of CD4 and CD8 while phIL-15+500V/cm group showed much 
more CD4, but few CD8. The phIL-15+groups showed more CD4 and CD8 staining than 
control groups at 24h, but less CD8 cells than the phIL-15 injection group.  
Results from tumor samples that were collected and sectioned at 48h after one 
treatment were observed (Figure 46). The no treatment group showed low presence of 
CD4 and no stimulation of CD8. The saline+1300V/cm group showed a slight increase of 
CD4 stimulation in the periphery and few in the center while there were a small amount 
of CD8 cells in the periphery. The saline+500V/cm group showed presence of CD4 in 
the periphery and in center, and there was low staining of CD8 detected toward the 
center of the tumor and periphery. The pVax injection group did not show CD4 or CD8, 
while the phIL-15 injection group showed the presence of CD4 in the periphery but not 
as much as saline+EP+ groups 1300V/cm or 500V/cm. No CD8 cells were detected in 
the phIL-15 injection group. No CD4 or CD8 cells were detected in the 
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pVax+EP+1300V/cm and 500V/cm groups. The phIL-15+EP+1300V/cm group showed 
low expression of CD4 similar to the phIL-15 injection group and most of the section was 
stained specifically for CD8 throughout the tumor and the periphery compared to other 
groups at 48h. The phIL-15+500V/cm did not show expression of CD4 or CD8. 
Results of tumor staining for CD4 and CD8 on samples collected at Day 7, 12h 
after 3Tx protocol Days 0, 3, and 6 are shown in Figure 47. These sections were 
evaluated for possible CD4 and CD8 infiltrate. The no treatment tumor groups showed 
presence of more CD4 compared to 24h-48h and some CD8 cells were detected. The 
pVax injection group showed a few CD4 cells in the periphery and in the center, there 
were some CD8 cells detected in the periphery.  
 
 
 
 
Figure 47: IHC Sections CD4+ and CD8+ T Cells Staining Day 7. 3Tx of mouse tumors 
collected on Day 7 and tested for specific CD4 and CD8 staining. 100x n=4 Bar= 50-
200µm.. Green staining is the methyl green counterstain, dark brown color is natural 
pigmentation of melanoma and the red staining is the specific antibody labeled CD4 or 
CD8 markers. 
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The phIL-15 injection group showed no CD4 or CD8 stimulation at Day 7. The 
pVax+1300V/cm and 500V/cm showed low presence of CD4 and no CD8 , while the pIL-
15+1300V/cm showed the most CD4 and CD8 cells in the periphery compared to the 
other groups. The highest number of CD4 and CD8 cells was detected in the periphery 
of the phIL-15+EP+ 500V/cm group. 
Figure 48 shows representative tumor sections that were collected on Day 11, 5 
days after the third treatment, the tumors were evaluated for infiltrating CD4+ and CD8+ 
T cells. The no treatment group showed no CD4 or CD8 stimulation. The pVax injection 
group showed low stimulation of CD4 and CD8 in the periphery and some infiltrate in the 
Figure 48: IHC Sections CD4+ and CD8+ T Cells Staining Day 11. 3Tx of 
mouse tumors collected on Day 11 and tested for specific CD4 and CD8 staining. 
100x n=4 Bar= 50-200µm. Green staining is the methyl green counterstain, dark 
brown color is natural pigmentation of melanoma and the red staining is the 
specific antibody labeled CD4 or CD8 markers. 
 
104 
 
center on Day 11 compared to Day 7 samples. The pVax+EP+1300V/cm showed a low 
higher CD4 stimulation at the periphery compared to pVax injection additionally more 
CD8 stimulation in the periphery infiltrated into the center of the tumor compared to pVax 
injection. Comparing the tumor sizes between pVax injection and pVax+1300V/cm 
groups, demonstrated a reduction of tumor size in pVax+1300V/cm with the same optical 
magnification 100x. The damaging conditions of pVax+500V/cm group showed an 
extremely high infiltrate of both CD4 and CD8 at the periphery and infiltrating into the 
tumor. Both pVax+EP+ groups showed tumor sizes that were smaller compared to pVax 
injection groups. The phIL-15 injection showed more CD4 and CD8 stimulation around 
the periphery compared to pVax injection. The phIL-15+1300V/cm group showed more 
CD4 and CD8 stimulation around the periphery and infiltration into the center compared 
to IL-15 injection and a more pronounced infiltrate than pVax+1300V/cm group. The 
tumors in phIL-15+ groups had decreased in size more quickly by Day11 than 
pVax+EP+ groups. The phIL-15+ 500V/cm group had comparable CD4 and CD8 T cells 
in the periphery and infiltrate towards the center similar to the pVax+500V/cm group. It 
was very difficult to section these tumor samples due to scabbing and scarring of the 
tissue.  During sample collection tumor cells were completely regressed in the phIL-
15+500V/cm groups compared to pVax+EP+ 500V/cm group. 
Additional experiments were performed on tumors treated with the 3Tx protocol 
to test for systemic IFNγ production. The purpose of the experiment was to analyze IFNγ 
production in treatment groups to explain IHC CD8 and CD4 infiltrate and regression 
data. ELISpot assay was used to analyze IFNγ production in splenocytes or PBMCs 
from mice that were treated with pVax injection, phIL-15 injection, pVax+EP+ or phIL-
15+EP+ 1300V/cm or 500V/cm. The splenocytes and PBMCs were re-stimulated with 
tumor cells in culture and evaluated for specific expression of IFNγ (Figure 49). It was 
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expected that mice exposed to plasmid plus EP would generate IFNγ production. 
General populations of cells were isolated from spleens and peripheral blood, not just 
CD8 specific T cells. Previous publications have reported that irradiated B16.F10 can 
stimulate splenocyte populations for IFNγ production
164
. The splenocytes and PBMCs 
were prepped for ELISpot analysis one day after samples were collected. The assay 
consisted of 300,000 splenocytes and 200,000 PBMCs freshly collected on Day 11 and 
Day 14.  
Initially Day 11 and Day 14, unstimulated cells were tested for IFNγ production 
without additional secondary B16.F10 stimulation. PBMCs did not show IFNγ production, 
were eliminated from analysis and all splenocytes tested at Day 11 did not show 
expression of IFNγ. At Day 14, splenocytes samples pVax and phIL-15+ 1300V/cm and 
500V/cm showed some expression of IFNγ compared to pVax and phIL-15 injection 
groups. The pVax injection group n=3, served as a control because the IHC staining 
demonstrated that pVax injection group showed CD8 infiltrate on Day 7. phIL-15 
injection n=3, served as a control because stimulation of CD8 infiltrate was observed on 
Days 1, 2, and 11 in IHC. Fresh, unstimulated splenocytes from pVax+1300V/cm mice 
showed a 2.1-fold increase on Day 14, n=3 compared to pVax injection group.  
The pVax+500V/cm, phIL-15+1300V/cm and phIL-15+500V/cm showed less 
IFNγ spot forming cells than pVax+1300V/cm. Testing the same general population of 
splenoctyes with B16.F10 plus recombinant IL-2 stimulation for 4 days there was a 
difference of INFγ production in treatment groups. Splenocytes from mice treated with 
pVax+1300V/cm showed a 2.5-fold increase compared to pVax injection and 
pVax+EP+500V/cm showed a 2.1-fold n=4 increase compared to pVax injection. 
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While IL-15+EP+1300V/cm showed a 1.3-fold increase and IL-15+EP+ 500V/cm 
showed a 1.4-fold n=4 compared to IL-15 injection alone. There was no real indication of 
differences between the pVax+EP+ and IL-15+EP+ groups for the production of 
systemic IFNγ. The ELISpot did not show an expression difference between the groups 
as was seen with IHC and regression studies. Splenocytes did demonstrate IFNγ 
production when stimulated with B16.F10 compared to unstimulated. This does suggests 
why there was CD8 and CD4 cellular infiltrate in plasmid+EP groups detected at Day 7 
and Day 11 as demonstrated by IHC.  
A multi-cytokine Luminex Bead Array (LBA) was performed to further 
characterize the immunological signals that are associated with the plasmid+EP delivery 
Figure 49: ELISpot Analysis IFNγ Spot Forming Cells Detecting IFNγ spot forming cells 
from mouse splenocytes and compared stimulation of treatment groups to injection alone 
groups. n=3 for Injection groups and pVax+1300V/cm, n=4 for pVax+500V/cm and phIL-
15+EP groups. Error bars were calculated as standard deviation. 
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system. Ten cytokines that are known to be stimulated by IL-15 were analyzed in tumor 
lysate and serum samples from many different treatment groups containing n=3 mice per 
group. Tumors were treated with 100µg (2.0mg/ml) of plasmid pVax or phIL-15 with or 
without EP.  Tumor and serum samples were collected at 12h, 24h, and 48h after 1TX, 
on Day 3 (12h) after 2 Tx, on Day 6 (12h) after 3Tx, and Day 11, Day 14, Day 30 and 
Day 60 after 3Tx. The expression of the cytokines that were measured in this multiplex 
assay included IL-1β, IL-2, IL4, IL6, IL-10, GMCSF, MIP1β, TNFα, IL-12, and IFNγ. The 
cytokines were analyzed in tumor tissue samples and recorded as average total 
picograms (pg), while the serum levels were recorded as average picograms per milliliter 
(pg/ml). Each analyte was measure in each of the varied groups and then plotted 
together on a graph to characterize the type of cytokines up-regulated by IL-15, T cells, 
and NK cells. These cytokines were endogenously expressed in the mouse in response 
to pro-inflammatory signaling. 
Figures 50-89 shows levels from 10 different cytokines expressed in tumor lysate 
and serum samples 12h, 24h, 48h, Day 3 and Day 6, after treatments. The 1Tx, 2Tx and 
3Tx protocols were analyzed against controls tumor alone, pVax injection, pVax 
+1300V/cm and pVax+500V/cm collected at 24h for each analyte. Cytokine expression 
levels within each group was determined by calculating fold change compared to phIL-
15 injection alone (Table 4-7, Appendix A Table A1-A6 detailed expression levels). A 
dotted or solid line superimposed on the graphs demonstrates increased cytokine 
stimulation compared to background levels expressed by the no treatment group. The 
controls no treatment, pVax injection, pVax+EP+1300V/cm and 500V/cm were collected 
at 24h, D11, D14, and naïve samples on D30 and D60 were used to compare stimulated 
vs unstimulated cytokine production between treatment groups. Table 4 and 6, describes 
fold change (fold) expression from tumor lysate for each analyte tested compared to 
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treatment groups and to the IL-15 injection only groups. Table 5 and 7 describe fold 
change for serum levels within the treatment groups compared to phIL-15 injection 
alone. Treatment groups, phIL-15+1300V/cm and 500V/cm, were also analyzed for 
overall cytokines expression compared to control pVax injection, pVax+1300V/cm and 
pVax+500V/cm. 
 
 
 
 
 
 
 
 
IL-1β is stimulated by stromal fibroblast in response to existing melanoma, 
mediating an inflammatory response, stimulating lymphocyte cell proliferation, 
differentiation and apoptosis
165
. The groups tested in tumor lysate and serum included 
backbone vector pVax injection, pVax+EP+ at 1300V/cm and 500V/cm, phIL-15+EP+ 
1300V/cm and 500V/cm. Results shown in Figure 50 demonstrate that the no treatment 
tumor group, pVax injection and pVax+EP+500V/cm groups did not stimulate expression 
of IL-1β at 24h and expressed lower levels than treatment groups. The control group 
pVax+EP+1300V/cm showed a 10-fold increase compared to pVax injection. The tumor 
samples treated with phIL-15+EP+ 1300V/cm and 500V/cm were collected at 12h, 24h, 
48h, after 1Tx showed an increase an IL-1β compared to controls and to pIL-15 
injection. At 12h, hpIL-15+1300V/cm showed a 4.2-fold increase and phIL-15+ 500V/cm 
showed a 3.3-fold increase of expression compared to IL-15 injection alone. At 24h phIL-
Fold Change IL-1β IL-2 IL-4 IL-6 IL-10 
IL15 1300 12h 4.21 4.32 1.47 7.66 0.93 
IL15 500 12h 3.26 2.15 1.20 14.06 0.26 
IL15 1300 24h 2.69 0.22 0.41 1.19 0.09 
IL15 500 24h 2.61 0.40 0.65 6.61 0.43 
IL15 1300 48h 1.65 0.32 0.99 0.38 0.59 
IL15 500 48h 0.88 0.08 0.91 1.33 0.01 
IL15 1300 D3 3.41 1.19 0.46 2.68 3.67 
IL15 500 D3 3.71 4.25 1.11 2.30 5.08 
IL15 1300 D6 1.65 0.13 0.38 1.14 0.01 
IL15 500 D6 1.05 0.05 0.20 6.66 0.01 
Table 4: Cytokines Evaluated in Luminex Bead Array Measured in Tumor Lysate. 
Fold change compared to phIL-15 injection group. 
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15+1300V/cm and 500V/cm had a 2.7-fold increase compared to IL-15 injection alone. 
At 48h there was a 1.7-fold increase in group phIL-15+1300V/cm compared to IL-15 
injection alone, but there was no increase with phIL-15+500V/cm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The stimulation of IL-1β expression was also measured after 2Tx, the first 
treatment was initially administered at day 0 and the second treatment was given on Day 
3. The tumors were collected 12h after the last treatment. There was a 3.4-fold increase 
in IL-1β expression using phIL-15+1300V/cm and 3.7-fold increase using phIL-
15+500V/cm EP conditions. The 2Tx protocol showed the highest level of IL-1β 
expression compared to the other treatment groups and time points at Day 3. The 
tumors were also treated three times on Day 0, Day 3 and Day 6. phIL-15 was delivered 
Figure 50: Luminex Bead Array Measures IL-1β in Tumor Lysate 12h-Day 6. 12h, 
24h, 48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression leves were 
compared to no treatment group. n=3. Error bars were calculated as standard deviation. 
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with EP and 12h after the last treatment tumors were collected and assessed for IL-1β 
stimulation. There was a 1.7-fold increase in the phIL-15+1300V/cm groups and 1.1-fold  
 
 
 
 
 
 
 
 
 
 
 
 
 
phIL-15+500V/cm increase in expression as compared to injection of IL-15 alone. The 
3Tx protocol expression levels were similar to the phIL-15+1300V/cm and 
phIL15+500V/cm of the 1Tx protocol at the 12h time point.  
The serum samples from tumor treatment groups were collected and analyzed. 
Additional serum groups were added for Luminex analysis such as Day 11, Day 14, Day 
30 and Day 60 collected after the 3Tx protocol 0, 3, and 6 (Table 5). Tumor samples and 
splenocytes for these groups were utilized for the previous IHC and ELISpot on Day 11, 
and 14. Samples were collected at Day 11, 5 days after the last treatment and on Day 
14, 8 days after, these time points were chosen based on tumor regression data. The 
observations indicate that treated tumors regressed as early as 4-7 days and were 
Figure 51: LBA Measures IL-1β in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day 3 
after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no treatment 
group. n=3. Error bars were calculated as standard deviation. 
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completely regressed by 16-21 days compared to controls groups. The serum samples 
were analyzed to identify cytokine expression in the blood and characterize the systemic 
response to tumor treatments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comparing cytokine expression levels in the tumor and serum showed mainly 
lower levels of cytokine expression in the serum than in the tumor. The expression levels 
detected in the serum were compared to control groups such as no treatment at early 
time points (similar to tumor sample), pVax injection on D11, Day 14, and naïve pooled 
samples for later time points Day 30, and Day 60. Results shown in Figures 51-53, 
demonstrate IL-1β expression from serum (Day 11 and Day 14) and late time points 
(Day 30 and Day 60). There was a slight up-regulation in the pVax+1300V/cm groups at 
Table 5: Cytokines Evaluated in Luminex Bead Array Measured in Serum. 
Fold change compared to phIL-15 injection group. 
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24h, Day 11, and Day 14, the pVax+500V/cm showed a slight increase at Day 11, but a 
more robust stimulation at Day14, compared to the no treatment group and pVax 
injection. All treatment groups from showed low stimulation of expression at 48h, Day 3, 
Day 6, Day 14, Day 30 and Day 60. IL-2 enhances T cell and NK cell proliferation and 
IL-15 down regulates IL-2 functions and competes with IL-2 receptor binding
77, 166
. In 
tumor lysate the control groups showed low expression in the no tx, pVax injection, and 
pVax+500V/cm groups, while in the pVax+1300V/cm group there was a 7-fold increase 
of IL-2 expression compared to pVax injection (Figure 54).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum levels were much lower than tumor samples, comparing treatment groups 
to phIL-15 injection Table 5 shows increased levels of expression depicted by change 
fold. Complete expression values can be obtained from supplementary Tables A1-A6 
located in the Appendices. 
Figure 52: LBA Measures IL-1β in Serum Day 11 and 14. 3Tx Protocol, 
expression levels were compared to pVax injection alone group. n=3. Error 
bars were calculated as standard deviation. 
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Expression of IL-2 was present in pVax+1300V/cm, similar to phIL-15 injection 
and phIL-15+1300V/cm at Day 3. At 12h, phIL-15+1300V/cm showed a 4.3-fold and 
phIL-15+500V/cm showed a 2.2-fold increase compared to IL-15 injection. IL-15 
injection was stimulated higher than phIL-15+EP groups at 24h, 48h and Day 6. The 2Tx 
protocol 12h after Day 3 showed 1.2-fold increase in the phIL-15+1300V/cm group and 
4.3-fold increase in phIL-15+500V/cm. The phIL-15+1300V/cm at 12h and phIL-
15+500V/cm on Day 3 showed the highest expression of IL-2 in the tumor compared to 
all other groups.  
 
 
Figure 53: LBA Measures IL-1β in Pooled Serum Day 30 and 60. 3Tx Protocol, 
expression levels were compared to naive group. n=3. 
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Figure 54: Luminex Bead Array Measures IL-2 in Tumor Lysate 12h-Day 6. 12h, 
24h, 48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were 
compared to no treatment group. n=3. Error bars were calculated as standard deviation. 
Figure 55 LBA Measures IL-2 in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day 3 after 
2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no treatment group. 
n=3. Error bars were calculated as standard deviation. 
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Figure 56: LBA Measures IL-2 in Serum Day 11 and 14. 3Tx Protocol, expression levels 
were compared to pVax injection. n=3. Error bars were calculated as standard deviation. 
 
Figure 57: LBA Measures IL-2 in Pooled Serum Day 30 and 60. 3Tx Protocol, 
expression levels werecompared to naïve group. n=3. 
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IL-2 expression levels were much lower in the serum compared to the tumor 
(Figures 55-57). At the early time points 1Tx, 2Tx and 3Tx there was very low 
expression in treatments than control groups. The pVax+1300V/cm 24h and IL-15 
injection at 12h showed a slight stimulation of IL-2 expression compared to the no 
treatment group. The expression detected at later and late time points after 3Tx also 
demonstrated low IL-2 expression in mouse serum. On Day 11, there was a slight 
simulation in the pVax+500V/cm and phIL-15+500V/cm groups compared to pVax 
injection. On Day 14, the pVax+1300V/cm and pVax+500V/cm groups showed a slight 
stimulation in expression over pVax injection, and all other treatment groups showed low 
stimulation compared to controls. The expression of IL-2 at later time points after 3Tx 
showed slight stimulation of IL-2 in pVax+1300V/cm on Day 30 and Day 60 as well as 
phIL-15+1300V/cm on Day 30, and Day 60. The phIL-15+500V/cm did not stimulate IL-2 
production at the later time points. 
 
 
 
 
 
 
 
 
 
 
 
Figure 58: Luminex Bead Array Measures IL-4 in Tumor Lysate 12h-Day 6. 12h, 24h, 
48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were 
compared to no treatment group. n=3. Error bars were calculated as standard deviation. 
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IL-4 stimulates monocyte differentiation into immature dendritic cells and is an 
anti-inflammatory cytokine
167
. As expected, IL-4 stimulation was low in the tumor lysate 
(Figure 58). The highest levels were observed with pVax+1300V/cm inducing a 2.5-fold 
increase compared to pVax injection. The groups at 12h had low detectable IL-4 
expression, at 24h and Day 6. The phIL-15 injection groups demonstrated low levels 
compared to control pVax+1300V/cm at early time points, but higher than phIL-15+EP 
groups. At 48h all phIL-15+EP+ groups showed similarly low expression compared to 
the control groups pVax injection and pVax+500V/cm. The next highest expression of 
IL4 was detected on Day 3 in the phIL-15 injection and phIL-15+500V/cm groups 
compared to pVax+1300V/cm, but there was very small difference between the groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 59: LBA Measures IL-4 in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day 
3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no 
treatment group. n=3. Error bars were calculated as standard deviation. 
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Figure 60: LBA Measures IL-4 in Serum Day 11 and 14. 3Tx Protocol, expression levels 
were compared to pVax injection group. n=3. Error bars were calculated as standard deviation. 
Figure 61: LBA Measures IL-4 in Pooled Serum Day 30 and 60. 3Tx 
Protocol, expression levels were compared to naïve group. n=3. 
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Serum levels of IL-4 were low in all groups at early time points (Figures 59-61). 
There was a defined increase in IL-4 expression by pVax+500V/cm on Day 14, but no 
other groups at Day 11, Day14, Day 30 or Day 60 stimulated expression.  
IL-6 expression is stimulated by TILs and restores the NK activity and IFNγ 
stimulation
168
. Tumor lysate from control groups showed IL-6 expression in 
pVax+1300V/cm and the highest expressing group was pVax+500V/cm measuring 66-
fold increase of IL-6 production compared to pVax injection (Figure 62). Amongst the 
treatment groups at the12h time point, phIL-15+1300V/cm showed a 7.7-fold increase 
and phIL-15+500V/cm showed a 14.6-fold increase compared to phIL-15 injection. At 
24h, phIL-15+1300V/cm showed a 1.2-fold and phIL-15+500V/cm showed a 6.6-fold 
increase. At 48h, phIL-15+1300V/cm did not demonstrate an increase in IL-6 production, 
but there was a 1.3-fold increase by phIL-15+500V/cm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 62: Luminex Bead Array Measures IL-6 in Tumor Lysate 12h-Day 6. 12h, 24h, 48h 
after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no 
treatment group. n=3. Error bars were calculated as standard deviation. 
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The 2Tx protocol showed a 2.68-fold increase in phIL-15+1300V/cm and 2.3-fold  in 
phIL-15+500V/cm groups. The 3Tx protocol showed a 1.1-fold increase in phIL-
15+1300V/cm and 6.7-fold increase in phIL-15+500V/cm groups, all compared to phIL-
15 injection group. 
IL-6 stimulation in the serum was similar to tumor lysate (Figures 63-65). 
Expression levels of IL-6 production in the treatment groups were less than control  
pVax+500V/cm at 24h showing >1000pg/ml of protein production. The following groups 
also showed IL6 stimulus, phIL-15 Injection 12h, 24h, phIL-15+1300V/cm 12h, 24h, Day 
3 and Day6. The phIL-15+500V/cm group showed stimulation at 12h, 24h, 10.2-fold 
increase compared to phIL-15 at 48h, 43.8-fold at Day 3 and 135.9-fold at Day 6 (Table 
5). At Day 11 and Day 14, there were lower levels of stimulation compared to earlier time 
points. On Day 11, the phIL-15 injection group was the only group that showed 
increased IL-6. The pVax+500V/cm group at Day 14 had IL-6 levels that were slightly 
greater than pVax Injection. From the groups measured at Day 30 and 60 the only 
groups that stimulated IL-6 were pVax+1300V/cm and phIL-15+1300V/cm at Day 30 and 
Day 60. The late time points showed much less IL6 expression than the earlier time 
points. 
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Figure 63: LBA Measures IL-6 in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, 
Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared 
to no treatment group. n=3. Error bars were calculated as standard deviation. 
 
Figure 64: LBA Measures IL-6 in Serum Day 11 and 14. 3Tx Protocol, expression 
levels were compared to pVax injection group. n=3. Error bars were calculated as 
standard deviation. 
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IL-10 is a mediator between Th1 and Th2 and functions to regulate IL-15 
production by macrophage, and suppresses TNFα and IFNγ by inhibiting IL-12 
production
169
. The stimulation of IL-10 expression in tumor lysate was enhanced in 
groups such as pVax+1300V/cm at 24h (Figure 66). The phIL-15+1300V/cm groups 
showed expression at Day 3, a 3.7-fold increase and phIL-15+500V/cm group showed a 
5.1-fold increase. Again IL-15 injection showed an increase in IL-10 expression at 12h, 
24h, 48h and Day 6 comparable to pVax+1300V/cm at 24h and similar to results found 
in IL-4 on a larger scale. 
IL-10 expression in the serum was similar to expression in the tumor lysate 
(Figure 67-69). The groups that slightly stimulated IL-10 were pVax+500V/cm 24h, phIL-
15 injection 12h, 24h, and Day 6. The phIL-15 +500V/cm group showed 18-fold higher 
expression than pVax+500V/cm Day 3 and 3.7-fold higher than phIL-15 injection on Day 
Figure 65: LBA Measures IL-6 in Pooled Serum Day 30 and 60. 3Tx Protocol, 
expression levels were compared to naïve group. n=3. 
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6 (Table 5). There was no stimulation of IL-10 at 12h, 24h, 48h and Day 11 in the 
treatment groups. On Day 14, the only groups that slightly stimulated IL-10 were 
pVax+500V/cm and phIL-15+500V/cm. At late time points Day 30 and Day 60 
stimulation of IL-10 were low in the serum in groups pVax+1300V/cm, pVax+500V/cm, 
and phIL-15+1300V/cm at Day 30 compared to naïve groups, while no groups 
stimulated IL-10 at Day 60. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66: Luminex Bead Array Measures IL-10 in Tumor Lysate 12h-Day 6. 12h, 24h, 48h 
after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to 
no treatment group. n=3. Error bars were calculated as standard deviation. 
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Figure 67: LBA IL-10 in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day 3 after 2Tx 
and Day 6 after 3Tx Protocol, expression levels were compared to no treatment group. 
n=3. Error bars were calculated as standard deviation. 
Day 6 
 
Figure 68: LBA Measures IL-10 in Serum Day 11 and 14. 3Tx Protocol, expression levels 
were compared to pVax injection group. n=3. Error bars were calculated as standard deviation. 
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Additional cytokines were assayed using the Luminex bead as shown in Table 6. 
Pro-inflammatory cyotokine IL-12 functions to up-regulate IFNγ, through NK, and CD8+T 
cell response and promotes CTL effector function
170
. The level of IL-12 was reduced in 
Fold Change IL-12 IFNγ GM-CSF MIP-1β TNFα 
IL15 1300 12h 1.47 62.84 2.97 1.33 1.58 
IL15 500 12h 1.20 30.50 9.21 1.19 1.62 
IL15 1300 24h 0.41 1.27 0.29 6.04 0.50 
IL15 500 24h 0.65 2.72 0.49 6.29 1.06 
IL15 1300 48h 0.99 1.51 0.55 3.58 1.26 
IL15 500 48h 0.91 1.22 2.09 3.99 1.31 
IL15 1300 D3 0.49 3.84 0.04 2.15 0.72 
IL15 500 D3 0.99 1.65 0.51 0.63 1.14 
IL15 1300 D6 0.38 1.07 0.77 2.39 0.79 
IL15 500 D6 0.20 0.42 0.11 1.87 1.34 
Figure 69: LBA Measures IL-10 in Pooled Serum Day 30 and 60. 3Tx Protocol, 
expression levels were compared to naïve group. n=3. 
 
Table 6: Cytokines Evaluated in Luminex Bead Array Measured in tumor lysate. 
 Fold change compared to phIL-15 injection group. 
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the tumor lysate, the group that showed an increase in expression compared to controls 
were pVax +1300V/cm with a 2.4-fold compared to pVax injection (Figure 70).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The phIL-15 injection group had slightly increased IL-12 expression compared to 
treatment groups at 24h, 48h, Day 3 and Day 6, but there were low levels at 24h 
compared to control. There were small differences between controls and treatment 
groups for this cytokine at the tumor level. 
Evaluation of IL-12 expression in the serum demonstrated that the treatment 
groups and control groups showed similar levels to expression levels found in the tumor 
(Figures 71-73). All samples expressed IL-12 lower than the no treatment group at the 
early time points. IL-12 expression in the serum were slightly higher at later time points 
than the early time points, the groups that demonstrated IL-12 stimulation were 
Figure 70: Luminex Bead Array Measures IL-12 in Tumor Lysate 12h-Day 6. 12h, 24h, 
48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were 
compared to no treatment group. n=3. Error bars were calculated as standard deviation. 
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pVax+500V/cm on Day 14, phIL-15+1300V/cm and 14.1-fold higher in phIL-15+500V/cm 
compared to phIL-15 injection on Day 14 (Table 7). At the late time points, IL-12 
expression levels were low again and comparing groups there was a stimulation of 
expression in groups pVax+1300V/cm on Day 30 and Day 60, pVax+500V/cm on Day 
60 and phIL-15+1300V/cm on Day 30, compared to naive groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 71: LBA Measures IL-12 in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, 
Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared 
to no treatment group. n=3. Error bars were calculated as standard deviation. 
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Pro-inflammatory IFNγ functions to further up-regulate T cells and CTL effector 
function
167
. IFNγ was stimulated in the treatment groups compared to controls groups 
(Figure 74). The highest expression of IFNγ was demonstrated in tumor lysate in the 
following groups phIL-15+1300V/cm showed a 62.8-fold and phIL-15+500V/cm showed 
a 30.5-fold increase compared to phIL-15 injection at 12h. At 24h, phIL-15+500V/cm 
showed a 2.7-fold increase in expression compared to phIL-15 injection. At 48h, all 
groups were lower than controls groups. The 2Tx protocol demonstrated a 3.8-fold 
increase in expression at Day 3 group phIL-15+1300V/cm and 1.7-fold increase in phIL-
15+500V/cm compared to injection. The 3Tx protocol showed a 1.1-fold increase phIL-
15+1300V/cm at Day 6, but the phIL-15+500V/cm did not show an increase in 
expression. 
 
Figure 72: LBA Measures IL-12 in Serum Day 11 and 14. 3Tx Protocol, expression levels 
were compared to pVax injection group. n=3. Error bars were calculated as standard deviation. 
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Table 7: Cytokines Evaluated in Luminex Bead Array Measured in serum. 
 Fold change compared to phIL-15 injection group. 
Figure 73: LBA Measures IL-12 in Pooled Serum Day 30 and 60. 3Tx Protocol, 
expression levels were compared to naïve group. n=3. 
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Levels of IFNγ in the serum were much lower compared to tumor lysate (Figures 
75-77). At early time points the groups that stimulated IFNγ in the serum were 
pVax+1300V/cm, pVax+500V/cm at 24h, phIL-15 injection at 12h, 24h and Day 6, phIL-
15+1300V/cm at 12h, 48h, and 21.2-Fold compared to phIL-15 injection on Day 3, phIL-
15+500V/cm at 12h, 7.2-Fold on Day 3 and Day 6 compared to controls and other 
treatment groups (Table 7). The stimulation of IFNγ was lower at later time points, there 
was no difference observed at Day 11 except for phIL-15+500V/cm on Day 14. Late time 
points showed very low stimulation in groups pVax+1300V/cm at Day 30, phIL-
15+1300V/cm Day 30 and Day 60 and phIL-15+500V/cm at Day 30 compared to 
controls and treatment groups.  
 
Figure 74: Luminex Bead Array Measures IFNγ in Tumor Lysate 12h-Day 6. at 12h, 
24h, 48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were 
compared to no treatment group. n=3. Error bars were calculated as standard deviation. 
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Figure 75: LBA Measures IFNγ in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day 3 
after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no 
treatment group. n=3. Error bars were calculated as standard deviation. 
 
Figure 76: LBA Measures IFNγ in Serum Day 11 and 14. 3Tx Protocol, expression levels 
were compared to pVax injection group. n=3 Error bars were calculated as standard deviation. 
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Figure 78, evaluates expression of GM-CSF which promotes differentiation of 
monocytes into immature dendritic cells and is produced by stimulated macrophages 
and neutrophils
167, 171
. The groups that stimulated GMCSF were pVax+1300V/cm at 
24h, phIL-15 injection at Day3, and Day 6, phIL-15 1300V/cm at 12h, and Day 6, phIL-
15+500V/cm at 12h, 48h, and Day 3 (Figure 78).  
The 1Tx protocol at 12h showed an up-regulation of GM-CSF in the phIL-
15+1300V/cm showing a 3-fold increase and phIL-15+500V/cm showed a 9.2-fold 
increase compared to phIL-15 injection, at 48h there was a 2.1-fold increase using the 
phIL-15+500V/cm compared to phIL-15 injection, but lower than controls. There was no 
increase of GM-CSF in the phIL-15+1300V/cm group and injection of phIL-15 showed 
higher expression of GM-CSF at 24h, Day 3 and Day 6 similar to IL-2, IL4, IL-10, and IL-
12.  
Figure 77: LBA Measures IFNγ in Pooled Serum Day 30 and 60. 3Tx Protocol, 
expression levels were compared to naïve group. n=3. 
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 GM-SCF expression in serum was lower than tumor lysate (Figures 79-81). At 
the early time points control pVax+1300V/cm showed stimulation at 24h and levels were 
higher than the treatment groups. phIL-15 injection showed GM-CSF stimulation at 12h, 
24h, 48h, and Day 6 compared to the treatment groups. The only group that reflected 
stimulation levels similar to controls was phIL-15+500V/cm at 24h.There was higher GM-
CSF stimulation in the IL-15+1300V/cm group 32.9-fold compared to phIL-15 injection 
(Table 7) at Day 11compared to phIL-15 injection and the other controls and at Day 14, 
the pVax+500V/cm seem to stimulate GM-CSF compared to the other controls and 
treatment groups. At the later time points the only group that stimulated very low 
expression levels was control pVax+1300V/cm at Day 30; there were no other groups 
that stimulated GM-CSF at Day 30 or Day 60. 
 
 
 
Figure 78: Luminex Bead Array Measures GM-CSF in Tumor Lysate12h-Day 6. 12h, 
24h, 48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were 
compared to no treatment group. n=3. Error bars were calculated as standard deviation. 
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Figure 79: LBA Measures GM-CSF in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, 
Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no 
treatment group. n=3. Error bars were calculated as standard deviation. 
 
 
Figure 80: LBA Measuring GM-CSF in Serum Day 11 and 14. 3Tx Protocol, 
expression levels were compared to pVax injection group. n=3. Error bars were 
calculated as standard deviation. 
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The chemokine MIP-1β (macrophage inflammatory protein) functions as a 
chemoattractant for tumoricidal monocytes
172
. The controls demonstrated low 
expression levels in tumor lysate except pVax+1300V/cm showing a 50-fold increase 
compare to pVax injection (Figure 82). The 1Tx protocol demonstrated expression at 
12h in the phIL-15+1300V/cm group showing a 1.3-fold increase and phIL-15+500V/cm 
showed a 1.2-fold increase and compared to the increased IL-15 injection group. At 24h, 
the phIL-15+1300V/cm showed a 6-fold increase and phIL-15+500V/cm showed a 6.3-
fold increase. At 48h, the phIL-15+1300V/cm group showed a 3.6-fold increase and 
phIL-15+500V/cm showed a 4-fold increase compared to injection of phIL-15. The 2Tx 
protocol showed a 3.3-fold increase at Day 3, in the phIL-15+1300V/cm, but the phIL-
15+500V/cm group did not show expression of MIP-1β. The 3Tx protocol on Day 6, 
demonstrated a 2.4-fold increase in the phIL-15+1300V/cm group and a 1.9-fold 
increase in the phIL-15+500V/cm group.  
Figure 81: LBA Measures GM-CSF in Pooled Serum Day 30 and 60. 3Tx Protocol, 
expression levels were compared to naïve group. n=3. 
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Expression of MIP-1β in serum was lower than tumor lysate. At the earlier time 
points, the groups that stimulated expression were phIL-15 injection 12h, 24h and slight 
stimulation at 48h and Day 6. The phIL-15+1300V/cm group showed stimulation at 12h, 
24h, 48h, 2.6-fold compared to phIL-15 injection on Day 3 and Day 6, and phIL-
15+500V/cm showed stimulation at 12h, 24h, 48h, 4.7-fold on Day 3 and Day 6 (Figures 
83-85, Table 7). The treatment groups at 48h were equivalent to injection of phIL-15 
injection group. At later time points there was no real difference in treatment groups 
compared to controls on Day 11. The groups that slightly stimulated MIP-1β at Day 14 
were pVax+500V/cm, pVax+1300V/cm and phIL-15 injection. At late time points there 
was an increase in MIP-1β expression at Day 30 and 60. The groups that stimulated 
MIP-1β were pVax+1300V/cm on Day 30 and Day 60, phIL-15+1300 Day 30 and Day 60  
and pIL-15+500 on Day 60 compared to controls and expression levels on Day 14. The 
Figure 82: Luminex Bead Array Measures MIP-1β inTumor Lysate 12h-Day 6. 12h, 
24h, 48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were 
compared to no treatment group. n=3. Error bars were calculated as standard deviation. 
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group that demonstrated the best MIP-1β expression was phIL-15+1300V/cm 
demonstrating a 4-fold increase compared to the naïve group on Day 30 and pVax+1300 
showing a 12.5-fold increase at Day 60.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 83: LBA Measures MIP-1β in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day 
3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no 
treatment group. n=3. Error bars were calculated as standard deviation. 
 
Figure 84: LBA Measures MIP-1β in Serum Day 11 and 14. 3Tx Protocol, expression levels 
were compared to pVax injection group. n=3. Error bars were calculated as standard deviation. 
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TNFα functions to cause tumor necrosis, enhances NK activity and facilitates 
leukocyte adhesion and migration
170, 172-173
.There was an increase in TNFα expression 
in control group pVax+1300V/cm with a 2.6-fold expression at 24h compared to the 
other control groups (Figure 86). At 12h phIL+1300V/cm and phIL-15+500V/cm groups 
showed a 1.6-fold increase, at 24h the phIL-15+1300V/cm did not express TNFα, but the 
phIL-15+500V/cm group showed a 1.1-fold increase compared to injection of phIL-15. At 
48h, the phIL-15+1300V/cm and the phIL-15+500V/cm groups showed a 1.3-fold 
increase. The 2Tx protocol did not show expression in the phIL-15+1300V/cm group, 
while the phIL-15+500V/cm group showed a 1.1-fold increase in expression compared to 
phIL-15 injection. The 3Tx protocol did not show expression in the phIL-15+1300V/cm 
group, while the phIL-15+500V/cm showed a 1.3-fold increase of TNFα expression. The 
IL-15 injection group showed an increase in expression at 24h, Day 3 and Day 6. There 
Figure 85: LBA Measures MIP-1β in Pooled Serum Day 30 and 60. 3Tx Protocol, 
expression levels were compared to naïve group. n=3. 
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was small expression differences identified between treatment groups expressing TNFα 
in tumor lysate. 
TNFα serum levels were slightly lower than tumor lysate. At early time points, the 
pVax+1300V/cm and pVax+500V/cm showed increased expression compared to pVax 
injection (Figures 87-89). The IL-15 injection group showed stimulation of expression 
higher then EP groups at 12h, 24h, and 48h, and was slightly stimulated at Day 3 and 
Day 6. The phIL-15+1300V/cm increased expression at 3.1-fold compared to phIL-15 
injection on Day 3 and phIL-15+500V/cm showed an increase of expression 15.1-fold at 
Day 3 and 5.11-fold Day 6 (Table 7), but much lower levels than tumor lysate. At later 
time points, there was not much expression detected between treatment groups on Day 
11, there was a prominent stimulation of TNFα in pVax+500V/cm at Day 14 and phIL-
15+500V/cm at Day with a14.3-fold increase (Table 7). The levels experienced in the 
serum at Day 30 and Day 60 were much lower than the earlier time points. The groups 
pVax+1300V/cm and phIL-15+500V/cm slightly stimulated expression compared to the 
naïve group. The phIL-15+1300V/cm group stimulated slightly more expression on Day 
30 and Day 60 compared to controls and other treatment groups. 
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Figure 86: Luminex Bead Array Measures TNFα in Tumor Lysate 12h-Day 6. 12h, 24h, 
48h after 1Tx, Day 3 after 2Tx and Day 6 after 3Tx Protocol, expression levels were 
compared to no treatment group. n=3. Error bars were calculated as standard deviation. 
Figure 87 LBA Measures TNFα in Serum 12h-Day 6. 12h, 24h, 48h after 1Tx, Day 3 after 
2Tx and Day 6 after 3Tx Protocol, expression levels were compared to no treatment group. 
n=3. Error bars were calculated as standard deviation. 
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Figure 88: LBA Measures TNFα in Serum Day 11 and 14. 3Tx Protocol, expression levels 
were compared to pVax Injection group. n=3. Error bars were calculated as standard deviation. 
 
Figure 89: LBA Measures TNFα in Pooled Serum Day 30 and 60. 3Tx Protocol, 
expression levels were compared to naïve group. n=3. 
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Summary 
Utilizing IHC, ELISpot and Luminex bead array assays characterized the 
expression of immune modulators present at different time points after tumor treatments. 
The three assays showed similar results and detailed the specific cytokines and T cells 
stimulated in the primary and secondary responses when delivering of phIL-15 using EP. 
The assays also demonstrated the type of immune response cells and cytokines that 
were up-regulated to promote tumor regression and enhance mouse survival as 
observed in Aim 2. The delivery of plasmid plus electroporation stimulated an innate and 
adaptive response against melanoma and facilitated a long-term response to tumor 
recurrence. 
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DISCUSSION 
Specific Aim 1 
3DTumor Model 
A unique biosynthetic 3D tumor model was generated to test EP delivery 
conditions and study cellular interactions. This large-scale, free floating 3D tumor model 
was used to elucidate EP parameters to enhance phIL-15 gene delivery into melanoma 
cell lines. Furthermore, the in vitro 3D tumor model was utilized to study the effects of 
EP on different cell types, and evaluate different EP conditions to improve delivery 
techniques in vivo. Utilizing the 3D tumor model, it demonstrated that similar levels of IL-
15 expression patterns were obtatined compared to the skin and tumor following in vivo 
delivery. Therefore, the goal was to use the EP conditions established in the 3D tumor 
model to develop a potential adjuvant system that would up-regulate IL-15 expression 
and induce an immune response against melanoma. 
Generating a Stable 3D Model System 
In Aim 1, the 3D model was used to obtain information about cellular behavior 
when subjecting cells to chemical and physical stimuli. The environment generated by 
the 3D scaffold encouraged melanoma cells to grow and develop into semi-normal, 
tumor cells populations. The objective was to understand how the 3D scaffold promoted 
an environment suitable for tumorigenesis and how this model could be used to optimize 
delivery methods for therapeutic interventions against cancer. Several matrices were 
evaluated to provide a framework that would support the growth of melanoma in a 3D 
construct (Figure 3-7). However, the initial matrices tested expanded melanoma growth 
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over many days, and were unable to provide a large enough structure for evaluating 
delivery applications. The aggregation of HaCaT cells forming a spheroid was able to 
support the proliferation and development of B16.F10 cells. This process was facilitated 
by the HARV’s horizontal rotation, laminar flow of fluid, hydrodynamic forces and passive 
oxygenation. It was these mechanical properties that provided a microenvironment 
suitable for cellular growth, encouraging cells to behave similar to those in nature
44, 53, 
56
. The HARV promoted aggregation of HaCaT into spheroids as quickly as 1 to 2 days, 
and measuring about 1 cm in diameter. The time period required for the scaffold to 
organize cells and support tumor mass formation exceeded the dimensions and time it 
took for cancer cells to develop on the bead, sponge and algi matrix scaffolding
44, 174-175
.  
Viability and Stability of Model 
The malleable, stable HaCaT construct mimicked the complex environment 
needed to integrate many small populations of melanoma cells throughout the scaffold 
thereby encouraging viable cellular interactions (Figure13-16, 21), proliferation (Figure 
19), cellular communication (Figure 18), expansion (Figure 17), differentiation (Figure 
18, 22), and production of its own extracellular matrix (Figure 20). The adherent 
scaffolding was able to keep loose, fluid B16.F10 cells in close proximity to promote 
tumorigenesis and stimulate B16.F10 differentiation. Maturation was observed by the 
production of mature pigmented cells (Figure 13-14) similar to malignant cancer 
development
176
.  
Due to the strong adhesive properties of the HaCaT scaffold, diffusion of 
nutrients into the center of the construct was reduced. However, injection of the B16.F10 
cells into the scaffold, caused an influx of the surrounding media and provided nutrients 
to the cells during proliferation. This injection technique enhanced cellular viability 4-6 
days after inoculation. Viability of both HaCaT and B16.F10 cells remained greater than 
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80% because they received an even exchange of nutrients and oxygen while rotating in 
the bioreactor (Figure 15-16). Viability and stability was monitored over a 10-15 day 
period. The heavily pigmented cells located in the center of the scaffold were mostly 
viable (Figure 13).  
The mechanism underlying the functionality of this model was determined by IHC 
analysis. The cellular makeup of the spheroid was determined to be a 3:1 ratio of HaCaT 
spheroids to B16.F10 cells. The HaCaT cells in the spheroid enhanced and regulated 
B16.F10 proliferation through keratinocyte’s adhesive proteins (Figure 15). IHC analysis 
showed evidence of cellular proliferation. This was indicated by variable nuclei staining 
of the B16.F10 and HaCaT cells. The varying shades of brown suggested that each cell 
was present at different stages of the cell cycle (Figure 19). Moreover, stable cellular 
proliferation, communication, signaling and survival properties were also observed by 
IHC staining. Immunofluorescence (IF) analysis demonstrated changes in B16.F10 
cellular morphology by Day 6. The cells underwent elongation to form dendrite-like 
processes suggesting that the B16.F10 cells were interacting and communicating with 
adjacent B16.F10 and HaCaT cells in the spheroid environment (Figure 18). HaCaT 
cells in the 3D model have the same properties as naturally occurring keratinocytes and 
have the ability to mimic with similar cellular reactions. HaCaT cells regulated B16.F10 
growth and survival, displayed organized growth patterns forming tight junctions with 
adjacent HaCaT cells and promoted cell-cell interaction of B16.F10 cells through their 
dendrite-like processes
71-72, 175, 177
. The IHC showed a collective grouping of B16.F10 
cells into smaller populations that readily integrated with HaCaT cells (Figure 17). The IF 
assay demonstrated that while HaCaT and B16.F10 cells resided in the spheroid, the 
cells would stack upon one another forming the walls of the scaffold (Figure 17). 
Interestingly, the tumors proliferated in the absence of the basement membrane and 
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matrix rigidity
43
. The HaCaT and B16.F10 cells stimulated the production their own 
extracellular matrix while proliferating and developing in the 3D spheroid construct 
(Figure 20).  
Communication and Functional Properties 
The spheroid model was shown to be a functional system that supported the 
production of E-cad protein production by keratinocytes. These adherent proteins 
function to control the fast growing properties of melanoma during early stages of 
development (Figure 22). Western blot analysis was used to confirm the up-regulation of 
E-cad expression and thereby the functionality of the 3D system (Figure 22). At early 
stages of melanoma development, the keratinocytes expresses E-cad to support and 
control melanoma growth
178-179
. As described in the literature, melanoma progresses 
into metastatic melanoma by decreasing E-cad production and increasing N-cadherin 
expression
178-179
. This process, termed cadherin-switch, facilitates the escape of 
melanoma from keratinocyte control allowing melanoma to metastasize, into deeper 
layers of the skin
177-180
. The data suggests that, HaCaT+B16.F10 cells residing in the 
3D model together up-regulated adherent properties of E-cad to ensure the proliferation 
and stability of tumor development. As expected, there was a definitive difference in E-
cad expression levels between HaCaT+B16.F10 cells compared to HaCaT alone and 
HaCaT+SKMEL-5. The low levels of E-Cad expression observed in the SKMEL-5 cell 
lines were expected because previous reports in the literature indicate these cells have 
lower levels of E-Cad expression when interacting with keratinocytes in vivo
181-182
.  
There was a reduction in terminal differentiation of the HaCaT cells when injected 
with B16.F10 cells. The evidence was provided by the western blot analysis 
demonstrating a decrease in Cyto 8 production compared to HaCaT cells alone. This 
suggests that HaCaT differentiation was reduced to promote B16.F10 survival and 
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progression. The 3D tumor model demonstrated its functionality through the production 
of human E-Cad and Cyto 8 collected on Day 2 and Day 4 after melanoma inoculation 
into the HaCaT scaffold. The expression of Cyto 8 and E-cad proteins were verified by 
the presence of positive control MCF-7 cells 
183
. Furthermore, it is known that cyto 8 is 
up-regulated during late stage cancer differentiation and decreased during early time 
points
184-185
. The slight decrease in cyto 8 by HaCaT+melanoma suggests that 
melanoma retards HaCaT terminal differentiation and helps to maintain the structural 
integrity of the spheroid by up-regulating adhesive protein E-Cad. The AE1/AE3 is a 
broad spectrum pan-cytokeratin antibody that measures all states of epithelial cell 
development at different states of differentiation
186
. It can be inferred from the staining of 
HaCaT with AE1/AE3 in IF analysis cells possibly expanded in an undifferentiated state 
or possibly driven to a state of differentiation to allow continuous survival of B16.F10 
cells, (Figure 15, 20-21). In IF staining, there was a strong fluorescent signal observed 
for HaCaT indicating that keratinocytes were undergoing proliferation and differentiation 
while a weak signal meant that cells were present at an undifferentiated stage (Figure 
17-18). Further testing to determine the state of differentiation, must be performed to 
confirm observations. 
Optimizing EP Conditions Using the 3D Tumor Model 
This large-scale, free-floating in vitro 3D tumor model is a functional and stable 
model that allows us to test delivery of genes using varying EP conditions and 
parameters. The goal was to generate an in vitro tumor model would withstand the 
electric fields of EP, transfect melanoma cells with phIL-15, to promote IL-15 protein 
expression and translate the delivery methods in vivo. Differences in IL-15 and GFP 
expression levels were observed between B16.F10 and HaCaT as well as EP conditions 
1300V/cm and 500V/cm. The differences in transfection efficiencies were confirmed by 
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immunofluorescence, flow cytometry and ELISA. As predicted, numerous melanoma 
cells injected into the spheroid were strongly transfected with GFP using tumor EP 
conditions 6PE 1300V/cm and 500V/cm compared to HaCaT spheroid electroporated 
with 4-needle and 4-PE conditions (Figure 23-24). One theory for this phenomenon is 
that loosely suspended B16.F10 cells injected into the spheroid are more likely to be 
transfected than the organized HaCaT spheroid. HaCaT cells express the adherent 
protein E-cad, which promotes tight aggregate formation in the spheroid and decreases 
EP transfection into cells
42
. The literature imply that the electric fields (EF) fired in 
multiple directions may help overcome cellular barriers in a 3D structure
28, 42, 160
. This 
information suggest that using electrodes that fire the electric field in multiple directions 
improved expression levels but it also depends on the cell type and its physiology. 
Testing In Vitro Delivery Conditions with phIL-15 
It was determined that a 6PE firing an electric field (EF) in multiple-directions increased 
GFP and phIL-15 transfection compared to the 4-needle or 4-PE. The transfection was 
not only dependent on the electrode, but also the cell type because during the 
experiment it was observed that B16.F10 cells were transfected more readily than tightly 
bound HaCaT cells. Also, GFP and IL-15 expression was dependent on the EP 
conditions used, plasmid transfection increased with lower EF, 500V/cm with longer 
pulses 20ms compared to higher EF, 1300V/cm with shorter pulses 100µs as 
determined by IF distribution (Figures 24-25), quantitative flow cytometry and ELISA 
analysis (Figure 26-28). The flow data showed a 7.3-fold significant increase in the 
GFP+500V/cm group (Figure 27).The ELISA analysis showed that there was a 10-fold 
increase of IL-15 expression at 24h and a 15-fold increase at 48h delivering phIL-
15+500V/cm into the HaCaT+B16.F10 group (Figure 28). In this model, it was important 
to fire the EF over a large radius. The 6PE contains a 0.8cm-1cm diameter gap between 
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the electrode plates, lower EF and longer pulses were needed to ensure delivery of GFP 
and phIL-15 to many cells at one time and overcome this potential cellular barrier while 
avoiding cell death (Figures 27-28). This data shows that different EP conditions and 
electrode configurations were required to obtain the desired delivery and expression 
amongst different cell types and their physiological properties. We also observed that 
closely packed HaCaT cells contributed to lower levels of IL-15 and GFP protein 
expression compared to the B16.F10 cells that were injected into the spheroid prior to 
EP. Decrease in HaCaT transfection was possibly due to the presence of adhesive 
proteins that could cause cells to aggregate and become less permeable thereby 
requiring different EP electrodes/conditions to enhance DNA delivery.  
Comparing phIL-15 Delivery Using the EP Conditions In Vitro vs In Vivo 
The in vivo studies demonstrated that the 3D model was able to predict IL-15 expression 
patterns similar to in vitro. The expression levels between skin and tumor differed; tumor 
samples were easily transfected compared to skin cells. Plasmid delivery and protein 
expression was enhanced at 500V/cm compared to 1300V/cm (Figure 29). There was a 
9.6-fold increase in expression using phIL-15+500V/cm and 7.1-fold increase using 
phIL-15+1300V/cm, similar to fold changes measured at 24h in the 3D tumor model. The 
amount of IL-15 expression differed between the in vitro 3D models and in vivo mouse 
models at different time points, but the overall trend in expression was the same 
between the groups. In vivo, IL-15 expression is regulated by many factors such as the 
plasmid promoter region, at the transcription and translation level, mRNA and protein 
short half-life, at the protein expression level, negative feedback inhibition mechanisms 
stimulated through paracrine and autocrine pathways, and decreased internal secretion 
controlled by the golgi. The advantage of the 3D model system is that investigators can 
study each pathway system independently from one another in culture, and compare to 
150 
 
cell signaling in vivo
187-189
. In nature, the skin undergoes homeostatic changes and 
regeneration. It is necessary to stabilize the synthetic 3D model for long periods of time 
to study the effects of complex signaling. For example, using a matrix that does not 
interfere with 3D cellular expansion or migration, could help stabilize the model and 
allow for cells to mimic natural processes more closely for functional studies
187-190
. 
Schoop et al., discussed the production of an organotypic co-culture system ranging 1-
2cm in size after a 2-week period that was used to study complex systems. This model 
was not a free floating construct, and was evaluated for potential skin transplantation not 
tumorigenesis
191
. This 3D tumor model is a unique system with the potential to have 
multiple functions. The 3D model is large scale functional model useful for adapting EP 
electrodes and testing delivery techniques in vitro. 
The 3D tumor model can be used to control experimental conditions for different 
experimental analysis. For example, this model would be useful for evaluating different 
cellular behaviors, isolating particular cell systems for analysis, increasing sample for 
assays and most importantly reduce live animal experiments. In these studies, the 3D 
model was used as a tool to predict how cells react to EP electric fields, stimulate gene 
expression, differentiate transfection efficiencies, determine protein expression levels, 
and optimize plasmid concentration. The goal was to verify that the plasmids worked 
optimally prior to moving delivery techniques in vivo. Specifically, the 3D system was 
used to analyze protein expression levels between different cell types and determine the 
best route for plasmid administration. These features were all important variables 
necessary for the development of an efficient delivery system for therapeutic purposes.  
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Specific Aim 2 
Examining phIL-15 Plasmid 
In Aim 2, EP delivery of phIL-15 was shown to stimulate an increase in primary 
and secondary immune responses against tumor antigens. Surprisingly, the delivery of 
pVax plasmid with EP also enhanced an immune response and promoted tumor 
regression as well. A restriction enzyme digestion was performed on the plasmids to 
ensure that the appropriate plasmids were utilized during EP experiments. The gel 
demonstrated that negative control pVax (back bone) plasmid was of appropriate size 
and absent of the IL-15 gene insert (Figure 30). This suggests that phIL-15 and pVax 
both had an adjuvant effect on tumor regression, cytokine production and T cell 
response stimulation. The literature suggests that DNA delivered by EP can stimulate 
pro-inflammatory effects when the DNA is internalized by cells. The inflammatory 
response occurs when unmethylated CpG oligonucleotides stimulate Toll like receptor 9-
dependent pathways in plasmocytoid dendritic cells
192-193
. On the other hand, TLR-9-
independent pathways promote inflammation by B-form DNA stimulating IκB kinase 
protein, Tank binding Kinase 1 in both immune and non-immune cells
193-194
. The 
stimulation of the immune response by pVax+EP delivery has not been completely  
established. The stimulation of IL-15 signaling improved the primary response and 
secondary response to challenge against B16.F10 compared to pVax stimulation. Tumor 
regression and challenge studies suggest that IL-15 protein production had a more 
specific effect on tumor regression and enhanced mouse survival compared to pVax 
plasmid delivery groups (Figure 44, Table 2-3). The low level of IL-15 production was 
reflected in expression studies and regression data. Low levels of IL-15 expression 
produced by transfected monocytes, dendritic cells and B16.F10 cells was possibly due 
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to a decreased hIL-15 binding to endogenous mouse IL-15Rα, decrease in transcription 
of IL-15 protein, or secretion pathways. Since IL-15 expression was reduced, there was 
a possible decrease in the long-term responses against melanoma antigens. 
 It has been suggested that the administration of exogenous IL-15 through an 
intra-peritoneal injection promotes short-lived memory CD8+T cells response and the 
exogenous administration of IL-7 enhances long-lived memory response
195
. Short and 
long-lived memory response is dependent upon the survival of CD8+Tcells
195
. This is 
important because IL-15 and IL-7 share a common γc receptor on NK and T cells
195-196
. 
IL-15 mainly functions to maintain memory by activating anti-apoptotic signals to 
enhance CD8+ T cell survival
197
. Some antigen specific CD8+ T cells from the initial 
expansion of effector cells are retained to establish long-term immunological memory 
response. In these studies, it is possible that the negative feedback mechanism of 
producing cells such as monocytes and DC, down regulated IL-15 production and 
reduced survival of CD8+T cells causing less IL7 stimulation during the contraction 
phase. The contraction phase is when most CD8+ T effector cells undergo cell death 
and few effector cells survive
195
. It was also found that IL-15 inhibits immunosuppressive 
function of T-regs on naïve or memory CD8+T cells
198
, These publications suggest that 
IL-15 is not only regulated at the innate immune response, but also at the memory 
response. This means that additional boosts of IL-15 delivery may need to be 
administered into the tumor and/or the muscle to enhance survival of CD8+T cells and 
reduce T-regulatory function. 
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Translating EP Conditions In Vivo to Further Test Delivery of phIL-15 
 In previous publications, it has been suggested that the benefit of using EP to 
deliver plasmid DNA for the therapeutic applications is that it enhances transfection 
efficacy and efficiency of specific cell types
27
. Increased plasmid transfection into cells 
found in the target tissue allows for increased production of the gene encoded by the 
plasmid and thereby enhancing therapeutic efficacy
27,36
. This was demonstrated in the 
in vivo mouse IL-12 and human IL-15 data. While delivering phIL-15 with EP had 
minimal effect on increase IL-15 expression, the IL-12 studies clearly demonstrated the 
ability of EP plasmid uptake and IL-12 expression. EP enhanced the production of IL-12 
compared to IL-15. The ability for EP to enhance IL-12 and not IL-15 production could be 
attributed to the highly regulated mechanisms associated with IL-15 expression and 
secretion. Also, the sequence homologies between mouse IL-15 and human IL-15 are 
73%
79
, but there may not be enough similarities in functional properties to promoted IL-
15 expression and enhanced IL-15 stimuli as expected. 
Regulation of phIL-15 
There are many publications suggesting that IL-15 is maintained at low levels 
through post-transcriptional and translational mechanisms because IL-15 messenger 
RNA is ubiquitously expressed in many tissues
77
. The overstimulation of IL-15 is known 
to cause many deleterious effects in the human body such as systemic lupus 
erythematoses, rheumatoid arthritis, Type I diabetes, hypertension, arthrosclerosis, and 
muscle disease
77
. Delivery of respective plasmids using EP increased IL-12 or IL-15 
expression and maintained protein levels over time (Figures 32-43). Additionally, the IL-
15 western blot analysis and the 3D tumor model demonstrated that IL-15 production  
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was reduced in vivo compared to mouse IL-12 expression data. This data suggests that 
the protein levels of IL-15 expression were tightly regulated at the tumor level. It has 
been shown that soluble IL-15 expression is difficult to detect in serum due to regulatory 
mechanisms at the transcriptional, translation and secretory stages
101, 150,199
. Several 
groups have investigated methods to improve IL-15 protein expression and 
secretions
149, 200
. These publications report that optimized human IL-15, also known as 
ECRO-IL-15, plasmid transfected into human Rabdomyosarcoma cells increased IL-15 
expression 87-fold higher than native pIL-15 and 5.7-fold higher than the long signal 
peptide (LSP) IL-15, while short signal peptide (SSP) was retained in the nucleus
199
. A 
recent publication by Beragamaschi et al 2009, reported that IL-15 SSP was involved in 
IL-15 regulation
201
. The experiments performed suggested that IL-15 SSP competed 
with IL-15 LSP for the binding of IL-15Ra possibly reducing IL-15 secretory pathway 
stimulation. A publication by Eisenman et al demonstrated that human IL-15 can be used 
in mouse models and that human IL-15 ligand does bind to mouse IL-15Rα, but activity 
may be hampered because optimal activity occurs with a mouse IL-15 ligand
196
. This 
idea is possible because there are sequence homologies between mouse/human ligand 
and receptor proteins. Mouse IL-15Rα is 54% homologous to human IL-15Rα and their 
active site sushi domains are 85% homologous
79
. The homology suggests that human 
optimized (opt) expressed IL-15 protein could bind the active sushi domain of mouse IL-
15Rα, out compete the IL-15 SSP protein binding and promote IL-15 secretion. The 
other possibility is IL-15 SSP protein binding blocks opt-IL-15 protein and promotes the 
negative down-regulation of IL-15 production.  
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Regulation of phIL-15 and Receptor phIL-15 
Bergamaschi et al., demonstrated that it is possible to up-regulate IL-15 secretion 
when delivering a duel expressing plasmid containing both IL-15 and IL-15Rα genes
201
. 
The co-expression of both IL-15 and IL-15Rα in one plasmid would promote intracellular 
complex formation and stabilization persuading IL-15 ligand to bind the IL-15Rα with 
high affinity. The co-expressing plasmid would result in two active forms; 1) a membrane 
bound IL-15Rα that would promote autocrine IL-15 binding and trans-presentation to 
responding cells and 2) a secreted active form of soluble IL-15/IL-15Rα ready to 
stimulate NK and T cells
201
. There is an abundance of literature reporting studies that 
have genetically altered the native IL-15 gene to enhance transcription, translation, 
expression, and secretion. The opt-IL-15 plasmid used in these studies was the 
optimized form, ligated into a vector containing constitutively active CMV promoter
149,199-
200 
published in Kutzler et al., to enhance protein expression and ensure secretion of IL-
15 plasmid from the transfected cells 
149
.  
Intra-tumoral Delivery of phIL-15 
The IL-15 expression levels obtained from intra-tumoral transfection were 
described in Aim 2. The tight regulation of IL-15 at the cellular level was overcome 
slightly by delivering the plasmid in high plasmid concentrations (100µg) with EP. 
western blot analysis demonstrated IL-15 protein expression at 24h, but expression was 
undetectable by 48h post-delivery (Figure 31). The studies conducted in the in vitro 3D 
tumor model, demonstrated that majority of the IL-15 protein produced was secreted into 
the supernatant, but there was still a detectable level of IL-15 protein in the spheroid 
homogenate (Figure 28). These experiments suggest that IL-15 expression occurs  
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earlier than 24h and that some IL-15 expression is retained intra-cellularly. Studies 
evaluating expression of IL-15 in vivo demonstrated that IL-15 expression was short-
lived. The tumors in the mice were tested at early time periods 12h and 18h in addition 
to the 24h and 48h time points. As expected, IL-15 expression was detected as early as 
12h in the phIL-15+1300V/cm and phIL-15+500V/cm groups. In the phIL-15+1300V/cm 
group expression peaked at 24h while in the phIL-15+500V/cm groups peaked at 12h. In 
both groups lower expression of IL-15 was seen by 48h (Figure 32). The same pattern of 
early expression was obtained from experiments testing the skin as a possible delivery 
tissue for transfection peri-tumorally to target tumor cells, but levels were much lower 
than direct tumor transfection (Figure 33).The IL-15 expression pattern detected in these 
studies is similar to that reported by Jalah et al. publication,
151
. The authors, compared 
expression leves between different engineered optimized IL-15 plasmids, including the 
opt-IL-15 plasmid used in this project. They described that a single hydrodynamic 
injection with the opt-IL-15 plasmids into mouse tail veins resulted in higher IL-15 
expression detected in the serum at early time points. The expression of the IL-15 from 
the optimized plasmids steadily increased up to 24h, at which point IL-15 expression 
peaked and then steadily decreased overtime after 1TX
151
. This study supports the IL-15 
expression levels obtained from the 3D tumor model and in vivo mouse experiments 
conducted in this project. 
Observations of the 3D tumor model and mIL-12 data; indicated that there was 
much lower transfection efficiency of IL-15 delivery to the skin than there was to the 
tumor. As discussed earlier, epidermal skin cells are keratinized cells containing mostly 
dead cells with tight adherent properties, while B16.F10 cells are mostly live viable cells 
with low adherent properties. Based on the skin and tumor experiments, the electric field  
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strength and blast radius encompasses more live tumor cells than viable dermal skin 
cells found below the epidermis. The difference in protein expression by different cells 
types depends on the stage of cell cycle, viability, and adherent properties
42
. B16.F10 
cells have less adherent properties, there more are viable cells and longer lived 
compared to keratinocytes. The keratinized skin cells undergo cell death as they move 
towards the epidermal layer
202
. The cells near the basal, germinal level are less 
keratinized and have less adherent proteins than cells in the epidermal layer
14
 and are 
more likely to uptake plasmid DNA delivered by EP. These observations suggest that 
intra-dermal EP would demonstrate better transfection of cells near the basal layer 
compared to keratinized cells near the epidermis
160
.  
Maintenance of phIL-15 Expression with Multiple Treatment Parameters 
The information gathered from the in vitro and in vivo experiments suggests that 
in order to obtain the highest level of IL-15 expression multiple evenly spaced treatments 
protocols should be administered to treat existing tumor cells. This project demonstrated 
that a series of EP plasmid deliveries could produce enough signal to stimulate the 
immune response and control the fast growth of aggressive B16.F10 cells. A 2Tx and 
3Tx protocol administered phIL-15+ EP (1.0mg/ml) at early time points at 0, 1, 2, days 
did not stimulate robust IL-15 expression. It was inferred that delivery of phIL-15 by EP 
at such close, adjacent time points may not allow sufficient time for cellular immune 
response. For example, there should be sufficient lag time to allow innate immune cells 
like phagocytes and macrophages to clear away dying cells, APCs. to process antigens 
and recruit new monocytes from the blood to the delivery area that could respond to 
additional plamid+EP treatments. Other limiting factors that may have interfered with IL-
15 expression during the early multiple treatment protocols was possibly due to 1) 
158 
 
enhanced destabilization of the plasma membrane from transfected cells by the applied 
electric fields causing some cell death and less time for clearance between the first 
treatment and the next treatment, and 2) also adjacent treatments did not allow enough 
time for IL-15 production to recruit cells to the area or IL-15 protein transpresention to 
responding cells, which was possibly due to IL-15 negative feedback properties as well. 
Experiments using the 3D tumor model demonstrated that the plasmid GFP delivered 
with EP to melanoma cells was readily taken up the plasmids and expressed within 24h, 
but there was a slight decrease in viability 5-10%. The HaCaT were much hardier cells 
with viability close to 92-96% but transfection was much lower than B16.F10 cells 
(Figure 26-27). The results suggest that using different EP parameters would increase 
the level of HaCaT expression. 
Increasing the time between the treatments for the 2Tx and 3Tx protocols 
delivering phIL-15+EP+ (2.0mg/ml) was explored on Days 0, 3, and 6. There was a 
significant 2-3-fold increase at Day 3, and 2-fold increase at Day 6 in both EP groups. 
The 3Tx protocol suggests that cellular turnover can occur as early as 72h after the first 
treatment. There was a slight, but significant increase in IL-15 expression at Day 3 and 
Day 6 compared to the 12h, 36h, 60h protocol, but not to the extent as predicted (Figure 
42-43). The 3Tx protocol on Days 0, 3, and 6 was selected for further studies to monitor 
tumor regression and mouse survival. The decision was based on the observations from 
early tumor regression studies (Table 2). Fast growing tumors began to regress in 
plasmid EP treatments groups by Day 4 and 7, while untreated tumors and tumors 
injected with pVax or phIL-15 exponentially grew after Day 9 (Figure 44a-c). These 
studies suggested that the multiple treatment protocols using phIL-15+EP required some 
time to recruit new cells to the area. This was further suggested by the up-regulation of 
IL-1β cell proliferation cytokine, MIP-1β recruitment chemokine and TNFα tumor 
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necrosis detected in tumor lysate when cells were treated with IL-15+ 1300V/cm and 
phIL-15+500V/cm at 12h, 24h, Day 3,and Day 6. The highly regulated IL-15 protein 
expression and delivery to the mouse model demonstrated that human IL-15 can 
possibly bind to mouse IL-15Rα, may trans-present to receptive cells such as NK cells
77
 
to promote IL-15 stimulated immunological activity in the mouse and can cause tumor 
regression. 
Analyzing Tumor Regression and Mouse Survival with Delivery of phIL-15 and EP 
The main goal of Aim 2 was to stimulate an immune response against tumor 
antigens and promote long-term responses to enhance mouse survival. Delivery of both 
phIL-15 and pVax using EP elicited a detectable immune response, but it was necessary 
to up-regulate a specific innate immune response and in turn stimulate down-stream 
signaling proteins to promote an adaptive immune response. The adaptive immune 
response would encourage T cells to recognize tumor antigens presented by dendritic 
cells and in turn mount a systemic response against B16.F10 cells. The mechanism by 
which IL-15 and EP stimulated tumor-specific response is not clear. Therefore 
experiments were designed to characterize the innate and adaptive immune responses 
that were initiated by IL-15/pVax+EP in tumors and prevented relapse of B16.F10 
growth. The combination of IL-15 or pVax with EP acts as an adjuvant therapy 
demonstrating tumor regression, cytokine stimulation, and T cell stimulation.  
The majority of the mice that had undergone tumor regression survived B16.F10 
challenge. The best groups that responded with long term effects were the phIL-
15+500V/cm group which contained 8 of 15 mice that had complete regression of 
primary tumor and had 75% (6 out of 8) of the mice that survived tumor-free after 
subsequent tumor challenge, the phIL-15+1300V/cm group contained 11 of 15 mice with 
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complete regression of primary tumor and 45% (5 out of 11) of the mice that survived 
tumor-free after subsequent challenge and the pVax+500V/cm group contained 11 of 15 
mice with complete regression of primary tumor and 36% (4 out of 11) of the mice that 
survived tumor-free after subsequent challenge (Table 3). Although the pVax+500V/cm 
and phIL-15+1300V/cm both demonstrated similar results, it was the phIL-15+500V/cm 
group that stimulated enough of the innate and adaptive immune response 50 days after 
challenge to enhance a possible memory response
203
. The lack of response in some 
mice may possibly be due to variability in tumor size or the metastatic properties of 
tumor cells that were injected deep into subcutaneous tissues. Perhaps, for the delivery 
of phIL-15, many more tumor cells must be subjected to electric fields to increase 
transfection area during each treatment and ensure delivery of IL-15 plasmid to increase 
expression levels that making up for regulatory processes of IL-15. The multiple 
treatment protocol allowed tumors to maintain IL-15 protein expression over time 
improving tumor regression and the mouse survival outcome (Figure 42). The regression 
and challenge data indicates that IL-15 delivery using EP may be an effective treatment 
regimen for melanoma. Evaluation of the data suggests that IL-15 can be used as a 
possible cytokine therapy against melanoma because of its ability to promote specific 
anti-tumor properties. Also, pVax delivery using EP demonstrates that the back bone 
delivered to melanoma can act as an adjuvant causing tumor regression and non-
specific anti-tumor properties. In the regression data, there were a few mice in the phIL-
15+1300V/cm group and all mice in the phIL-15+500V/cm group with pigmentation loss 
to the skin and hair due to EP effects (Table 2-3, Figure 44). Vitiligo occurs as a result of 
the TH1/INFγ or TH2/IL-4 balance between the pro-inflammatory and autoimmune 
stimulation
204
. It is possible that inducing vitiligo with EP may also contribute to 
maintenance of immune response.  
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Specific Aim 3 
Characterizing Immune Response Delivery of pVax and phIL-15 Plus EP Using IHC 
Characterization of the immune response that stimulated tumor regression was 
further explored by IHC, ELISpot and bead array to explore the immune mechanisms 
that promoted regression and mouse survival. IHC demonstrated the presence of CD8+ 
and CD4+ T cell in response to different control and treatment groups (Figures 45-48). 
The saline+EP groups both caused stress to the surveying CD4+ T cells resident to the 
area compared to the no treatment group on Day 1 and 2. The saline+500V/cm 
stimulated many residential CD4+ T cells and a few CD8+ T cells. This signified that EP 
alone evoked an initial stimulatory effect on residential CD4+ and CD8+ T cells or cells 
already stimulated by melanoma. The phIL-15 injection group which expressed very low 
amounts of protein from tumors (described in Aim 2), promoted a few more CD4+ and 
CD8+ T cells compared to saline+500v/cm and pVax injection on Day 1 and less on Day 
2. The pressurized injection of phIL-15 into the tumor could have possibly caused 
production of IL-15 expression and promoted the activation of residential CD4+ and 
CD8+ T cells. The phIL-15+500V/cm group also stimulated more of both CD4+ and 
CD8+ T cells activity compared to pVax+EP groups and phIL-15+1300V/cm on Day 1 
and decreased stimulation of T cells by Day 2. Also on Day 2, phIL-15+1300V/cm group 
stimulated residential CD8+ Tells. This indicates the possibility that IL-15 had an effect 
on priming T cells against melanoma. The IL-15+EP groups containing higher electric 
field strengths with shorter pulses, such as the phIL-15+1300V/cm groups, stimulated 
initial CD8+T cells more quickly than phIL-15+500V/cm. On the other hand, IL-15+EP 
groups with lower field strengths and longer pulses stimulated CD4+Tcells more quickly 
at early time points. On Day 7, phIL-15+1300V/cm and phIL-15+500V/cm showed more 
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CD8+T cells stimulation compared to the other control groups indicating the CD8+T cells 
were recruited by IL-15 to remove tumor antigens most likely through CTL effector 
activity. The response was more defined at Day 11 showing an up-regulation of 
expanded specific CD8+and CD4+T cells in groups pVax+1300V/cm, pVax+500V/cm, 
phIL-15+1300V/cm and phIL-15+500V/cm. Also by Day 11, the tumor size had 
regressed significantly in these groups suggesting that CTLs were actively removing 
tumor cells. The increased stimulation of CD8+ T cells CTL response was possibly 
facilitated by increased CD4+ T cells helper cytokine activity and/or promotes CTL 
differentiation by APC through the help of antigen-stimulated CD4+ T cell
166
. These 
conclusions were made based on the fact that more CD4+T cells were present in phIL-
15+1300V/cm group compared to pVax+1300V/cm. The lower amount of CD4+T cells in 
the pVax+1300V/cm group may explain why there was a relapse of tumors during the 
challenge. CD4+T cells provide help for antigen-specific CD8+Tcells stimulation and to 
activate the destruction of melanoma by CTL effector cells
166
. In contrast to these 
observations, on Day 11, there were increased amounts of CD4+ T cells stimulated in 
the pVax+500V/cm groups than there were in phIL-15+500V/cm group. These results 
indicate that phIL-15+500V/cm stimulated an early response of CD4+ T cells at Day 1, 
the levels were beginning to diminish since tumors in the phIL-15+500V/cm groups were 
necrotic and only residual tumor cells were left behind for CTL and macrophage 
removal. Both phIL-15+500V/cm and pVax500V/cm+EP+ groups had sufficient numbers 
of CD8+ T cells present but the pVax+EP+ group had small tumors that were still intact 
compared to phIL-15+500V/cm by Day 11, based on tumor volume measurements. The 
ELISpot and bead array assays show up-regulation of IFNγ in plasmid+EP+ which 
agrees with increased CD4+T cell infiltration and CD8+T cells increase observed in IHC.  
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ELISpot Assay Performed to Identify Presence of IFNγ Producing Cells 
To provide further evidence of possible stimulation of immune response up-
regulation through IFNγ expression, an ELISpot assay was performed on splenocytes 
collected from plasmid+EP+ mouse groups. On Day 14, the ELISpot assay showed an 
increase in IFNγ production in all four pVax+EP+ and phIL-15+EP groups stimulated 
with B16.F10 and rIL-2. The ELISpot results complimented the IHC images showing the 
recruitment of primed CD8+T cells that had homed into the tumor area at Day 11 and 
reduced tumor volume possibly through CTL and NK activity. Based on the literature, IL-
15 binds to IL-15Rα expressed on APC and monocytes and trans-present IL-15 to 
responding CD8+T cells and NK cells that express the popular βγc receptor complex
118
. 
Trans-presentation and direct stimulation of responding cells depends on expression of 
IL-15Rα. It is known that CD8+T cells express IL-15Rα while NK cells do not express IL-
15Rα making trans-presentation essential for NK stimulation and further enhancement of 
CD8+T cell activation
118,197,205
. The bead array also demonstrated an up-regulation of 
IFNγ stimulation at 12h, 24h, Day 3 and Day 6 in the tumor from groups phIL-
15+1300V/cm and phIL-15+500V/cm. Although serum levels of IFNγ levels decreased, 
expression was still detected at 24h in pVax+1300V/cm at 12h and 48h in phIL-
15+1300V/cm, Day 3 and Day 6 in phIL-15+500V/cm and phIL-15+1300V/cm. The 
detection method used in this study to measure NK response, did not show NK 
stimulation, there was stimulation of both CD8+ T cells and IFNγ indicative of possible 
NK activity involvement since tumor regression began as quickly as Day 4 after 2Tx. The 
IHC, Luminex bead array and ELISpot data also suggests that IL-15 may stimulate NK 
secretion of IFNγ at early time points (12h-Day 6), and indirectly through up-regulation of 
IL-12 production by dendritic cells, monocytes or NK cells to promote additional CD8+T 
cell CTL response and infiltrate
163
 at later time points (Day 11-14) Also, since the bead 
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array identified low levels of IL-12 production by tumor cells and serum levels at early 
time points. The only groups that demonstrated an increase of IL-12 in the serum at Day 
14 were pVax+500V/cm and hIL-15+500V/cm possibly indicating stimulation T cells 
expansion and T cell effector response. Heller et al., demonstrated that early IFNγ 
expression was detected in the serum on Day 4 after delivering 1Tx intra-dermal to mice 
in groups vector+EP+ control, pmIL-12 injection, pmIL-12+1500V/cm groups
160
. 
Additionally, a publication from Lucas et al., demonstrated that intra-tumoral delivery of 
pmIL-12+1500V/cm treatment stimulated IFNγ in the tumor lysate at Day 5
28
. These 
results indicated that plasmid delivered via EP were able to stimulate an innate immune 
response and an adaptive immune response that caused tumor regression and possibly 
explains long-term effects against melanoma. In this study, the delivery of phIL-15+EP+ 
possibly restored immune surveillance
118
 and controlled melanoma growth, since there 
were no visible metastatic melanoma lesions located in the lung, liver, lymph nodes or 
spleens from mice survived and were analyzed on Days 7, 11, 14, 30 and 60 (Samples 
from Figures 45-48 and Table 2).  
Comparing Differences in Plasmid Constructs pmIL-12 and phIL-15 
The primary tumor regression levels stimulated by plasmid+EP groups were 
similar to results detailed in Lucas et al,.
28
 for the delivery of pmIL-12. Comparing the 
results, there were similar primary tumor regression levels in the pmIL-12+1500V/cm 
group compared to phIL-15+1300V/cm group, but phIL-15+1300V/cm group was 
approximately 55% less effective against challenge compared to pmIL-12+1500V/cm 
group. Although, there was no correlation between pmIL-12 and phIL-15+500V/cm gene 
expression experiments, this group demonstrated the best long-term responses against 
challenge for the IL-15 experiments. The phIL-15+500V/cm group demonstrated the 
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highest IL-15 protein expression levels secreted from tumor cells in vitro and in vivo 
compared to phIL-15+1300V/cm. Challenged mice in 5000V/cm demonstrated 25% less 
effective than mIL-12.  In IHC the phIL-15+500V/cm group showed an increased CD8+T 
cells, quickly removing tumor cells compared to the rate at which phIL-15+1300V/cm 
removed tumor cells by Day 11. Furthermore, 1300V/cm showed the best primary 
response causing tumor regression in more mice, possibly due to mild EP conditions 
causing less tissue damage compared to phIL-15+500V/cm. However, it was the phIL-
15+500V/cm group that up-regulated long-term responses and possibly promoted 
CD8+T cell memory response against melanoma compared to phIL-15+1300V/cm and 
pVax 500V/cm.  
Utilizing the Luminex Bead Array to Characterize Cytokines Stimulated by pVax and 
phIL-15+EP 
In Aim 3, a 10-cytokine bead array assay was used to characterize the innate 
and adaptive immune responses stimulated by the plasmid+EP+ delivery system 
(Figures 50-89). Treatment groups and controls groups (no treatment and pVax 
injection) were analyzed using the bead array to characterize the immune response 
stimulated by phIL-15+EP and pVax+EP+. It was expected that non-specific innate 
immune cells (i.e. macrophage, NK cells, dendritic cells and monocytes) were present in 
the tumor and serum during normal surveillance. It was predicted after the delivery of 
phIL-15 using EP, the IL-15 protein would activate mature NK cells and the cytotoxicity 
of NK and T cells to target tumors. Macrophages would recognize and process antigens 
for presentation to receptive cells
77,197,206
. The receptive NK and T cells would then 
mount a specific response by secreting signaling cytokines and chemokines. These 
signals would induce proliferation and help prime CD4+T and CD8+T cells for expansion 
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to target melanoma. The specific stimulation of CD8+T cells would then promote a long 
term response against recurrent tumor antigens
77,197,206
. The purpose for utilizing the 
phIL-15+EP+ delivery system was to transfect the tumor cells and promote IL-15 
expression to re-stimulate a tolerant system. The stimulated immune cells would 
enhance the concentration of cytokine signaling and effector cells signaling
207
 in the 
tumor location and promote melanoma elimination.  
Examining the Stimulation of Different Cytokines Up-regulated by the Innate and 
Adaptive Cellular Responses 
The expression of cytokines up-regulated by phIL-15+EP+ or pVax+EP+ delivery 
and involved in tumor regression, preventing tumor relapse, were analyzed by Luminex 
bead array. Macrophages are the first to respond to tumor cells. The macrophages 
engulf tumor cells, disrupt the cells and present the antigens to T lymphocytes
206
. 
Macrophages produces a multitude of cytokines IL-1β, IL-6, IL-10, IL-12, IL-15, and 
TNFα that function to increase CD4+ helper T cells, additional macrophages, neutophils, 
and dendritic cells populations. CD4+ helper T cells produce IL-2, IL-15, and IL-12 to 
stimulate NK and LAK cells. IL-12, IL-2, and IFNγ can then stimulate CD8+T cells and 
CTLs. Also, helper T cells produce IL-2 to continuously stimulate proliferation and 
differentiation of CD4+ helper T cells, CD8+ T cells and CTLs. It is known that IL-15 
does not stimulate IL-4, which promotes a Th2 response, but IL-10 production can be 
stimulated in Th1 and Th2 mediated responses
166,206
. MIP-1β and IL-15 are chemokines 
that help recruit monocytes from blood to the tissue and into the stimulated area, while 
GM-CSF induces the production of granular cells, and maturation of macrophage and 
dendritic cells (DC) from bone marrow cells. Neutophils stimulate macrophage and T 
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cells through TNFα, and macrophage stimulate neutrophils through IL-1 and TNFα. T 
cells stimulate macrophage through IL-1, IL-10, TNFα, IL-4 and IFNγ
166, 208
. 
Expression of IL-2 stimulates T cell proliferation, but can also compete for IL-
2Rβγ binding with IL-15 ligand
169,173
. IL-2 can stimulate its own expression through 
autocrine factors to help promote T cell proliferation. It has also been suggested that IL-2 
can promote T cell survival thereby enhancing memory response
169, 173
. The goal of 
these studies was to enhance IL-15 production at early time points to activate NK cells, 
IFNγ and then stimulate IL-12 to increase systemic response against recurrent 
melanoma tumors. Macrophage inflammatory proteins are chemokines that have 
tumoricidal properties that drives Th1 responses
172,209
, IL-1 and TNFα facilitate 
leukocyte adhesion and migration
172
. IL-15 promotes the production of GM-CSF, IFNγ, 
and TNFα from activated NK cells and synergizes with macrophage stimulation of IL-12 
to enhance NK activity
173
. This analysis helped characterize the signals activated in the 
tumor by delivery of IL-15 with EP, which amplified a local response and in turn 
promoted a systemic, long-term response against melanoma. 
Analysis of phIL-15 Injection Alone Group 
Tumor lysate was tested to identify local cytokine production in the tumor, while 
serum samples were tested to identify systemic cytokine production. The bead array 
results were analyzed for levels of cytokine production at different time points compared 
to the background levels of control groups no treatment, pVax injection or naïve 
samples. Each treatment group tumor lysate and serum samples will be analyzed for 
each cytokine in the sections below. The tumors injected with phIL-15 alone induced the 
production of different cytokines than the control groups such as IL-1β, IL-2, IL-10, and 
MIP-1β. These cytokines were mostly activated at early time points in the tumor. The 
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stimulation of these cytokines suggests that IL-15 protein activated macrophage 
proliferation, DC differentiation, T cells and NK cell proliferation and recruitment of 
neutrophils and monocytes to the area. Also IL-4, IL-12, IL-6, IFNγ, GM-CSF, and TNFα 
were mildly increased at early time points. Low stimulation of these cytokine suggests 
that IL-15 protein expression was short-lived, but was sufficient to activate CD4+ T cells 
surveillance. The reduced concentration of the cytokines suggested that CD8+ T cells or 
CTLs were not present. Based on IHC, phIL-15 injection did stimulate some CD4+and 
CD8+T cells in the tumor area, but the tumors were able to escape innate and cellular 
immune responses. The IHC data showed phIL-15 injection stimulated more surveillance 
cells than the no treatment group and pVax injection groups. Similar cytokine 
concentrations were detected in the serum of the phIL-15 group; all cytokines 
expressions were very low except for IL-1β, IL-2, IL-6, and MIP-1β at early time points. 
This suggests that IL-15 stimulated recruitment of lymphocytes from the blood to 
infiltrate the tumor and also stimulated monocyte, macrophage, T cell and NK cell 
proliferation, monocyte and macrophage differentiation and restored NK/ IFNγ stress 
signals.  
Analysis pVax+1300V/cm Group 
Analyzing tumor lysate samples from the pVax+1300 V/cm group, demonstrated 
an up-regulation of cytokines IL-1β, IL-2, IL-4, IL-6, IL-10, GM-CSF, MIP-1β, TNFα, and 
IL-12. These cytokines were the same as those stimulated in phIL-15 injection group. In 
addition to stimulation of monocyte, macrophage, and T cell proliferation, DC 
differentiation, recruitment of tumor infiltrating lymphocytes (TILs), this group also 
stimulated tumor necrosis, enhanced restoration of NK and IFNγ signaling, some anti-
inflammatory signals, and regulation of tumor infiltrating monocytes. In the serum the 
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cytokines that were stimulated included IL-1β, IL-10, and MIP-1β at early time points 
(12h, 24h, 48h, Day 3 and Day6) and IL-2, IL-6, GM-CSF, and MIP-1β at later time 
points (Day 11 and Day 14). The pVax+1300V/cm group also showed an increase in 
INFγ at Day 14, as detected by ELISpot. IHC demonstrated low levels of T cell infiltrate 
at early time points and these levels increased at later time points signifying that the 
response was delayed, but strong primary response, and a weak secondary response 
causing tumor recurrence. MIP-1β, TNFα and IL-12 seem to be the key cytokines 
stimulating tumor regression.  
Analysis of pVax+500V/cm Group 
The pVax+500V/cm group demonstrated up-regulation of the following cytokines 
in tumor lysate IL-6 and MIP-1β. This suggests that TILs, NK and IFNγ caused the CD4+ 
and CD8+T cells recruitment. In the serum the cytokines stimulated were IL-6, IL-10 
IFNγ GM-SCF, and TNFα at early time points. IL-1β, IL2, IL4, IL6, GM-CSF, IL-10, IL-12, 
MIP-1β, and TNFα at later time points and IL-12 and MIP1β at late time points (Day 30 
and Day 60). This indicates that pVax+500V/cm stimulated a robust primary response 
and secondary response as well as long-term effects due to the burning caused by the 
electric field. The extensive tissue damage stimulated macrophage and DCs to enhance 
a strong immune response to the wounds and promoted secondary response to antigens 
because of tumor ablation. Up-regulation of IL-4, GM-CSF, IL-6, MIP-1β, and TNFα 
indicated monocyte and DC differentiation, maturation, tumor necrosis and stimulation of 
TILs. There was an increase in IL-12 at late time points suggesting a secondary 
response and newly recruited T cells. This could explain the robust immune response at 
the tumor site and subsequently regression. Also, there was an increase of IFNγ 
observed by the ELISpot at Day 14, and IHC showed CD4+T and CD8+ T cells infiltrate 
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at Day 11, signifying that the pVax+500V/cm group did prime T cells for a strong 
secondary response and enhanced survival by 36%, and stimulated long-term 
responses to challenge. The tissue damage caused by EP simulated an increase in 
cytokine production causing a robust secondary response and T cell stimulation as seen 
in IHC at Day 11. IHC showed increased CD8+and CD4+ T cell and tumor regression by 
Day 11. Tumor cells slowly regressed compared to phIL-15+500V/cm group that showed 
lots of tumor degradation.  
Analysis of phIL-15+1300V/cm Group 
The phIL-15+1300V/cm group demonstrated stimulation of the following 
cytokines in the tumor (some cytokines expressed increased levels and are designated 
by the word “high”), high IL-1β, IL-2, high IL-6, IL-10, GM-CSF, high MIP-1β, high TNFα, 
IL-12, and high IFNγ. In the serum the cytokines expressed were high IL-6, GM-CSF, 
MIP-1β, and TNFα at early time points. At later time points IL-12, IFNγ, GM-CSF, and 
MIP-1β were expressed and at late time points IL-12, MIP-1β, TNFα, and IFNγ were 
expressed. The ELISpot also demonstrated IFNγ production in splenocytes at Day 14. 
Since INFγ is found highly expressed at the level of the tumor this suggests that NK cells 
were present and promoting cytotoxic activity. The high concentrations of cytokines 
found in the tumor and in the serum suggest that these were the signals that promoted 
increased tumor regression and up-regulation of a secondary response. The enhanced 
CD8+ T cell response could have increased mouse survival to 45% and promoted long 
term tumor rejection when challenged. IHC showed tumor regression and up-regulation 
of many CD4+ and CD8+ T cells. These results suggest the up-regulation of the innate 
immune response promoted increased cytokine production, and recruitment of primed T 
cells, CTL and NK cells through IFNγ expression. The IL-12, MIP-1β and TNFα 
171 
 
produced at the late time points could be the underlying cause of long-term responses 
against tumor challenge.  
Analysis of phIL-15+500V/cm Group 
The phIL-15+500V/cm group stimulated the following cytokines high IL-1β, high 
IL-2, IL-4, high IL-6, IL-10, high GM-CSF, high MIP-1β, high TNFα, IL-12, and IFNγ. In 
the serum the cytokines that were stimulated included IL-1β, high IL-6, high IL-10 at 
early time points IL-1β, IL-10 IL-12, IFNγ, GM-CSF, high MIP-1β, and TNFα at later time 
points IL-1β, high IL-12, IFNγ, high MIP-1β, and TNFα at late time points. The ELISpot 
also demonstrated stimulation of INFγ from treated splenocytes. Higher levels of 
cytokine stimulation in the tumor and in the serum contributed to tumor regression, 
mouse survival and the best long term response resulting in 75% of the mice remaining 
tumor free after challenge. IHC showed a more dismantled residual tumor with 
unrecognizable tumor cell shapes and some scar tissue due to EP damage. There was 
an abundance CD4+ and CD8+ T cells infiltrating the area. The only differences 
observed between the phIL-15+1300V/cm and phIL-15+500V/cm groups were increased 
levels of IL-2 and IL-4 in the tumor and increased levels of IL-10 and IL6 in the serum 
that possibly contributed to CD8+ T cells survival and a potential memory response. 
Analyzing the Immune Response to Tumor Antigens 
NKs function as immunosurveillance cells. Mature NK cells are stimulated by IL-
15 to promote anti-tumor effects. NK cells remove malignant cells through cytolytic 
properties and stimulate TNFα and IFNγ to promote an adaptive immune response
6
. 
Although it is known that IL-15 causes an anti-tumor effect by NK and CD8+Tcells, 
studies show that when depleting NK and CD8+T cells in an IL-15 transgenic mouse that 
anti-tumor mechanisms still occur. It is still unknown if it is a direct effect by IL-15 
172 
 
stimulation of cells involved in innate anti-tumor activity through the γc-chain signaling 
independently of NK and CD8. One theory is that IL-15 can stimulate macrophages 
directly
6
. NK cells secrete the cytokines IFNγ, GM-CSF, and TNFα upon activation and 
require increased stimulation for cytolytic activity. IL-15 mediates NK cell proliferation 
through DC encounter
170
. The activity of NK cells were not directly measured, but the 
cytokines associated with NK cells were measured and detected by the bead array, 
ELISpot and IHC. The phIL-15+1300V/cm and phIL-15+500V/cm showed an increase in 
TNFα, IFNγ, IL-12 and CD8+T cells. 
 IL-10 up-regulates IL-15 production by macrophages and over expression of IL-
10 suppresses TNFα and IFNγ, which in turn inhibit IL-12 synthesis by mononuclear 
cells at early time points. The up-regulation of IL-15 would re-stimulate IFNγ and 
TNFα
169
. IL-10 acts to regulate pro-inflammatory IL-15 production and anti-inflammatory 
effects on IFNγ and TNFα. The bead array demonstrated that phIL-15+1300V/cm and 
phIL-15+500V/cm increased TNFα, IFNγ, and IL-10. 
In vivo delivery using EP can stimulate many of the same cytokine and promote 
differentiation of DC. In vitro, studies have demonstrated that monocytes differentiate 
into immature DC stimulated by GM-CSF and IL-4, and that differentiation can also 
occur through GM-CSF and IL-15. DCs mature in the presence of TNFα, IL-1β and IL-6 
expressed together, and additional expression through intracellular toll like receptor 7/8 
stimulated IFNγ and TNFα
167,210
. GM-CSF stimulates neutrophils and IL-15 stimulates 
IL-1β by neutrophils
171
.  
ELISA demonstrated an increase in IL-15and the multi-plex bead array showed 
comparable stimulation of different cytokines responding in the tumor lysate. The 
cytokines expressed in the tumor stimulated by phIL-15+EP+ suggested that monocytes 
matured to DCs and migrated to peripheral lymph nodes. In the peripheral lymph nodes 
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they differentiated, matured into APCs and up-regulated Th1 IL-12, which in turn 
promoted T cell synapse leading to T cell expansion
167
. IL-12 stimulates IFNγ by T cells 
and NK cells. phIL-15+EP+ groups showed an increase in IL-12, IFNγ, IL-1β, IL-2, MIP-
1β, GM-CSF, IL-6 and TNFα indicating the therapy may have induced APC proliferation, 
differentiation and T cells expansion. 
Comparing Recombinant Protein Experiments and Gene Delivery Treatments 
Lewko et al., demonstrates that recombinant IL-15 protein influences TILs or 
TDAC outgrowth to eliminate primary culture melanoma cells by Day 7. This shows that 
recombinant IL-15 was able to cause tumor elimination by Day 7 in culture
211
. Similarly, 
in the IHC experiments there was an increase in tumor regression by Day 7 and there 
was possibly newly infiltrating T cells migrating to tumor site by Day 11 in the phIL-
15+EP+groups. It is possible that the low levels of IL-2 were detected because IL-15 
competed for binding of the IL-2 receptor due to high affinity binding capabilities
211
. In 
the bead array assay, both serum and tumor cells showed low IL-2 expression in phIL-
15+EP+ groups. Some IL-2 was possibly stimulated through its own autocrine 
pathway211-212. Additionally, it is suggested in the literature that human IL-15 binds 
mouse IL-15Rα up-regulates mature NK cells and acts as a growth factor for new T cells 
development by Days 7-11
76,196-197
. The experiments similarly stimulate immune 
responses as the recombinant protein experiments suggesting that the gene delivery 
system is enhancing immune responses against melanoma. 
Tumor Evasion and Importance of Gene Therapy 
One of the major reasons tumors escape anti-tumor control is because they lose 
MHC class I expression rendering tumors unrecognizable by CTLs due to self tolerance. 
NK cells can recognize MHCI deficient cells, but the overgrowth of tumors escape 
lysis
213
. IL-15 is known to enhance NK cell recruitment and development, it has been 
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suggested that this cytokine would be beneficial to use as a therapy against MHCI 
deficient melanoma cells
213-214
. The purpose would be to effectively stimulate an 
immune response against poorly immunogenic B16.F10 using a cytokine treatment to 
enhance tumor regression and survival
215-216
. Previous studies indicated that neither 
inactivated B16.F1 or short term pre-incubation with IFNα (B16Fα) introduced into 
existing disease like melanoma were able to enhance mouse survival
215
. Although, 
inactivated and co-inoculation of active B16.F1 cells with IFNα or a long-term exposure 
to IFNα enhanced mouse survival
215
. Intraperitoneal (IP) vaccination of B16F1 pre-
incubated with IFNα recombinant proteins stimulated an immune response with long 
term effects, but did not up-regulate long term protective response against B16.F1. The 
mice had an established tumor at a distant site from inoculation. When treated IP or 
subcutaneously 3 days after inoculation with B16Fα 53% of mice showed a complete 
response, surviving 90 days after treatment but no challenge experiments were 
performed
215
. An IL-15 transgenic mouse study demonstrated importance of IL-15’s 
ability to stimulate CD8+T cell (CTL) response against inoculation of B16.F10 cells 
compared to non transgenic mice. The authors suggested that early production of IFNγ 
by NK cells developed a CTL response against B16.F10 in transgenic mice by over-
expressing IL-15. The transgenic mouse enhanced CTL and inhibited tumor 
establishment, but was not protective against tumor growth
217
. Some researchers have 
switched to direct delivery of cytokine therapy using EP to transfect plasmids encoding 
therapeutic genes directly into existing tumors to enhance tumor regression, mouse 
survival and long-term protective response.  
IL-15 Used as an Adjuvant 
Previous publications suggest that IL-15 is a useful adjuvant against existing 
tumors as long as there are pre-existing populations of tumor specific CD8+T cells. They 
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also suggest that IL-15 has the ability to stimulate preexisting CD8+T cells through tumor 
specific CD8+T recall responses218. This was demonstrated in the IHC results showing 
small presence of T cells at early time points Day 1 and Day 2 in phIL-15+EP+ groups, 
and a definite increase in T cells by Day 11. There was a robust CD4+ and CD8+T cell 
population specifically targeting tumor cells and causing regression. The serum levels 
show an increase in IL-6, MIP-1β, and TNFα causing tumor infiltrate at early time points 
12h, 24h, 48h, Day 3, Day 6 and at the tumor level and there was definitely an up-
regulation of cellular infiltrate from the blood because IL-1β, IL-6, MIP-1β, IL-12 and 
IFNγ were recruited to the area by 12h, 24h, 48h, Day 3 and Day6 and at later time 
points. 
It is difficult to measure levels of IL-15 in the serum because expression is highly 
regulated. Studies have shown that the IL-15 leader sequences must be replaced to 
enhance protein production in transfected tumor cells to promote tumorigenicity
214
. This 
study discusses the importance of CD8+ T cell anti-tumor activity when CD8+T cells are 
knocked down. IL-15 transfected tumors were injected into CD8+ T cell knockout mice. 
Initially the mice rejected tumor growth, but over time tumor cells eventually escaped 
immune effector activity and enlarged rapidly
214
. Targeting tumors with EP is a beneficial 
approach because the delivery system allows targeting of specific tissue, efficient 
transfection tumor cells efficiently allows transient transfection and recruits innate and 
adaptive immune response to the electroporated area
26
. 
EP is an Adjuvant Delivery System that Stimulates an Inflammatory Response 
The effect of plasmid delivery using EP stimulated an inflammatory immune 
response, caused cellular infiltrate, cytokine stimulation and recruitment of T cells for 
primary response
219
. EP enhancement of the inflammatory response proved to be 
beneficial for increased gene delivery to recruited cells during multiple EP treatment 
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protocols. The more cells that are recruited to the tumor area the more cells that are 
transfected, results in a more potent induction of protein stimulus and tumor regression 
as seen in pVax compared to phIL-15 delivery with EP. The difference is that IL-15 was 
able to stimulate long-term and protective immune response at higher levels than pVax 
thereby demonstrating specific immune responses induced by IL-15 protein. As 
mentioned in publications, plasmid+EP+ induces more antigen uptake and cross 
presentation. T cells are primed by antigens in the T cell zone of draining lymph 
nodes
219
. This was indicated during experiments on Day 7, Day 11 and Day 14 in IHC, 
increased cellular infiltrate on those days indicated that new T cells were being primed 
and recruited to remove tumor antigens and causing tumor regression. The combination 
of EP and plasmid acts as an adjuvant to promote immune stimulus. This gene delivery 
system works synergistically to enhance immune effector cells, stimulating anti-tumor 
signaling and promoting prophylactic responses
219
.  
Intra-tumoral Delivery Stimulates Local Response 
Intratumoral EP delivery of IL-15 and IL-6 plasmids into canine melanoma 
caused tumor regression by up-regulating tumor infiltrating lymphocytes (TILs) in 
progressing cancer cells. The TILs stimulated high concentrations of IL-6 expression 
suppressed TGFβ activity, and restored NK and IFNγ activity. Transfection of IL-15 
restored NK activity and T cells as well as other growth factors to enhance anti-tumor 
effects
168, 220
. IL-15 may require the combination of other cytokines as an additive 
response against tumor antigens to produce stronger primary and protective immune 
responses. In addition to protein stimulus, EP itself serves as an adjuvant to enhance 
immunostimulatory signals by the electrical impulses causing stress and damage to 
stimulated cells in the area
221
. As observed in the IHC experiments on Day 11, the 
500V/cm group stimulated a robust adaptive immune response recruiting more T cells 
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and enhancing IL-15 expression to stimulated protective response. pVax and EP 
showed similar results of immune infiltrate, but showed less protective response against 
antigen challenge. The key is to recruit DC, CD4+T cells locally and to stimulate CD8+ 
CTL response. 
Comparing Electroporation Parameters 
Dayball et al. illustrated the importance of EP effects in mice using low voltage 
electric fields with long pulse durations and also demonstrated the importance of 
stimulating CD4+T cells with EP plasmid delivery
221
. The experiments in this study 
compared delivery of pCMVβ luciferase plasmid into the muscle of MHC class II deficient 
mice using a 2 needle EP applicator at different pulse lengths with same electric field 
strengths. They tested 200V/cm at 20ms and 200V/cm at 50ms and found that both EP 
conditions increased luciferase expression. The 200V/cm with 50ms pulse duration EP 
condition was able to elicit a cellular response in MHC Class II deficient mice while 20ms 
did not. The 20ms did elicit a cellular response in wild type mice. The 50ms pulses were 
able to overcome the MHC class II requirement eliciting a CD8+T cell response and 
bypassing CD4+T cell activation. These observations suggest that MHC Class II 
presentation to CD4+T cells was required for CD8 +T cell expansion
221
. This paper also 
suggests that EP activity enhances its own adjuvant properties for eliciting a cellular 
immune response. The experiments also detected a cellular immune response with 
delivery of pVax+1300V/cm and pVax500V/cm. There was an up-regulation in CD4+T 
cell stimulation in the EP groups compared to Injection alone and no treatment groups 
as seen in IHC. Poorly immunogenic such as B16.F10 do have CD4+T cells present and 
can help stimulate and recruit CD8+ T cells to the tumor area and enhance CTL 
activity
218
. The rapid tumor regression observed by Day 14 was due to the phIL-
15+1300V/cm and phIL-15+500V/cm groups, which enhanced both CD4+ and CD8+T 
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cells response to promote rapid tumor regression, improve mouse survival and possibly 
support a long-term immune response against B16.F10 challenge. This indicates in this 
mouse model the presence of CD4+T cell stimulation is important for up-regulating 
CD8+T cells. Additionally, the stimulation of CD8+ T cells was maintained by the 
presence of TNFα, IFNγ, and IL-12 in the tumor, serum and circulating lymphocytes. 
EP Stimulates an Adaptive Immune Response 
EP itself helps break tolerance for immune cells that do not recognize evading 
tumor antigens
222
. The stress and damage caused by EP at 500V/cm does stimulate 
cells to undergo apoptosis and promotes macrophage phagocytosis to removing tumor 
cells. Macrophages release of cytokines to recruits APCs and stimulates residential 
CD4+T cells to present and stimulate CD8+T cells causing an up-regulation of CTL 
cytotoxicty activity and apoptosis by TNFα
222
. The data shows that TNFα is stimulated at 
the tumor and serum levels causing tumor necrosis in EP groups as early as Day 3 and 
Day 6. It is important to cause tumor necrosis, apoptosis and CTL response not only at 
the tumor levels but systemically
222
. Delivery of IL-15 at early time points may have 
stimulated NK activity which amplified the signal stimulating IFNγ production and 
activation of primed T cells. The process of eliminating subcutaneous melanoma has 
been previously demonstrated by Lucas et al., This publication showed that pmIL-12 
delivered using EP into the tumor increased IFNγ, CD4+ and CD8+Tcells promoting a 
80% response against primary tumors and 100% protective response against 
challenge
28
. These results were comparable to the results from the IL-15 experiments 
presented here which showed a 73.3%-79% response (Table 2) to primary tumors and 
75%response to challenge (Table 3). 
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Restimulation of Immune Surveillance with phIL-15 Delivery and EP 
Tumors resemble normal tissue, derived from self cells and they maintain normal 
non-self tolerance to the immune response. Tumor antigens are identified by the 
following characteristics: antigen mutations, germ-line silenced genes, over expressed 
tumor antigens, oncogenic viral antigens and tissue-specific differentiated antigen
222
. 
The goal of a therapeutic approach, like the one presented in Aim 2, is to establish an 
immune response using a system that will remove cells expressing tumor antigens. The 
goal is to protect the body from tumor recurrence and re-stimulate effector function to 
tolerant cells, inducing sufficient concentration of immune cells in the tumor area that will 
recognize tumor antigens and cause extensive lymphocytic infiltration of cells to tumor 
stroma
222
. EP is an ideal way to introduce genes of interest like IL-15 into tumors without 
invasive surgeries or dangerous side effects. EP delivers genes to cells and does cause 
stress and damage to cells, depending on the cell type and EP parameters. The phIL-
15+EP+ multiple treatment protocols helped to enhance short-term IL-15 protein 
expression and, maintain IL-15 expression over time in a controlled manner and 
prevents toxic effects due to over expression of protein. Most importantly the multiple 
treatment protocol recruits immune cells to the area causing tumor regression. IL-15 is 
highly regulated; this regulation may help or hinder cytokine therapies. IL-15 stimulates a 
controlled amount of cytokine production that may reduce the survival of CD8+T cell 
memory and limit short term/long term memory expansion in the mice. Based on the 
experimental results IL-15 combined with EP can potentially serve as an adjuvant 
therapy to potentially treat existing disease such as melanoma.  
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FUTURE DIRECTIONS 
3D Tumor Model  
The 3D tumor model is an adaptable construct that can be modified to fit different 
experimental interests such as wound healing, tissue regeneration, transplantation, 
cloning, drug delivery techniques and genetic manipulations
42,187,190,223
. The 3D model 
can also be used to study different cellular behaviors when subjected to salt, pH, protein 
concentrations, ligand/receptor concentration, temperature, adhesive properties, and 
oxygen solubility
43
. This 3D model can help in elucidating the differences in cellular 
properties when grown in a 3D environment or as a monolayer of cells in culture, in the 
hopes of discovering new information about cells grown in vitro. Also, this model can be 
utilized to determine how tumor cells react in the presence of other stimuli that can 
promote or inhibit tumor development. For example, this model can aid investigators 
study proteins that are present during tumorigenesis such as FGF, interleukin 8, and 
VEGF
43-44,51-53,56,224
. Moreover, the 3D model would be a useful tool to understand how 
tumor cells react in the presence or absence of immune cells and compare to reactions 
with wild type, knockout, transgenic, NUDE or SCID mice models
53
. Future studies could 
be adaptable to clinical therapies such as plastic surgery, organ transplantation, species 
specific diseases, and toxicity of drugs
43,52
.  
To further improve the model, the HaCaT spheroids could be reinforced by using 
different concentrations of growth factors, using a network of collagen type I and IV or 
introducing a heterogeneous population of cells such as fibroblasts to stimulate cell 
communication
43
. Fibroblasts have many signaling properties useful for skin and tumor 
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development. The heterogeneous population of cells could help in the study of the 
expansion, growth cycles and development of B16.F10 in the absence of a basement 
membrane and stroma. Introduction of an engineered-linker could help facilitate drug 
delivery or enhance nutrient exchange to cells residing in the center of the model
190
. To 
further test functionality of the 3D tumor model and explore the activity of E to N 
cadherin-switch, angiogeneic STAT3/5 pathways and VEGF production to study 
metastatic transformation is also possible in vitro
177-179,226
. Additionally, the 3D model 
could be used to study specific gene expression, mutations, and cell signaling such as 
autocrine loops that regulate tumorigenesis 
43-44,51-53,56,224
. The 3D model is a highly 
reproducible system that could be used in many studies such as to optimizing EP 
delivery conditions before moving to in vivo animal studies and thereby reducing the use 
of animals for experimentation. The information gathered thus far from the 3D model 
indicated it can provide a wide range of information and has the potential as an 
adaptable model to mimic cellular in vivo processes
177,223
.  
 
phIL-15 Delivery +EP Enhance Immune Stimuli 
The delivery of IL-15 using EP is a promising approach that could be an effective 
gene therapy option for the treatment of melanoma. Additional pre-clinical experiments 
should be performed to ensure its functionality. Based on experiments detailed in Aim 2, 
non-responsive, abnormally shaped tumors or deep tumors could escape immune 
control between Day 9 and Day 12. One option to avoid the pitfall is to increase the 
number of treatment regimens of IL-15, 2 or 3 separate treatments additional to the 3Tx 
protocol using low voltage and long pulse durations.  
The delivery of phIL-15 using EP conditions at 500V/cm 20ms provided the 
strongest immune response against existing B16.F10, but was the most damaging. The 
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damage actually assisted in recruiting more cells to the area for plasmid up-take as seen 
in pVax+500V/cm group. To reduce damage and maintain delivery efficacy, additional 
EP conditions should be explored with the goal of stimulating IL-15-mediated tumor 
regression, but reducing tissue damage. Varying the delivery conditions could possibly 
promote different cellular responses to EP stimulus. One suggestion for future studies is 
to deliver the IL-15 with 500V/cm 20ms on the first treatment and then on the second 
and third treatment use milder conditions such as 804V/cm 400µs or 300V/cm-400V/cm 
with 20-50ms. The end goal of this therapeutic approach is to stimulate a strong initial 
immune response with IL-15 and then maintain expressions levels of the protein to 
promote stable immune cell recruitment. The expression data demonstrated that the 
highest levels of IL-15 protein were recorded at the earliest time points 12h or 24h and 
then decreased at 24h or 48h depending on the EP conditions. Each plasmid reacts 
differently to EP stimuli. The 3D model could be used to provide information about 
expression levels for optimization of IL-15 expression prior to moving farther with in vivo 
studies. For IL-15 experiments, it seemed as though IL-15 expression reached a 
threshold with the strongest EP condition 500V/cm and did not express higher levels 
with additional boosts. This suggests that inherent tight regulatory mechanisms that 
control IL-15 protein levels inhibited further expression.  
 
Different Cytokine Combination Delivery Systems 
It would also be important to evaluate different cytokine combinations that could 
complement IL-15 signaling and produce a synergistic response. Some suggested 
combinations are IL-15 plus IL-15Rα to enhance the availability of the high affinity IL-
15Rα for IL-15 when co-expressed in the same cells when either bound to the 
membrane or secreted as an active, soluble form for trans-presentation to receptive 
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cells
201,225
. Another option is to use plasmid IL-12 encoding the mouse IL-12 delivered 
by EP increased expression, and based on previous studies, enhanced immune 
response
28
. The combination of IL-15 and IL-12 could possibly promote tumor 
regression, CD8+T cell survival and memory responses. Researchers have 
demonstrated that some CD8+ memory T cells are long lived while others are short 
lived
195
. To enhance memory, researchers combined IL-15 and IL-7 because IL-15 
stimulates the survival of CD8+T cells and the short-lived memory, while IL-7 stimulates 
the long lived memory precursor CD8+T cells. The combination of IL-15, IL-7 and 
possibly IL-12 may enhance the innate, adaptive and memory responses resulting in a 
robust response against melanoma. The timing of delivery, plasmid concentrations and 
routes of delivery will be important to optimize for future immunological studies. The 
future of the immunogene therapy field may be in these combination delivery systems, to 
enhance multiple signaling pathways to mount a protective response against recurring 
tumors. 
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